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Breast cancer is a multistep disease controlled by a wide spectrum of genetic and 
epigenetic changes occurring within a cell as well as environmental influences; and it is 
the most common malignancy in women worldwide, often fatal because of metastasis 
dissemination. Aberrant miRNA expression can influence several gene networks and 
pathways implicated in tumorigenesis and metastasis formation. 
To unravel the role of miRNAs during breast cancer progression we investigated 
miRNA expression in 77 ductal breast carcinoma biopsies and 17 mammoplasties by 
microarray analysis. Sixteen differentially expressed miRNAs were identified 
comparing patients with or without disease relapse, within 72 months from surgery. 
This signature correlates with survival and/or distinguishes tumor subtypes in different 
datasets. 
Among them, miR-148b, down-regulated in aggressive breast tumors, was found 
to be a major coordinator of malignancy. In fact, it is able to oppose various steps of 
tumor progression when overexpressed in cell lines by influencing invasion, survival to 
anoikis, extravasation, lung metastasis formation, and chemotherapy response. miR-
148b controls malignancy by coordinating a novel pathway involving over 130 genes 
and, in particular, it directly targets players of the integrin signaling, such as ITGA5, 
ROCK1, PIK3CA/p110α, and NRAS, as well as CSF1, a growth factor for stroma cells. 
 Our findings reveal the importance of the identified 16 miRNAs for disease 
outcome predictions and suggest a critical role for miR-148b in the control of breast 
cancer progression.  
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 Il tumore al seno è una malattia multifattoriale controllata sia da un ampio 
spettro di variazioni genetiche ed epigenetiche che si verificano all'interno di una 
cellula, sia da fattori ambientali. E’ sicuramente la neoplasia più diffusa tra le donne di 
tutto il mondo ed è spesso fatale a causa della diffusione metastatica. Recentemente è 
emerso che l’espressione aberrante dei miRNA può influenzare il comportamento di 
diverse reti genetiche e pathway biologici implicati nel processo tumorigenico e nella 
formazione di metastasi. 
 Per meglio comprendere il ruolo dei miRNA, durante la progressione tumorale, 
abbiamo definito il loro profilo trascrizionale, utilizzando una piattaforma microarray, 
in settantasette pazienti affetti da carcinoma mammario duttale e diciassette 
mammoplastie (controlli sani). Abbiamo identificato sedici miRNA differenzialmente 
espressi in grado di discriminare i pazienti che presentano, o meno, recidiva dopo 72 
mesi dall’intervento chirurgico. E’ interessante notare come l’espressione di questo 
gruppo di miRNA correla con la sopravvivenza dei pazienti e sia in grado di distinguere 
sottotipi tumorali in altri dataset di espressione. 
 All’interno di questo gruppo è stato identificato il miR-148b, sottoespresso nei 
pazienti con prognosi più infausta, che si è dimostrato essere uno dei principali 
coordinatori del processo metastatico. In particolare questo miRNA, una volta 
sovraespresso nelle linee cellulari, è in grado di bloccare la formazione di metastasi 
influenzando l’invasività, la sopravvivenza delle cellule tumorali nel torrente 
circolatorio (anoikis), la fuoriuscita dai vasi sanguigni, la formazione di metastasi 
polmonari e la risposta alla chemioterapia. Abbiamo dimostrato che il miR-148b 
coordina l’azione di 130 geni e, in particolare, regola direttamente l’espressione di vari 
membri della via di segnalazione mediata dalle integrine tra cui ITGA5, ROCK1, 
PIK3CA/p110α e NRAS, così come CSF1, che è un fattore di crescita delle cellule 
stromali. 
 I nostri dati dimostrano il valore prognostico dei 16 miRNA identificati e 
suggeriscono un ruolo critico del miR-148b nel controllo del processo metastatico in 
pazienti affetti da carcinoma mammario. 
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1.1 Breast cancer biology and classification 
 Breast cancer is a heterogeneous disease characterized by a collection of breast 
tumor subtypes that have diverse histopathologies, genetic and genomic variations, and 
clinical outcomes [Bertucci & Birnbaum, 2008, Vargo-Gogola & Rosen, 2007]. It is the 
most common malignancy in women worldwide, often fatal because of metastasis 
dissemination [Jemal et al., 2010]. The transformation of breast epithelial cells in a 
metastatic breast cancer is due to epigenetic and genetic changes and aberrant 
interactions within the microenvironment such as described in Figure 1. During this 
multistage process, control of proliferation, survival, differentiation and migration 
become deregulated, and aberrant tumor–stromal cell interactions facilitate this process 
(Figure 1).  
 
 
Figure 1. Schematic representation of the breast cancer formation and progression. In 
order to form metastases, cancer cells must invade the basement membrane, enter the 
vasculature (intravasate), survive in the absence of adhesion, exit the vasculature (extravasate) 
and establish a new tumour in a foreign microenvironment (Reprinted and modified from 
Vargo-Gogola & Rosen, 2007). 
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 Fortunately, the mortality is decreasing in most western countries, because of 
mass mammography screening, frequent use of post-surgery chemotherapy and/or 
hormone therapy and the recent introduction of new drugs [Siegel et al., 2012].  
 Clinical and pathological parameters, including tumor size, lymph node 
involvement, histological grade and age [Dunnwald et al., 2007], are routinely 
employed to categorize patients with breast tumors in order to assess prognosis and to 
determine the appropriate therapy.  The additional use of molecular tumor markers, 
such as the receptors for estrogens (ER) and progesterone (PR) or the ERBB2 gene, 
significantly enhances the ability to stratify patients according to risk and better allows 
the appropriate therapy tailoring [Colozza et al., 2005]. The HER2 gene (ErbB2, 
commonly referred to as HER2/neu) is a newer biological marker routinely tested in all 
breast cancer tumors [Harris et al., 2007; Harari & Yarden, 2000]. 
 The combination of morphological and molecular markers provides better 
clinical results than the use of single approaches. The combination of these two 
methodologies has been successfully applied to group patients in different categories of 
risk such as the St. Gallen criteria [Goldhirsch et al., 2009], the NIH consensus criteria 
[Eifel et al., 2000] the Nottingham Prognostic Index [Galea et al., 1992]. However, 
since patients with similar combinations of features may often have different clinical 
outcomes, it is necessary to identify new ways to classify the disease.  
 In recent years, protein-coding gene expression profiles have been used to 
improve breast cancer classification allowing to identify at least five subtypes of 
invasive ductal carcinoma that constitute approximately 80% of all breast cancers: 
Luminal A and Luminal B (both estrogen receptor positive, ER+); Basal (ER-); ERBB2 
(HER2 overexpressing); and normal-like [Sorlie et al, 2001]. Specific clinical features, 
responses to treatment and prognosis have been observed to correspond to the various 
subgroups in agreement with the concept that breast cancer is not a single disease. 
Furthermore, the expression of certain gene sets, defined as “signatures”, appeared to 
have a prognostic and/or predictive role for patients [Sotiriou & Piccart, 2007]. 
Interestingly, microarray expression profiling of the tumor-associated stroma derived 
from breast cancer patients reveals characteristic expression signatures associated with 
metastatic outcome demonstrating the critical roles of stromal cells in enabling the 
malignant behavior of carcinoma cells [Finak et al., 2008]. 
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 Recently many studies have demonstrated the central role of microRNAs 
(miRNAs) in the establishment and progression of human tumors. A pioneering 
investigation for miRNA levels in human tumors showed that miRNA expression, 
which is globally downregulated in tumours compared to normal tissues, could classify 
human cancers more accurately than mRNA expression profiles, according to 
developmental lineage and differentiation status [Lu et al., 2005]. 
 
1.2 miRNA definition, biogenesis and mechanism of action 
 miRNAs are a class of small non-coding RNAs (~22 nucleotides (nt) in length) 
that negatively regulate protein-coding gene expression post-transcriptionally by 
targeting mRNAs, mostly at the 3′ untranslated region (3′-UTR), and triggering either 
translational repression or RNA degradation [Bartel, 2004; Bartel, 2009]. MicroRNA 
genes represent approximately 1% of the genome of different species, and each of them 
has hundreds of different conserved or non-conserved targets. It has been estimated that 
about 30% of the genes are regulated by at least one microRNA. According to their 
genomic localization, microRNAs can be classified in: exonic microRNAs located in 
non-coding transcripts, intronic microRNAs located in non coding transcripts, and 
intronic microRNA located in protein-coding trancripts [Kim & Nam, 2006]. 
 MicroRNAs are transcribed, by RNA polymerase II, as long primary transcripts 
characterized by hairpin structures (pri-microRNAs) and containing typical mRNA 
features such as cap structures and poly(A) tail. The pri-microRNAs are processed in 
the nucleus by RNAse III enzyme, Drosha, and the double-stranded-RNA-binding 
protein, Pasha, into 70-100-nucleotide pre-miRNAs, which fold into imperfect stem-
loop structures. These nucleotide hairpin pre-miRNA precursors are exported into the 
cytoplasm by the RAN GTP-dependent transporter exportin5 and undergo further 
processing by another RNAse III enzyme, Dicer, which leads to the formation of a 22-
nucleotide miRNA duplex that is incorporated into the multiprotein/RNA complex 
called "Multiprotein RNA-Induced-Silencing Complex" (RISC) (Figure 2) [Kim et al., 
2009]. According to thermodynamic properties, one strand of the duplex, named 
miRNA* species (star miRNA; many publications refer to the two strand pair as 
miRNA-3p/miRNA-5p, referring to the direction of the functional miRNA), gets 
degraded whereas the other strand represents the mature miRNA and negatively 
regulates its target genes through partial complementarity (2-8 nt, “seed region”) to the 
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3’-UTR [Filipowicz et al., 2008]. However increasing evidence points to essential roles 
for star-microRNAs (miRNA*), which are usually expressed at much lower levels 
respect to mature miRNAs [Bhayani et al., 2012; Mah et al., 2010]. 
 
 
Figure 2. Biogenesis and mechanism of action of miRNAs. (Reprinted from Winter et al., 
2009) 
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1.3 miRNAs biological role and expression 
 miRNAs have a primary impact on animal development and clearly animals 
cannot live without miRNAs [Alvarez-Garcia & Miska, 2005]. MicroRNAs are further 
implicated in a variety of important biological processes including differentiation 
[Landgraf et al., 2007], apoptosis [Leonardo et al., 2012], fat metabolism [Poy et al., 
2007], viral infection [Stern-Ginossar et al., 2007] and pathological processes, such as 
tumorigenesis [Voorhoeve & Agami, 2006; Wiemer, 2007; Cho, 2007; Zhang et al., 
2007; Hammond, 2007]. Since a single miRNA can pleiotropically influence the 
expression of multiple genes, miRNAs have obvious diagnostic value, as showed for 
tumour classification [Calin et al., 2005; Subramanian et al., 2008]. The first evidence 
of the involvement of miRNAs in human cancer derives from analysis of the 13q14 
deletion in human chronic lymphocytic leukemia (CLL) which revealed that the only 
genes present within the deleted region where two miRNAs, miR-15a and miR-16-1. 
The same genes were found to be down regulated in 50% to 60% of human CLL [Calin 
et al., 2002]. 
 The first study describing a microRNA signature of breast carcinoma was 
published in 2005. The authors have identified 13 microRNAs able to discriminate 
tumors and normal tissues with an accuracy of 100%. Recent studies demonstrated that 
breast cancers can be classified into specific tumor pathological phenotypes (ER, PR, 
proliferation, stage, metastasis, ERBB2) as well as subtypes (Luminal A or B, Basal-
like, ERBB2+ and Normal-like) based on their miRNA expression profiles [Blenkiron 
et al., 2007; Enerly et al., 2011]. Thus, it seems essential to combine miRNA and 
protein-coding gene expression analyses to obtain information for prognosis and cancer 
treatment. 
 microRNAs, recently named “metastamiRs”, have been demonstrated to have a 
crucial role not only in controlling the primary tumor growth by regulating pathways 
involved in cell cycle and proliferation, but also to be determinant in modulating 
migration, invasion and the interaction with the microenvironment, mechanisms related 
to the acquisition of a more aggressive phenotype and promoting the onset of the 
metastatic process [Hurst et al., 2009].  
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1.4 microRNAs and the Invasion-Metastasis Cascade in breast cancer 
 Metastases are characterized by a series of successive cell-biology events, which 
are collectively named the invasion-metastasis cascade. During this process epithelial 
cells in primary tumors: 1) invade locally through surrounding extracellular matrix 
(ECM), 2) enter into the lumina of blood vessels (intravasation), 3) disseminate 
systematically by surviving transport through the blood circulation, 4) arrest at distant 
organ sites, 5) exit the vessel lumina and enter into the parenchyma of distant tissues 
(extravasation), 6) survive in these foreign microenvironments in order to form 
micrometastases, and 7) reinitiate their proliferative programs at metastatic sites 
generating macroscopic and clinically detectable neoplastic formations (metastatic 
colonization) [Valastyan & Weinberg, 2011]. 
 
1) Local invasion: 
 Local invasiveness is the first step in the metastatic process allowing tumor 
cells, previously well encapsulated in primary tumors, to escape these confines and to 
invade the surrounding stroma and adjacent normal tissue parenchyma. So, cancer cells 
have to breach the basement membrane (BM), a specialized ECM that provides a 
physical barrier between the epithelial and stroma compartments of various tissues (see 
Figure 1). After the degradation of BM by matrix metalloproteinases (MMP) whose 
actions are frequently hyper-activated during the malignant progression, cancer cells 
can invade the stroma as cohesive multicellular units (“collective invasion”) or as 
individual cells via two different programs known as “mesenchymal invasion” and 
“amoeboid invasion” [Valastyan & Weinberg, 2011]. Interestingly, an important 
property of breast cancer cells is represented by the dynamic plasticity to interconvert 
between above described invasion programs. 
 Numerous miRNAs have been found to affect the local invasiveness of breast 
cancer cells. For example miR-10b promotes the invasion via suppression of its target 
HoxD10 and the consequent upregulation of RhoC activity [Valastyan, 2012]. MiR-31 
inhibits breast cancer invasion via concomitant suppression of key effectors of both 
mesenchymal (such as integrin α5) and amoeboid (such as RhoA) invasion programs 
[Valastyan et al., 2009]. MiR-21 is able to inhibit the expression of the MMP antagonist 
tissue inhibitor of metalloproteinase-3 (TIMP3) enhancing the invasive potential of 
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breast cancer cells [Song et al., 2010]. Conversely, miR-29b can suppress invasiveness 
through the inhibition of MMP2 expression, while miR-31 can post-transcriptionally 
suppress MMP16 levels [Valastyan et al., 2009].  
 In order to proceed in the process of stromal invasiveness, cancer cells have 
acquired a cell-biological program known as epithelial mesenchymal transition (EMT), 
which involves dissolution of adherent and tight junctions and a loss of cell polarity, 
dissociates the cells within epithelial cell sheets into individual cells that exhibit 
multiple mesenchymal attributes, including a great invasiveness. Recently, it has been 
demonstrated that the miR-200 family regulate EMT programs. MiR-200 members 
promote an epithelial phenotype suppressing the expression of the ZEB1 and ZEB2 
transcription factors, which organize entrance into a mesenchymal state. Acting in the 
opposite direction, ZEB1 and ZEB2 are also able to transcriptionally repress miR-200 
family members, thereby establishing a double-negative-feedback loop that maintains 
cells into either the epithelial or mesenchymal state [Thiery et al., 2009, Korpal & 
Kang, 2008]. In addition to the miR-200 family, other miRNAs have been found to 
control the EMT, such as the E-cadherin-targeting miR-9 and the ZEB1- and ZEB2 
suppressing miR-205 [Valastyan, 2012]. Furthermore, miR-103/107 family promotes 
the EMT by suppressing Dicer expression and so dampening the activity of miR-200 
family miRNAs [Martello et al., 2010]. 
 
2) Intravasation: 
 The term intravasation describes the cellular events that allow locally invasive 
cancer cells to enter into the lumina of lymphatic or blood vessels. The hematogenous 
circulation appears to represent the major mechanism by which metastatic carcinoma 
cells disperse systematically [Valastyan & Weinberg, 2011]. The mechanics of 
intravasation are likely to be strongly influenced by the structural features of tumor-
associated blood vessels. In fact, cancer-associated vessels are tortuous, leaky, and 
continuously in a state of reconfiguration. The weak interactions between the 
endothelial cells of tumor-associated microvessels are likely to facilitate intravasation. 
 Currently, only miR-21 is known to promote intravasation, at least in vitro 
assays, controlling the expression of the programmed cell death-4 (PDCD4). There 
some evidences that miR-9 expression leads to the activation of vascular endothelial 
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growth factor (VEGF) signaling, whereas miR-205 antagonizes VEGF-mediated 
transduction events [Valastyan, 2012]. 
 
3) Survival in the circulation: 
 Once tumor cells have successfully intravasated into the lumina of blood vessels, 
they are able to disseminate widely through the venous and arterial circulation. 
Circulating tumor cells (CTC) must survive a variety of stresses in order to reach distant 
organ sites. For example, in the absence of cellular adhesion to ECM components, 
epithelial cells are susceptible to a form of apoptotic cell death known as anoikis. 
Furthermore, CTCs are subjected to the damage caused by hemodynamic shear forces 
and predation by cells of the innate immune system, specifically natural killer cells 
[Valastyan & Weinberg, 2011]. 
 There are some evidences that miRNAs play an important role in regulating the 
capacity of CTCs to survive through the vasculature. For example miR31 triggers 
anoikis responses by the suppression of ITGA5, RDX and RhoA and similarly miR-7 
controls the expression of EGFR [Webster et al., 2009]. Also miR-155, that is a well-
characterized controller of immune system responsiveness, could be important in 
facilitating the dissemination of tumor cells in the systemic circulation [Tili et al., 
2009]. 
 
4) Arrest at distant organ site: 
 Two alternative models have been proposed to explain how circulating tumor 
cells decide where to arrest. According to the first model, this arrest is due to the layout 
of the vasculature and size restrictions imposed by blood vessel diameters. In contrast, 
the second model considers that CTCs are able to recognize particular distant organ 
sites thanks to specific ligand-receptor interactions [Valastyan & Weinberg, 2011]. 
 At present, not a single miRNA has yet been described to influence the capacity 
of CTCs to lodge in the microvessels of distant organ sites. 
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5) Extravasation: 
 The term extravasation is defined as the escape of tumor cells from the vessel 
lumina into the tissue parenchyma of a distant organ. Recently, Taverna’s group has 
elucidated the role of miR-214 during the extravasation step modulating the expression 
of integrin α3 (ITGA3) and the transcription factor AP2 gamma (TFAP2C) [Penna et 
al., 2011]. A recent study has also demonstrated the involvement of miR-31 in the 
extravasation process by modulating the expression of ITGA5 and RhoA [Valastyan et 
al., 2009]. 
 
6) Micrometastasis formation: 
 In order to produce micrometastases, extravasated tumor cells have to survive in 
the new microenvironment that they found in the parenchyma of distant tissues but this 
microenvironment is very different from that present in the site of primary tumor 
formation. Indeed, cancer cells must rapidly adapt to this new stroma in order to survive 
and to produce a new neoplastic formation. 
 MiRNAs play a fundamental role in controlling the initial survival of cancer 
cells in the parenchyma of a distant organ. For example the miR-15/16 and miR-34 
families modulate the expression of the anti-apoptotic factor B-cell lymphoma-2 (Bcl-2) 
suppressing aggressive cell behavior. 
 
7) Metastatic colonization: 
 This process is characterized by the initial survival of disseminated cancer cells 
as micrometastases and their capacity to generate macroscopic metastatic formations. 
Metastatic colonization represents a highly organ-specific process that is mainly 
dependent on the particular microenvironmental context of the distant organ site that the 
disseminated tumor cells are colonized. Definitely, the metastatic colonization 
represents the rate-limiting step of the invasion-metastasis cascade because only 
subpopulations of the neoplastic cells, present within a tumor, possess a self-renewal 
capability [Valastyan & Weinberg, 2011]. 
 Several miRNAs have been implicated in the regulation of metastatic 
colonization. For example, it has been demonstrated the anti-metastatic role of miR-31 
in breast cancer by modulating the expression of ITGA5 and RDX that are genes 
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involved in cell survival and proliferation [Valastyan et al., 2009]. Similarly, miR-126 
arrests the metastatic colonization of breast tumor cells in lung and bone by the 
disruption of recruitment of endothelial cells to metastatic nodules and the consequent 
inhibition of neo-angiogenesis process [Png et al., 2011]. Furthermore, there are various 
evidences that the miR-200 family opposes self-renewal in breast cancer cells via the 
suppression of EMT-controlling transcription factors ZEB1 and ZEB2, but also through 
modulation of BMI1, Sox2 and Klf4. However, other studies have demonstrated that 
miR-200 family is able to promote metastatic colonization by the suppression of Sec23a 
[Valastyan, 2012].  
 
1.5 Therapeutical role of miRNAs 
 An important consideration in the design of antimetastatic agents is that cancer 
patients frequently have already significant numbers of disseminated tumor cells, at the 
diagnosis, in their blood, bone marrow and distant organ sites. Indeed, an effective 
tumor therapy have to be able of impairing the proliferation and survival of already 
disseminated cancer cells rather than only trying to block the escape of these cells from 
primary tumors [Braun et al., 2005; Pantel et al., 2008, Valastyan & Weinberg, 2011]. 
 For this reason therapeutic agents directed against miRNAs that solely impact 
initial dissemination events, such as miR-10b antagonists, will only have modest effects 
on patient outcome respect to agents targeting miRNAs involved in the metastatic 
colonization [Ma et al., 2010]. In fact, recent studies have demonstrated that 
reactivation of miR-31, which is involved in breast tumor dissemination, leads to a 
marked metastatic regression in mice. Similarly, reintroduction of miR-15a/16–1 
induces apoptosis in leukemic MEG01 cells and inhibits tumor growth in vivo in a 
xenograft model [Calin et al., 2008], whereas the inhibition of oncogenic miR-21 with 
antisense oligonucleotides generates a pro-apoptotic and antiproliferative response in 
vitro in different cellular models, and reduces tumor development and metastatic 
potential in vivo [Si et al., 2007]. Furthermore, microRNAs could also alter the 
sensitivity to radiotherapy, as recently reported by Slack’s group [Weidhaas et al., 
2007] that used anti-miR-34 as a radiosensitizing agent in p53-mutant breast cancer.  
 These pre-clinical studies are definitely interesting, but effective delivery and 
stability into target tissues remains a major technical problem for microRNA-based 
therapy, including the applications of antagomirs and synthetic microRNA duplexes. 
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Fortunately, a number of recent technological advances have improve the delivery of 
relatively stable species of miRNA therapeutical agents, such as chemically modified 
antimiR oligonucleotides (AMOs), locked nucleic acid (LNA)-oligonucleotides and 
microRNA sponges, via the bloodstream of mammals [Iorio et al., 2011]. 
 
1.6 Aim of this work 
 In our work, we investigated the relationship between altered miRNA expression 
and breast cancer metastasis by analyzing miRNA levels in a cohort of patients 
characterized by different disease relapse. We identified a signature of 16 miRNAs that 
is able to discriminate patients with bad prognosis (Relapse positive) respect to patients 
with a better clinical outcome (Relapse negative).  
 Among the deregulated miRNAs, miR-148b, down-regulated in more aggressive 
breast tumors, was able to predict survival per se and to coordinate tumor cell growth 
and progression as well as chemotherapy-induced apoptosis via a novel pathway 
involving over 130 genes such as the adhesion receptor ITGA5 and its downstream 
players ROCK1, PIK3CA/p110alpha, NRAS as well as CSF1. Among them ITGA5, 
ROCK1, PIK3CA/p110alpha and CSF1 were found to be direct targets of miR-148b. 
Our findings underline the relevance of the identified relapse-signature for patient 
prognosis and suggest a critical role for miR-148b in breast cancer progression.  
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2. MATERIALS & METHODS 
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2.1 Cell culture 
 Human MDAMB231, 4175 TGL [Minn et al., 2005], MCF7, T47D and mouse 
4T1, cells were maintained in standard conditions: Dulbecco's Modified Eagle's 
Medium containing 10 mM Glutamax and 4.5 g/mL glucose (DMEM Glutamax™, 
GIBCO Invitrogen Life Technologies, Carlsbad, CA), supplemented with 10% heat-
inactivated FCS (Biochrom AG, Berlin, DE), 1 mM sodium pyruvate, 25 mM HEPES 
pH 7.4 and 100 mg/mL gentamycin (all from GIBCO Life Technologies, Carlsbad, 
CA). 
 
2.2 Patients and Samples 
 77 frozen tumor specimens were selected from the Tumor Bank of the 
Department of Obstetrics and Gynecology, University of Turin, obtained from patients 
who underwent primary surgical treatment between 1988 and 2001 at a median age of 
54 years (25-82 age). Eligibility criteria were the following: diagnosis of invasive breast 
cancer, all T and N stages, no distant metastasis at diagnosis (M0), complete clinical-
pathological data and updated follow up for at least 72 months and up to 100 months. 
All patients were treated with radical modified mastectomy or quadrantectomy and 
axillary dissection plus breast irradiation. High-risk node-negative and node-positive 
patients received adjuvant treatments (generally 6 cycles of CMF, 600 mg/m2 
cyclophosphamide, 40 mg/m2 Metotrexate, 600 mg/m2 5-Fluorouracil) and/or 20 mg 
tamoxifen daily for 5 years in ER+ cases. Patient stage distribution was assessed as 
prescribed by the Union for International Cancer Control (UICC) clinical staging 
guidelines, and tumor grading was performed as described previously [Simpson et al., 
2000]. As normal breast controls 17 frozen mammoplastic reductions were included in 
the screening (provided from dr. C. Brisken, EPFL, Lausanne, Switzerland). 
Appropriate ethical approval was obtained for this study. 
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2.3 Reagents and antibodies 
miR precursors and inhibitors: 
Pre-miR miRNA Precursor Molecules–Negative Control 1, miRNA precursors hsa-
miR-148b (PM10264) and hsa-miR-214 (PM12124). Anti-miR miRNA Inhibitor–
Negative Control 1, and miRNA inhibitor hsa-miR-148b (AM10264) were from 
Ambion (Austin, TX, USA). 
 
miR detection: 
TaqMan miRNA assays: hsa-miR-148b (ID: 000471), hsa-miR-187 (ID: 000487), hsa-
miR-365 (ID: 001020), hsa-miR-10a (ID: 000387), has-miR-19a (ID: 000395), hsa-
miR-342-3p (ID: 002260), hsa-miR-214 (ID: 002306), hsa-RNU44 (ID: 001094), and 
U6 snRNA (ID: 001973) were from Applied Biosystems (Foster City, CA, USA). 
 
Extracellular matrix (ECM): 
Collagen IV and fibronectin were from Sigma-Aldrich (St. Louis, MO, USA). 
 
Apoptosis reagents: 
FITC-conjugated annexin V was provided by Boehringer Mannheim (Indianapolis, IN, 
USA). PE-conjugated annexin V was provided by BD Biosciences (Bedford, MA, 
USA). Tetramethylrhodamine methyl ester (TMRM) was provided by Molecular Probes 
(Invitrogen, Life Technologies). Paclitaxel (Onco-Tain brand) was from Mayne Pharma 
(Melbourne, Australia), cisplatin was from Ebewe Italia Srl. (Rome, Italy), and 
doxorubicin was from Sigma-Aldrich. 
 
RNAi: 
si-ITGA5 (Hs_ITGA5_5 siRNA) and All Stars Negative Control siRNA were 
purchased from Qiagen (Stanford, CA, USA). 
 
Primary antibodies: 
Anti-N-RAS mAb F155, anti-hsp90 mAb F-8, anti-ROCK1 pAb H-85, and anti-actin 
pAb I-19 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PIK3CA 
(4255) was from Cell Signaling Technology (Danvers, MA, USA). Anti-ITGA5 pAb 
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RM10 was kindly provided by G. Tarone (University of Torino, Turin, Italy) [Tarone et 
al., 1993]. Anti-CSF1 mAb M01-1A9 was from Abnova (Taipei, Taiwan), and anti-α-
tubulin mAb B5-1-2 was from Sigma-Aldrich. 
 
Secondary antibodies: 
Goat anti-mouse and goat anti-rabbit HRP-conjugated IgG were from Santa Cruz 
Biotechnology. All antibodies were used at the producer’s suggested concentrations. 
Matrigel used for in vivo tumor growth experiments (BD Matrigel Basement Membrane 
Matrix High Concentration) was from BD Biosciences. 
 
Primers: 
RT-PCR assays (Qiagen) employed in this study are listed in Table 1. Cloning 
oligonucleotides employed in this study are listed in Supplemental Table 1.  
 
QuantiTect	  Primer	  ID	   Assay	  ID	  	  
COPZ1 QT00087024 
CSF1   QT00035224 
CTSA   QT00087381 
CXCL5   QT00203686 
DYRK2   QT01011073 
GRB2   QT00065289 
ITGA5   QT00080871 
MMP15   QT00014063 
NRAS   QT00076874 
NRP1  QT00023009 
PIK3CA   QT00014861  
ROCK1   QT00034972 
RRN18S  QT00199367 
 
Table 1. RT-PCR assays employed in this study 
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2.4 Plasmid Construction and lentiviral infections 
 Luciferase reporter vectors containing the partial 3’-UTR of the indicated 
miR-148b target genes were generated following PCR amplification of the 3’-UTR 
from human cDNA and cloned into the Firefly Luciferase reporter pMIR-ReportTM 
vector (Ambion, Life Technologies). When indicated the 3’-UTRs were mutagenized at 
the miR-148b recognition site/s using the QuickChange Site- Directed Mutagenesis kit 
(Stratagene, Agilent Technologies) according to the manufacturer’s instructions. miR-
148b-sensor was obtained by annealing, purifying and cloning short oligonucleotides 
containing three perfect miR-148b binding sites into the SpeI and HindIII sites of the 
pMIR-ReportTM vector. 
 The human pre-miR-148b sequence (a 306 bp fragment containing the pre-miR 
sequence) was amplified from genomic DNA, extracted from MDAMB231 cells, and 
cloned  into pLemiR-tRFP (Open Biosystems) vector to obtain pLemiR-148b (still 
containing tRFP) vector. The human pre-miR-187 sequence (a 251 bp fragment 
containing the pre-miR sequence) was amplified from genomic DNA, extracted from 
MDAMB231 cells, and cloned into pWPT (AddGene) vector to obtain pWPT-miR-187 
vector. Stable cell lines were generated by lentiviral infection. Lentiviruses were 
produced by calcium phosphate transfection of 293T cells with 20 µg of specific vector 
together with 15 µg packaging (pCMVdR8.74) and 6 µg envelope (pMD2.G-VSVG) 
plasmids in, according to Trono’s lab protocol (http://tronolab.epfl.ch). Supernatant was 
harvested 48h post-transfection, filtered with 0.45 µm filters, diluted and used to infect 
3.5 x 105 cells in 6-well plates, in presence of 8 µg/mL Polybrene (Sigma-Aldrich). 
 ITGA5 overexepression was obtained by transfecting pEGFP-N3-ITGA5 
expression vector (plasmid 15238, AddGene) [Laukaitis et al., 2001]. 
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2.5 Total RNA isolation from tissues or cells 
 After surgical removal, tumor samples were macro-dissected by pathologists, 
quickly frozen and stored at –80°C. Total RNA was isolated with Concert Cytoplasmic 
RNA Reagent (Invitrogen, Life Technologies) from 20 to 50 mg tumor tissues, 
according to the manufacturer's guidelines. Frozen tumors were placed in this reagent 
and homogenized using a ball mill (MM200, Retsch, Dusseldorf, Germany). The 
suspension was centrifuged at 14,000 x g for 5 min at 4°C, then lysed with 0.1 ml of 
10% SDS followed by 0.3 ml of 5M Sodium chloride and 0.2 ml of chloroform per ml 
of reagent. The lysate was centrifuged at 14,000 x g for 15 min at 4°C and the upper 
aqueous phase was removed and combined with 0.8 volume of isopropyl alcohol for 10 
min at room temperature. The total RNA was recovered by centrifugation washed with 
75% ethanol and finally dissolved in RNAse-free water.  
 Total RNA from normal samples or cells in culture was isolated with TRIzol® 
Reagent (Invitrogen Life Technologies). Each frozen tissue sample was homogenized in 
the denaturing lysis solution using an ULTRA TURRAX® T50 Basic homogenizer 
(IKA) followed by acid-phenol:chloroform extraction according to the manufacturer's 
guidelines. 
 RNA quantitation was performed using the NanoDrop-1000 spectrophotometer 
(Nanodrop, Wilmington, DE, USA). Total RNA integrity and the content of miRNAs 
(percentage, %) in each sample were assessed by capillary electrophoresis using the 
Agilent Bioanalyzer 2100 with the RNA 6.000 Nano and the Small RNA Nano 
LabChips respectively (Agilent Technologies, Palo Alto, CA, USA). Only total RNA 
samples with an RNA Integrity Number (R.I.N.) ≥ 6 and the miR percentage < 30% 
were used for miRNA microarray analysis. 
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2.6 miRNA and gene expression profiles 
 miRNA expression profiles were carried out using the “Human microRNA 
Microarray kit (V2)” (Agilent Technologies), that allows the detection of 723 known 
human (miRBase v.10.1) and 76 human viral miRNAs. Each slide contains eight 
individual microarrays, with ~15.000 features each, including 48 negative controls, used 
to estimate fluorescence background and background variance. Each miR was targeted 
by 16-20 array-probes of different sizes. Total RNA (200 ng) was labeled with pCp 
Cy3, according to the Agilent’s protocol and unincorporated dyes were removed with 
MicroBioSpin6 columns (BioRad, Hercules, CA) [Wang et al., 2007]. Probes were 
hybridized at 55°C for 22 hours using the Agilent's hybridization oven that is suited for 
bubble-mixing and microarray hybridization processes. Slides were washed by Agilent 
Gene expression wash buffer 1 and 2 and scanned using an Agilent microarray scanner 
(model G2565CA) at 100% and 5% sensitivity settings. 
 Gene expression profiling was performed with the “Whole Human Genome 
Oligo Microarray” (Agilent Technologies) consisting of ~41.000 (60-mer) 
oligonucleotide probes, which span conserved exons across the transcripts of the 
targeted full-length genes. Each slide contains four individual microarrays, each with 
about 44.000 features. 800 ng of total RNA were labeled with “Agilent One-Color 
Microarray-Based Gene Expression protocol” according to the manufacturer’s 
instructions. The synthesized cDNA was transcribed into cRNA and labeled with 
cyanine 3-labelled nucleotide. Labeled cRNA was purified with RNeasy Mini columns 
(Qiagen). The quality of each cRNA sample was verified by total yield and specificity 
calculated with NanoDrop ND-1000 spectrophotometer measurements (Nanodrop). 
1.65 µg of labeled cRNA were used in each reaction and the hybridization was carried 
out at 65°C for 17 hours in an hybridization oven rotator (Agilent Technologies). The 
arrays were washed by Agilent Gene expression washing buffers and Stabilization and 
Drying Solution as suggest by the supplier. Slides were scanned on an Agilent 
microarray scanner. 
 Agilent Feature Extraction software version 10.5.1.1 was used for image 
analysis of both miRNA and gene expression arrays. Raw miRNA and gene expression 
data are available in the U.S. National Center for Biotechnology Information Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) database with the 
Accession N. GSE26666. 
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2.7 Statistical analysis 
2.7.1 Statistical analysis of miRNA and gene expression data 
 Inter-array normalization of expression levels was performed with cyclic 
Lowess for miR experiments and with quantile for gene expression profilings [Bolstad 
et al., 2003; Risso et al., 2009] in order to correct possible experimental distortions. 
Normalization function was applied to expression data of all experiments and then 
values of spot replicates within arrays were averaged. Furthermore, Feature Extraction 
Software provides spot quality measures in order to evaluate the quality and the 
reliability of the hybridization. In particular, flag "glsFound" (set to 1 if the spot has an 
intensity value significantly different from the local background, 0 otherwise) was used 
to filter out unreliable probes: flag equal to 0 will be noted as "not available (NA)". So, 
in order to make more robust and unbiased statistical analyses, probes with a high 
proportion of NA values were removed from the dataset. 40% of NA was used as 
threshold in the filtering process, obtaining a total of 237 available human miRNAs and 
31.315 available human genes. 
 Principal Component Analysis (PCA), cluster analysis and profile similarity 
searches were performed with Multi Experiment Viewer version 4.5.1 (tMev) of the 
TM4 Microarray Software Suite [Saeed et al., 2006]. To perform differential gene 
expression analysis the level of each miRNA was calculated as log2 (tumor 
sample/mammoplastic reduction median). The identification of differentially expressed 
genes and miRNAs was performed with two class-Significance Analysis of Microarray 
(SAM) algorithm [Tibshirani et al., 2002] with default settings. SAM uses a 
permutation-based multiple testing algorithm and identifies significant genes and 
miRNA with variable false discovery rates (FDR). This can be manually adjusted to 
include a reasonable number of candidate genes with acceptable and well-defined error 
probabilities. All heath maps were obtained by tMeV software using an unsupervised 
two-dimensional hierarchical clustering approach with average linkage method and 
Pearson correlation. 
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2.7.2 Statistical analyses of biological samples 
 Data are presented as means ± SEM or SD, and 2-tailed Student’s t test was used 
for comparison analysis, with value of P < 0.05 considered to be statistically significant. 
Box and whisker plots were prepared based on Liu (2008). The bottom and top of the 
box are, respectively, the first (bottom) and third (top) quartile; the line in the middle 
corresponds to the median, and circles label outliers. 
 
2.7.3 Statistics for survival analysis 
 In collaboration with dr. P. Provero (MBC, University of Turin), survival 
association analyses were performed using the SPSS 18.0 statistical software (SPSS 
Inc.) and the Bioconductor suite of software tools (http://www.bioconductor.org). The 
receiver operating characteristic (ROC) method [Zweig & Campbell, 1993] was used to 
categorize samples according to miRNA or mRNA expression. Kaplan-Meier survival 
curves were used to estimate time-to-event models in the presence of censored cases. 
Risk differences between the two groups were assessed using the Mantel-Haenszel log-
rank test [Mantel, 1966]. 
 Survival analysis was carried out in both univariate and multivariate setting 
using Cox’s proportional hazard model [Gill, 1982]. ITGA5 survival association was 
evaluated in GSE2034 [Wang et al., 2005]; gene expression values were calculated as 
described previously [Damasco et al., 2011], and results were divided into two 
categories according to gene expression levels. 
 
2.7.4 Analysis of human breast cancer data sets 
 Blenkiron (2007) and Enerly (2011) miR expression values and sample 
phenodata were obtained respectively from GSE7842 and GSE19536 (GEO database, 
NCBI) and from the supplementary materials of these publications. 
 
2.8 Target Prediction and Pathway Analysis 
 The TargetScan 5.1 algorithm [Lewis et al., 2005] was used to predict miR 
targets. The Ingenuity Pathways Knowledge Base (http://www.ingenuity.com/) is 
currently the world’s largest database of knowledge on biological networks, with 
annotations organized by experts. We exploited this database to look for enrichments in 
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specific pathways among the relapse (or other categories) associated miRNA putative 
targets. The negative Log10 of the P-value indicates enrichment significance in 
pathways analysis. The P-value is calculated with the right-tailed Fisher’s Exact Test. 
Ingenuity networks are scored based on the number of Network Eligible Molecules they 
contain. The network Score is based on the hypergeometric distribution and is 
calculated with the right-tailed Fisher's Exact Test. The score is the negative log of this 
P-value. 
 
2.9 qRT-PCR for miRNA or mRNA detection 
 miRNA microarray result validations and miRNA detection for in vitro 
experiments were performed by the TaqMan® miRNA Assay kit (Applied Biosystems) 
[Chen et al., 2005]. Briefly, each RT reaction (15 µl) contained 10 ng of total purified 
RNA, 5X stem-loops RT primer, 1X RT buffer, 0.25 mM each of dNTPs, 50U 
MultiScribe™ reverse transcriptase and 3.8U RNAse inhibitor. The reactions were 
incubated in a Thermal Cycler (Applied Biosystems) in 0.2 ml PCR tubes for 30 min at 
16°C, 30 min at 42°C, followed by 5 min at 85°C, and then held at 4°C. The resulting 
cDNA was quantitatively amplified in 40 cycles on an ABI 7500 Real-Time PCR 
System, using TaqMan Universal PCR Master Mix and Taqman MicroRNA Assays. 
For each real-time PCR reaction three replicates of each sample and endogenous control 
were amplified. 
 For mRNA detection, 1 µg of DNAse-treated RNA (DNA-free™ kit, Ambion) 
was retrotranscribed with RETROscript™ reagents (Ambion, Austin, TX) and qRT-
PCRs were carried out using gene-specific primers, by a 7900HT Fast Real Time PCR 
System (standard settings) at the Molecular Biotechnology Centre (University of 
Torino). 
 As endogenous normalizers of the expression, RNU44 small nucleolar RNA or 
of 18S ribosomal RNA were chosen for miRNA or mRNA detection, respectively. The 
relative expression levels between samples were calculated using the comparative delta 
Ct (threshold cycle number) method (2-ΔΔCt) [Livak & Schmittgen, 2001]. In the case of 
tumor samples, the median expression for miRNA or mRNA was used across samples 
as calibrator; while for cell lines the control sample was the reference point [Bookout & 
Mangelsdorf, 2003]. 
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2.10 In vitro analysis 
2.10.1 Transient transfections of pre-miRs, anti-miRs, siRNAs or plasmids 
 To obtain transient anti-miR, pre-miR, or siRNA expression, cells were plated in 
6-well plates at 30-50% confluency and transfected 24h later using RNAiFect 
(QIAGEN) reagent, according to manufacturer’s instructions, with 75 nM anti-miR, 40 
nM pre-miR or 100 nM siRNA. 
 For ITGA5 overexpression, 80% confluent cells were transfected with the 
pEGF-ITGA5 vector using LipofectamineTM2000 (Invitrogen Life, Technologies), 
according to manufacturer’s instructions. Cells were tested for miRNA or protein-
coding gene overexpression/knockdown 24h, 48h or 72h later. 
 
2.10.2 Invasion and transendothelial migration assays 
 To measure invasion 5x104 MDA-MB-231, 4175 TGL or 4T1 cells were seeded 
in serum-free media in the upper chambers of cell culture inserts (transwells) with 8 µm 
pore size membrane (24-well format, Becton Dickinson) pre-coated with 10µg/mL 
fibronectin, or 4 µg/well growth factor reduced Matrigel (Becton Dickinson), or in the 
upper chambers of BioCoat™ Matrigel Invasion Chambers with 8µm pore size 
membrane (Becton Dickinson, NJ). The lower chambers were filled with complete 
growth media. After 18-20 h, the migrated cells present on the lower side of the 
membrane were fixed with methanol, stained with haematoxylin and eosin (Diff-Quik, 
Medion Diagnostics) and photographed using an Olympus IX70 microscope. 
 For transendothelial migration assay 105 HUVECs-GFP were seeded in 
complete medium in the upper part of transwell inserts with 5.0 µm pore size membrane 
(24-well format, Costar, Corning) coated with fibronectin at 5 µg/cm2, and grown for 
72h, till confluence. Then, 5x104 MDAMB231 cells were labeled with CellTracker™ 
Orange CMRA (Molecular Probes, Invitrogen Life Technologies), according to the 
manufacturer’s instructions and seeded in HUVEC’s complete medium onto the 
HUVEC-GFP monolayer on the upper side of the transwell. 20h later the HUVEC-GFP 
monolayer was photographed using Zeiss Axiovert 200M microscope. Then, HUVECs 
and non transmigrated cells were removed and the red-fluorescent cells that migrated on 
the lower side of the membrane were fixed in 4% paraformaldhyde and photographed 
using Zeiss AxioObserver microscope with ApoTome Module. Invasion and 
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transendothelial migration were evaluated by measuring the area occupied by migrated 
cells using the ImageJ software [Collins, 2007]. 
 
2.10.3 Adhesion and proliferation assays 
 5x104 cells/well were seeded onto 5 µg/mL collagen IV or 10µg/mL fibronectin 
or 5 µg/mL laminin (all from Sigma-Aldrich) precoated 96-well plates, for 1h at 37°C. 
Cells were washed thoroughly to remove non-adherent cells, fixed with methanol and 
stained with haematoxylin and eosin (Diff-Quik, Medion Diagnostics). Wells were 
photographed using Olympus IX70 microscope and the area occupied by the adherent 
cell was measured by using the ImageJ software [Collins, 2007]. 
 5x103 cells/well were plated in 96-well plates in complete medium and starved 
for 24h. Complete medium was then added and cells were allowed to grow for 1, 2, 3, 4 
days, fixed with 2.5% glutaraldehyde and stained with 0.1% crystal violet. The dye was 
solubilized using 10% acetic acid and optical density measured directly in plates using a 
Microplate Reader Mithras LB940 (Berthold Technologies, GmbH) at 570 nm 
wavelength [Kueng et al., 1989]. 
 
2.10.4 Anoikis analysis and apoptosis assays 
 Cells were plated on a 2% agarose pad in serum-free medium for 48h, collected, 
washed in PBS buffer, resuspended in 10 mM Hepes, 150 mM NaCl, 5 mM CaCl2 
buffer containing FITC conjugated Annexin-V (Bender MedSystems, GmbH) and 200 
nM tetramethyl-rhodamine-methyl-7ester (TMRM, Molecular Probes, Invitrogen) and 
incubated at 37° C for 15 minutes. Flow cytometry analysis was carried out by using a 
FACS Calibur flow cytometer (Becton Dickinson). Data acquisition was performed 
using CellQuest software (Becton Dickinson) and data analysis with WinMDI software 
(version 2.8, Scripps Institute, CA). Results were displayed in bidimensional plots, with 
gates indicating the percentages of healthy and apoptotic populations [Rasola & Geuna, 
2001]. 
 In order to trigger apoptosis, 72 h after miR transfection, cells were plated at 
45.000/cm2 density, grown in complete medium with or without Paclitaxel (PTX) 5 µM, 
Cisplatin (CDDP) 100 µM or Doxorubicin (DOXO) 1 µM for 24 or 48h. After apoptosis 
induction cells were washed once in phosphate-buffered saline (PBS) and detached by 
trypsinization. Labeling and analysis was performed as in anoikis analysis. 
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2.11 Luciferase assays 
 15x104 cells were co-transfected with 50 ng of the pMIR-Report™ (Ambion) 
Firefly Luciferase constructs containing the wild type or mutant/deleted 3’-UTRs of the 
indicated miR-148b potential target genes and 20 ng of pRL-TK Renilla Luciferase 
normalization control (Promega), using LipofectamineTM2000 (Invitrogen Life 
Technologies). Lysates were collected 48h after transfection and Firefly and Renilla 
Luciferase activities were measured with a Dual- Luciferase Reporter System (Promega, 
Madison, WI). 
 
2.12 Protein preparation and Immunoblotting 
 Total protein extracts were extracted from cultured cells or from frozen breast 
tumor specimens. A boiling buffer containing 0.125 M Tris/HCl, pH 6.8 and 2.5% 
sodium dodecyl sulphate (SDS) was used. 25 µg proteins were separated by SDS 
polyacrylamide gel electrophoresis (PAGE) and electroblotted on to polyvinylidene 
fluoride (PVDF) membranes (Bio-Rad). Membranes were blocked in 5% BSA Tris 
buffered saline (TBS)-Tween buffer (137 mM NaCl, 20 mM Tris/HCl, pH 7.6, 0.1% 
Tween-20) for 1h at 42 °C, then incubated with appropriate primary and secondary 
antibodies in 1% BSA TBS-Tween buffer, respectively overnight at 4 °C and for 1h at 
room temperature and visualized by enhanced chemiluminescence (ECL®, Amersham 
Biosciences). 
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2.11 In vivo analysis (Prof. D. Taverna) 
2.11.1 In vivo tumor and metastasis assays 
 6-weeks-old female NOD/SCID IL2Rγnull mice [Quintana et al., 2008] were 
injected in the mammary gland fat pad with 6x106 4175 TGL cells transduced with 
pLemiR-148b or pLemiR-empty vectors, expressing Turbo-Red Fluorescent Protein 
(tRFP) in 1:1 medium/matrigel (BD Biosciences). Tumor growth was monitored every 
3 days. Mice were dissected 12 days after injection and tumor weight was evaluated. 
Spontaneous metastasis formation was also evaluated in these mice, lungs were 
dissected and photographed using a Leica MZ16F fluorescence stereomicroscope; red-
fluorescent metastatic foci were analyzed in the fresh total lungs using the ImageJ 
software [Collins, 2007]. Three representative pictures of the whole lung per mouse 
were considered. 
 Total lungs were formalin-fixed, cut in small pieces and paraffin-embedded, 
sectioned and haematoxylin & eosin (H&E)-stained. Micrometastases were 
photographed on specimens, with an Olympus BH2 microscope, on at least three 
different sections. Alternatively, lung metastases formation was evaluated in 14 weeks 
old female immunocompetent BALB/c mice injected via tail vein with 5x105 4T1 cells 
either transfected with pre-miR-148b or negative controls. Lungs were dissected 5 days 
after injections, formalin-fixed, cut in small pieces and paraffin-embedded, sectioned 
and haematoxylin & eosin (H&E)-stained. For 4T1 cells, micrometastases were 
evaluated on specimens, with an Olympus BH2 microscope, on at least three different 
sections using the ImageJ software [Collins, 2007]. 
 
2.11.2 In vivo extravasation assay 
 7-weeks-old female CD1 nude mice (Charles River Laboratories, Wilmington, 
MA) were injected via tail vein with 1.6x106 MDAMB231 cells transduced with 
pLemiR-148b or pLemiR-empty vectors, previously labeled with CellTracker™ Orange 
CMRA (Molecular Probes, Invitrogen, Life Technologies) and resuspended in PBS. 2h 
or 48h later mice were sacrified and 4% paraformaldeyde was injected in the trachea. 
Total lungs were dissected and photographed using a Leica MZ16F fluorescence 
stereomicroscope and red fluorescent cells were counted 48h following injections using 
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the ImageJ software [Collins, 2007]. Lungs were included in freezing resin (OCT 
Killik, Bio-Optica, IT) and cryostat-cut in 4 µm thick sections. 
 For immunohistochemistry staining of blood vessels, samples were blocked in 
5% bovine serum albumin (Sigma-Aldrich) for 1h, incubated with anti CD31 primary 
antibody (1:100 dilution) overnight and anti-rat secondary antibody conjugated with 
biotin for 1 hour at room temperature (1:100 dilution) (Dako). Peroxidase was 
developed with DAB (ABC kit Vectastain PK-6100 from Vector Labs, Burlingame, 
CA). Specimens were examined and photographed using a Zeiss AxioObserver 
microscope with the ApoTome Module. 
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3. RESULTS 
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3.1 microRNA expression profiling in breast cancer 
 In a retrospective study, we analyzed miRNA expression in 77 primary human 
breast ductal tumors as well as 17 mammoplastic reductions (Table 3), using 
microarrays (Agilent Human miRNA Microarray V2) and a Two-class Significance 
Analysis of Microarray (SAM).  
Characteristics  N  % 
Tumor samples 
Number of patients   77   
Age (years) median range 
54   
25-82   
Tumor Stage 
1 20 26 
2 51 66.2 
3 3 3.9 
4 3 3.9 
Tumor Grade 
1 4 5.2 
2 35 45.4 
3 33 42.8 
Unknown 5 6.5 
LN  
Positive 44 57.1 
Negative 33 42.9 
ER* 
Positive 53 68.8 
Negative 24 31.2 
PR* 
Positive 42 54.5 
Negative 35 45.4 
Subtype** 
Luminal 53 68 
ERBB2** 14 18 
Basal 10 12 
Relapse (at least 72 months) 
yes 41 53.2 
   ER+ 25 61*** 
    ER -  16 39*** 
no  36 46.7 
   ER+ 28 78*** 
   ER - 8 22*** 
Normal samples 
Number of patients   17   
Age (years) median range 
43   
20-67   
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Table 3. N: number; %: percentage, LN: Lymph node status, ER: Estrogen receptor status, PR: 
Progesterone receptor status. * ER and PR are defined positive when tumors contain more than 
10 fmol of receptors/mg proteins or less than 10% positive tumor cells. **Samples were 
classified according to ERBB2 mRNA level combined to ER and PR status. ***Percentage 
refers to the total of relapsing or not relapsing samples.  
 
 In particular, when we compared patients with (Relapse, n=41) or without (No 
Relapse, n=36) disease relapse, within at least 72 months from surgery, 16 differentially 
expressed miRNAs (FDR=16%) were identified and expressed as Fold changes (FCs) 
or levels, relative to the median of the healthy controls (log2 tumors/controls) (Figure 
3A and 3B).  
 
Figure 3. Expression of 16 miRNAs in Relapse positive (+) or negative (-) primary cancers. 
(A) Clustering (Pearson correlation, average linkage) for the 16 most modulated miRNAs 
considering relapsing (n=41) versus not relapsing (n=36) tumors. The heatmap represents 
relative miRNA levels referring to the median expression across all samples; row: miRNAs; 
column: tumors. (B) Graph showing the levels of expression of the 16 most modulated miRNAs 
expressed as averaged levels (Log2) in R+ or R- tumor samples versus mammoplastic 
reductions (controls). SAM two classes, False Discovery Rate (FDR): 16%. 
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 Instead, when ER or PR positive (+) or negative (-) tumors were compared, 
respectively 29 (FDR=14%) and 56 (FDR=9.30%) differentially expressed miRNAs 
were found, as presented in Supplemental Figures S1 and S2.  
 Microarray data validation was performed by qRT-PCR analysis for miR-148b, 
miR-365, miR-10a and miR-342-3p (Figure 4) for R+/R- or ER+/ER samples (n=10 per 
group). The expression values obtained with quantitative RT-PCR for all tested 
miRNAs were in agreement with microarray results (Gene Expression Omnibus Series 
No. GSE26666). 
 
 
Figure 4. Validation of the miRNA microarray analysis results by qRT-PCR. 
miRNA expression levels were represented by box-and-whisker plots. Normalized qRT-PCR 
data were expressed as fold changes (FC) relative to the median expression for each group of 
patients. U44 RNA was used for normalization. R, relapse; ER, Estrogen Receptor; +, positive; 
-, negative. N=10 tumor samples per group. *P<0.05; **P<0.01; ***P<0.001. 
 
 By using the 16-relapse associated miRNAs together as a whole (as a group), we 
were able to identify two groups of patients with different overall (OS, P-value=0.018) 
and disease-free (DFS, P-value=0.016) survival, independently of the lymph node (LN) 
status (Cox proportional-hazards regression model, P-value=0.015) in our study. The 
same was found when certain individual specific miRNAs were used, for instance miR-
148b, downregulated in relapsing tumors (OS, P-value=0.027; DFS, P-value=0.036). 
However, a correlation with survival was not found when our 16-relapse associated 
miRNAs were used as a whole for two other available public datasets [Blenkiron et al., 
2007; Enerly et al., 2011]. These studies refer to around 100 patients each; the primary 
tumors were used to measure mRNA and miRNA expression with the goal to identify 
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tumor subtypes. Importantly, in these datasets, our group of 16-relapse associated 
miRNAs was able to identify tumor subtypes and to separate more (ERBB2+ or Basal-
like) versus less (Luminal A/B) aggressive cancers (Figure 5, compare black versus 
gray symbols), based on the breast cancer classification in Sorlie et al. (2001). 
Moreover, our 16-miRNA signature could also predict survival, in our cohort, when 
only Luminal tumors (n=53) were considered (DFS, P-value=0.0097). In conclusion, 
we identified 16-relapse associated miRNAs that could be used in the clinics to identify 
tumor subtypes and to predict disease outcome.  
 
	  	  
Figure 5. Tumor subtype identification.  
Principal Component Analysis (PCA) plots for tumor subtypes using all 16 miRNAs in 
Blenkiron et al. (2007) and Enerly et al. (2010) datasets. Basal_like: Basal; ERBB2+: ERBB2 
positive; Lum_A: Luminal A; Lum_B: Luminal B; Normal_like: normal like breast cancer. 
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3.2 The biological function of miR-148b 
 
 A detailed bioinformatics analysis was carried out for the putative targets of the 
16-relapse associated miRNAs, as predicted by TargetScan 5.1, using Ingenuity 
Pathways Analysis (IPA) in order to identify pathways and functions in which each 
miRNA was involved (Figure 6). This analysis, together with literature searches, let us 
to conclude that miR-148b has the potential to coordinate a very high number of 
pathways relevant for breast cancer and that its function has still to be elucidated.  
 
 
Figure 6. Pathway enrichment for relapse-associated or miR-148b putative targets. 
Pathway analysis was performed for relapse-associated (A) or miR-148b (B) putative targets 
using the Ingenuity Pathway Analysis Systems (http://www.ingenuity.com) and enrichments 
were accepted when P<0.05 (Fisher test). Abbreviations: CMM: Cancer Molecular 
Mechanisms; Wnt/β-cat: Wnt/β-catenin; GH: Growth Hormone; G-Prot Coup Rec: G-Protein 
Coupled Receptor; Ins Rec: Insulin Receptor; RAR Activ: RAR Activation; NANOG in SC: 
Role of NANOG in stem cell; SC Pluripotency: Stem Cell Pluripotency; G1/S Reg: G1/S 
Checkpoint Regulation; T.J: Tight Junction; HER-2 in BC: HER-2 in Breast Cancer; Myc 
Apoptosis: Myc Mediated Apoptosis; Cav Endocytosis: Caveolar-mediated Endocytosis; HBC: 
Hereditary Breast Cancer Signaling; Actin Mot Reg: Actin-based Motility Regulation; Actin 
Cyt: Actin Cytoskeleton; G2/M Reg: G2/M Checkpoint Regulation. 
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3.2.1 Analysis of miR-148b expression 
With this in mind, we investigated the biological role of miR-148b in neoplasia by 
modulating (up or down) its expression in MDAMB231, 4175 TGL, 4T1, T47D and 
MCF7 mammary tumor cell lines with a different level of malignancy (independently of 
ER, PR and ERBB2 expression) [Holliday & Speirs, 2011]. We first analyzed miR-
148b expression in several mammary epithelial cell lines (human and mouse) by qRT-
PCR. Low miR-148b expression was found in the human SKBR3, MDAMB468, 
MDAMB231 cell lines and in the mouse 4T1 mammary tumor cells. Instead, 
intermediate or high levels of expression were identified in the human HBL100, 
MCF10A, MCF12A, MCF7, T47D, MDAMB435, MDAMB453, BT474 cell lines and 
in 66cl4 mouse tumor cells (Figure 7). 
 
 
Figure 7. miR-148b expression levels in breast cancer cell lines.  
miR-148b expression was evaluated for the indicated human or mouse tumor cell lines by qRT-
PCR analysis. Results were normalized on U44 RNA levels and presented as Fold Changes 
(FC) of mean±SD relative to miR-148b expression in HBL100 cells. 
 
 On the basis of these results we decided to study the biological role of miR-148b 
in the human T47D, MCF7, MDAMB231, 4175 TGL cell lines and the mouse 4T1 cell 
in which it was easier to over-express (MDAMB231, 4175 TGL and 4T1) or down-
modulate (T47D, MCF7) miR-148b (Figure 8A). 
 Transient modulations were obtained using miR-148b precursors or inhibitors or 
negative controls (pre-miR-148b, anti-miR-148b, or pre-control or anti-control) and 
evaluated 48h or 72h post-transfection for expression and biology (Figure 8B and 8C). 
Instead, for stable expression, cells were transduced with pLemiR-empty or pLemiR-
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148b overexpressing lentivirus vectors and selected with puromycin as pools; 
expression evaluation is shown in Figure 8C.  
 
 
 
Figure 8. Analysis of miRNA expression. (A) miR-148b expression was evaluated for the 
indicated human or mouse tumor cell lines by qRT-PCR analysis. (B) qRT-PCRs were 
performed to evaluate miR-148b expression levels in MCF7 or T47D cells transiently 
transfected with miR-148b inhibitors or negative controls (anti-miR-148b or anti-control). (C) 
qRT-PCR were performed to evaluate miR-148b, miR-214 and miR-187 expression levels in 
MDAMB231, 4175 TGL or 4T1 cells transiently transfected with the indicated miR-precursors 
or negative controls (pre-miR-148b, pre-miR-214 or control) or stably transduced with pLemiR-
empty (pLemiiR-EV) or pWPTempty (pWPT-EV) or miR-148b (pLemiR-148b) or miR-187 
(pWPT-miR-187) overexpressing vectors. Results were normalized on U44 RNA levels and 
presented as Fold Changes (FC) of mean±SD relative to miR-148b expression in T47D cells (A) 
or to controls (B, C). Representative overexpressions/downmodulations are shown. 
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3.2.2 miR-148b involvement in tumor cell growth, invasion and adhesion 
In vitro proliferation was not affected or only slightly modulated up to 4 days for 
MDAMB231, 4175 TGL and 4T1 cells in stable or transient conditions (Figures 9A). 
However, tumors derived from transduced pLemiR-148b 4175 TGL cells grew 
significantly less compared to controls (pLemiR-EV) when analyzed up to 12 days 
following injection in the fat pad of immunocompromised NOD/SCID IL2Rγnull mice 
(see below). When invasion through Fibronectin or Matrigel was evaluated by transwell 
assays for the same cell lines, reduced cell movement was observed in presence of miR-
148b overexpression compared to controls (Figures 9B). However, no effect was 
observed when cells were transduced with pWPT-miR-187 (negative control) lentivirus 
overexpression vectors compared to controls (pWPT-EV or pre-control) (Figures 9B). 
Instead, increased cell invasion was observed when miR-214 was overexpressed in 
these cells (Figure 9B) such as previously demonstrated by Penna et al. (2011). 
 
 
 
Figure 9. miR-148b involvement in tumor cell growth and invasion.  
MDAMB231 or 4175 TGL or 4T1 cells transiently transfected with miR-148b or miR-214 
precursors their negative controls (pre- or control) or stably transduced with pLemiR-EV 
(empty) or pWPT-EV (empty) or pLemiR-148b or pWPT-miR-187 overexpression vectors were 
used to analyze proliferation (A) or invasion (B). Results are shown as mean±SD of the 
increased percentage (%) of proliferation, measured by optical density (OD) at 1-4 days (A) or 
as area covered by matrigel-invading (B) or adherent cells. Two or three independent 
experiments were performed in triplicate and representative results are shown. *P<0.05; 
**P<0.01; ***P<0.001. 
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 When cell adhesion was investigated, increased adhesion on fibronectin and 
collagenIV was found for MDAMB231 cells overexpressing miR-148b compared to 
controls. Conversely, downmodulation of miR-148b in MCF7 and T47D cells led to 
decreased adhesion (Figure 10).  
 
 
 
Figure 10. miR-148b involvement in tumor cell adhesion.  
MDAMB231 or MCF7 or T47D cells transiently transfected with miR-148b precursor or 
inhibitor or their negative controls (pre- and anti-miR-148b or control) were used to analyze 
adhesion on collagenIV or fibronectin. Results are shown as mean±SD of the area covered by 
adherent cells. Adhesion of miRNA-modulated cells is shown relative to controls. Two or three 
independent experiments were performed in triplicate and representative results are shown. 
*P<0.05; **P<0.01; ***P<0.001. 
 
3.2.3 miR-148b impairs metastasis formation 
 In collaboration with the Taverna’s group (MBC, University of Turin) in order 
to study the role of miR-148b in in vivo metastasis formation we injected miR-148b-
overexpressing (pre-miR-148b) 4T1 cells, in the tail vein of female BALB/c syngeneic 
mice and analyzed dissemination in lungs. A significant reduction in the number of lung 
colonies or area occupied by the lesions was found five days post-injections compared 
with controls as measured in H&E stained sections (Figure 11A). More relevantly, 
when red fuorescent pLemiR-148b-transduced 4175 TGL cells, were injected 
orthotopically in NOD/SCID IL2Rγnull mice and primary tumors formed (Figure 11B), a 
striking reduction of malignant cell dissemination from the primary tumors to the lungs 
was observed compared to controls (Figure 11B). Quantitation refers to the red 
fluorescent metastatic foci (number/area) in the lungs, 12 days post-injection (Figures 
11B) and H&E sections are shown (Figure 11B). Similar results were obtained with 
pLemiR-148b-transduced 4T1 cells (not shown). Importantly when similar experiments 
were previously performed with miR-214-overexpressing 4T1 cells, increased 
dissemination was observed (Penna et al., 2011). 
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Figure 11. miR-148b impairs metastasis formation in mice. 
A) 4T1 cells transiently transfected with miR-148b precursors or their negative controls (pre-
miR-148b or control) were used to evaluate lung colony formation in BALB/c mice, 5 days 
after tail vein injection.  
B) Alternatively 4175 TGL cells stably transduced with pLemiR-EV or pLemiR-148b 
overexpression vectors were injected in the mammary gland fat pad of NOD/SCID/IL2Rgnull 
mice and primary tumor growth as well as metastasis formation in the lungs analyzed 12 days 
post-injection. Two independent experiments were performed, results pooled together (n= 10 
mice/group) and shown as box and whisker plots for primary tumor weights (B) or number (or 
area) of microscopic colonies (A) or metastasis (B) in the lungs. Tumor cell dissemination was 
evaluated in H&E-stained sections at day 5 (A) or as fluorescent lesions in the whole lung at 
day 12 (B). Representative H&E stainings are shown. Scale bars: 60 µm (A; Bc, Bd), 2 mm 
(Ba, Bb). *P<0.05; **P<0.01; ***P<0.001. 
 
 Based on this, we assessed the involvement of miR-148b in extravasation and 
survival in the blood circulation, two essential steps of the metastatic dissemination. To 
investigate extravasation in vivo, red fluorescent pLemiR-148b transduced 
MDAMB231 cells were injected in the tail vein of immunocompromised mice and cell 
seeding/extravasation in the lung was evaluated 2h or 48h post-injection. A high 
percentage of cells lodged in the lung at 2h (within the vessels or outside) in presence or 
absence of miR-148b. However, extravasation was highly reduced for miR-148b 
overexpressing cells compared to controls, as quantitation of the area occupied by 
metastatic cells showed (Figures 12A and 12B). Vessels were labeled for CD31 in 
Figure 12C.  
 To investigate survival in the blood circulation, we evaluated apoptosis in miR-
148b-overexpressing MDAMB231 cells kept without serum and with or without 
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(anoikis) adhesion for 48h, by cytofluorimetric analyses and reduced survival was 
observed compared to controls (Figure 12C), suggesting a potential role for miR-148b 
in tumor cell intraluminal viability and initial survival. 
 
 
 
Figure 12. miR-148b impairs metastasis formation in mice by affecting extravasation and 
survival.  
A, B) In vivo seeding/extravasation assays following tail vein injections in nude mice of red 
fluorescent MDAMB231 cells, stably transduced with pLemiR-EV or pLemiR-148b 
overexpression vectors. A) Representative fields of lung sections 2h or 48h post-injections, 
stained for CD31 (black) and containing red fluorescent MDAMB231 cells. No cells were 
found in the vessels at 48h. B) Red fluorescent cells in the whole lungs 2h or 48h post-injection 
(a-d); on the right, quantitation of the red fluorescent cells (area) at 48h (c and d) for n=8 
mice/group. Scale bars:  2 mm (B), 120 µm (Ba), 30 µm (Cb).  
C) MDAMB231 cells transfected with miR-148b precursors or their negative controls (pre-
miR-148b or control) were grown in presence or absence (anoikis) of attachment and without 
serum for 48h. The percentage (%) of apoptotic cells was evaluated by TMRM and AnnexinV-
FITC stainings in a FACS analysis. HighTMRM-LowAnnexinV: healthy cells; LowTMRM-
HighAnnexinV: apoptotic cells. Three independent experiments were performed in duplicate and 
pooled quantitations are shown as mean±SEM. *P<0.05; **P<0.01; ***P<0.001. 
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 All these experiments strongly suggest that miR-148b is involved in metastatic 
cell dissemination by controlling tumor growth and cell survival in anoikis but mostly 
by inhibiting cell escaping through the endothelial cells of the vessels. 
 
3.2.4 miR-148b expression enhances chemotherapy-induced apoptosis 
 Considering the relevance of chemotherapy response for tumor progression, we 
analyzed the response to Paclitaxel, Doxorubicin, Cis-Platin following 24h or 48h-
treatment in miR-148b-overexpressing (MDAMB231, 4175 TGL, 4T1) or 
downmodulated (T47D) cells by cytofluorimetric analyses. A significant modulation in 
cell survival was found for all cell lines and treatments compared to controls (Figures 
13) favoring a positive role for miR-148b in chemotherapy response. 
 
 
 
Figure 13. miR-148b affects chemotherapy-induced apoptosis. 
MDAMB231 (A) or T47D (B) or 4T1 (C) cells transfected with miR-148b precursors or 
inhibitors or their negative controls (pre- and anti-miR-148b or control) or 4175TGL (D) cells 
stably transduced with pLemiR-EV or pLemiR-148b overexpression vectors were grown in 
complete medium with or without Paclitaxel or Doxorubicin or Cis-Platin for 24h or 48h. The 
percentage (%) of apoptotic cells was evaluated by TMRM and AnnexinV-FITC stainings in a 
FACS analysis. HighTMRM-LowAnnexinV: healthy cells; LowTMRM-HighAnnexinV: apoptotic 
cells. Three independent experiments were performed in duplicate and pooled quantitations are 
shown as mean±SEM. *P<0.05; **P<0.01; ***P<0.001. 	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3.3 Identification of miR-148b target genes 
 To identify direct or indirect miR-148b modulated genes, miR-148b 
overexpressing MDAMB231 cells were first used to perform gene expression analysis 
by microarrays. 129 differentially expressed genes (49 up-regulated and 80 down-
regulated) were found, considering a 1.5 fold change (FC) and a 16% false discovery 
rate (FDR) (Supplemental Table S2). qRT-PCR analysis was used to validate  
expression of the non-modulated NRAS, ROCK1, PI3KCA, COPZ1, GRB2, CXCL5 and 
of the differentially expressed DYRK2, CSF1, CTSA, ITGA5, MMP15, NRP1 (Figure 
14). 
 
 
Figure 14. Validation of the protein-coding microarray analysis results. 
A) MDAMB231 cells transfected with miR-148b precursors or negative controls (pre-miR-148b 
or control) were used to perform a whole-genome microarray analysis 48h post-transfection. 
Results are displayed as gene expression Fold Changes (FC) referring to controls, for 12 chosen 
proteincoding genes. B) Validations of the same 12 genes were performed by qRTPCR analysis; 
results were normalized on 18S ribosomal RNA and calculated as gene expression FC 
(mean±SD) referring to the negative controls (B); n=3; on the right: differentially expressed 
genes; on the left: no differential expression. *P<0.05; **P<0.01; ***P<0.001. 
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 By crossing these results with putative miR-148b targets (TargetScan 5.1) 
twenty common genes (19 down and 1 up) were found and are shown in Figure 15. 
Among them Integrin alpha 5 (ITGA5), known to modulate apoptosis, adhesion, 
migration/invasion [Mierke et al., 2011; Desgrosellier et al., 2010] and Colony 
stimulating factor 1 (CSF1), involved in tumor-stroma interactions [Abraham et al., 
2010; Aharinejad et al., 2004] 
 
 
 
Figure 15. Microarray analysis of miR-148b over-expressing cells 
MDAMB231 cells transfected with miR-148b precursors (pre-miR-148b or pre-control) 
analyzed 48h post-transfection were used to perform microarray analysis. Clustering (Pearson 
correlation, average linkage) was performed for 20 putative miR-148b targets. Heatmap 
represents relative gene expression referring to the median across all samples; row: protein-
coding gene; column: cell preparation.  
 
 Using TargetScan predictions for an Ingenuity Pathway Analysis (IPA) analysis, 
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Integrin pathways 
were identified as statistically significant (Figure 16). Therefore, we investigated the 
plausible direct regulation of these pathways by miR-148b and their involvement in 
breast tumor progression.  
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Figure 16. Pathway enrichments obtained using the Ingenuity Pathway Analysis Systems.  
First TargetScan 5.1 algorithm (non-conserved) was used to predict miR-148b miR targets 
(996) and then Ingenuity Pathway Analysis was performed to identify miR-148b modulated 
pathways. 63 pathways related to tumorigenesis and cancer aggressiveness were found and a 
selection of them is shown here together with the negative Log 10 of the p-value, - Log10 (P-
value) with P<0.05 (Fisher test). CMM, Cancer Molecular Mechanisms; BC, Breast Cancer. 
 
3.3.1 miR-148b modulates multiple genes of the integrin pathway 
Protein expression was evaluated for ITGA5 and its downstream players, Rho-
associated, coiled-coil containing protein kinase 1 (ROCK1), PI3-kinase p110 subunit 
alpha (PI3KCA/p110α), Neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) 
(predicted targets) and for CSF1 in miR-148b overexpressing MDAMB231 or 
4175TGL cells by Western Blot (WB) analysis and strong reductions were found 
compared to controls (Figures 17). 
 Instead, when miR-148b was downmodulated in MCF7 cells, increased levels of 
ITGA5 proteins were observed (Figure 17). Interestingly, ROCK1, PI3KCA/p110α and 
NRAS were not modulated at the mRNA level (Figure 14).  
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Figure 17. miR-148b modulates multiple genes. 
MDAMB231 or MCF7 cells transfected with miR-148b precursors or inhibitors or their 
negative controls (pre- and anti-miR-148b or pre- and anti-control) analyzed 48h post-
transfection or 4175TGL cells stably transduced with pLemiR-EV or pLemiR-148b 
overexpression vectors were used to perform Western Blot (WB) analysis for five putative miR-
148b targets, ITGA5, ROCK1, p110α (PIK3CA), NRAS and CSF1. Protein expression was 
calculated relative to controls, following miR-148b-overexpression or down-modulation, 
normalized on the indicated loading controls (hsp90/actin/atubulin) and expressed as repression 
percentages (%). Three independent experiments were performed with independent protein 
preparations and representative results are shown. 
 
 Direct modulation of miR-148b on its targets, was proven by performing 
luciferase assays in miR-148b-overexpressing or control MDAMB231 cells transfected 
with reporter vectors containing wild type or mutated 3’-UTRs (Figures 18A and B). As 
positive control, a miR-148b-sensor construct was used (Figure 18A). Importantly, 
when we evaluated miR-148b target expression on a subset of R+/R- human tumors, 
differential expression was found (Figure 18C).  
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Figure 18. Luciferase array and analysis of miR-148b modulated genes in human tumors. 
A-B) MDAMB231 cells transfected with miR-148b precursors (pre-miR-148b or pre-control) 
analyzed 48h post-transfection were used to perform Luciferase assays (A) in cells transfected 
with reporter constructs containing wild type or mutant 3’-UTRs (B) for the indicated genes or a 
synthetic sequence including three perfect miR-148b binding sites (sensor). Results are shown 
as mean±SEM of Firefly Luciferase activity relative to controls, normalized on Renilla 
Luciferase activity. mut=mutation; del=deletion; a/b: a and b binding sites. In (A) results of 
three independent experiments are pooled together. *P<0.05; **P<0.01; ***P<0.001. 
C) Proteins were extracted from relapsing or not relapsing primary breast tumors and Western 
Blot (WB) analysis was performed for the direct miR-148b targets, ITGA5, ROCK1, PIK3CA, 
NRAS, and CSF1. miR-148b expression is indicated as low (L) or high (H), according to 
previous microarray and/or qRT-PCR analyses. αtubulin or actin were used as loading controls. 
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 Relevantly, when the 23 predicted and modulated miR-148b target genes were 
used in Ingenuity System Analysis to look for gene connections the “Cell-To-Cell 
Signaling and Interaction, Tissue Development, Cellular Movement” network was 
identified (Figure 19A, Ingenuity score=22). Giving the relevance of the integrin 
pathway in our investigations, we evaluated the possibility that the upstream player, 
ITGA5, can be used to predict survival in a large microarray dataset of human breast 
tumor [Wang et al., 2005]. Performing hierarchical clustering and Kaplan-Meier 
analyses, referring to ITGA5 median expression, disease-free survival (DSF) was 
predicted (Figure 19B). This, together with similar results reported in Nam et al. (2009), 
suggests that repression of ITGA5 correlates with better clinical outcome and can be 
used as a prognostic marker. 
 
 
 
Figure 19. Analysis of miR-148b modulated genes by Ingenuity Systems Analysis. 
A) 20 miR-148b down-modulated genes identified in the microarray analysis (Figure 15) plus 
the three direct targets, ROCK1, PIK3CA and N-RAS, were used to perform an Ingenuity 
Systems Analysis searching for gene connections; the “Cell-To-Cell Signaling and Interaction, 
Tissue Development, Cellular Movement” functional network was generated. Ingenuity score 
22: negative Log10 of the P-value. Gene products are represented as nodes and biological 
relationships between two nodes as a line. Continuous lines indicate direct interactions, while 
dashed lines represent indirect connections. Shapes of nodes symbolize functional classes of 
gene products (see figure legend). The green symbols represent down-regulations, while the 
white symbols indicate genes absent in the input but related with the dataset used. (B) Kaplan-
Meier analyses of the probability of disease-free survival of breast cancer patients based on 
ITGA5 expression (median) in Wang et al., 2005 dataset for 286 breast tumor samples. P value 
was calculated using the Log Rank test. 
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3.3.2 Downmodulation of ITGA5 accounts for miR-148b chemotherapy response 
 The impact of the integrin signaling on cell survival and chemotherapy response 
was evaluated in absence of serum and adhesion (anoikis) or in presence of Paclitaxel. 
When ITGA5 was silenced with siRNAs in MDAMB231 cells, reduction in cell 
survival was observed in anoikis conditions and for Paclitaxel-treated cells versus 
controls (Figure 20A). Instead, when ITGA5 (cDNA lacking its 3’-UTR) was 
overexpressed (pEGFP-ITGA5), together with pre-miR-148b, in MDAMB231 or MCF7 
cells (Figure 20B) and cells were kept in presence of Paclitaxel, the effect of miR-148b 
on cell death (Figure 13) was abolished. To note that, in Figure 20B, only the difference 
(delta) observed comparing presence or absence of miR-148b is considered. 
 ITGA5 and miR-148b levels were evaluated by qRT-PCR analysis (Figure 20A-
C). From these results, we can conclude that ITGA5 directly controls, at least partially, 
miR-148b-driven apoptosis in anoikis conditions and in presence of Paclitaxel. 
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Figure 20. miR-148b-mediated down-modulation of ITGA5 leads to increased 
chemotherapy-induced apoptosis.  
A) Basal or anoikis- or Paclitaxel- induced apoptosis was evaluated in MDAMB231 cells 
transiently transfected with ITGA5-targeting or negative control siRNAs (si ITGA5 or control). 
B) Alternatively, MDAMB231 or MCF7 cells were first transfected with miR-148b precursors 
or their negative controls (pre-miR-148b or pre-control) and then transfected again (24h later) 
with empty EGFP or EGFP-ITGA5 overexpressing vectors. No 3’-UTR is present for ITGA5 
cDNA. Then cells were treated with Paclitaxel and apoptosis evaluated 48h later. Cell death was 
measured by TMRM and AnnexinV-FITC (A) or AnnexinV-PE stainings (B) by FACS 
analysis. (A) HighTMRM-LowAnnexinV: healthy cells; LowTMRM-HighAnnexinV: apoptotic cells. 
(B) LowAnnexinV: healthy cells; HighAnnexinV: apoptotic cells. Two or three independent 
experiments were performed in duplicate and pooled quantitations shown as mean±SD. C, D, 
E) qRT-PCR analyses were performed to evaluate ITGA5 mRNA or miR-148b expression for 
the cells shown Figure 20. Two independent experiments were performed in triplicate, and a 
representative one is shown. *P<0.05; **P<0.01. 
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  ITGA5 and miR-148b levels were evaluated by qRT-PCR analysis (Figure 21A-
C). From these results, we can conclude that ITGA5 directly controls, at least partially, 
miR-148b-driven apoptosis in anoikis conditions and in presence of Paclitaxel.  
 
 
Figure 21. Evaluation of ITGA5 expression values by qRT-PCR. 
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 In this work we identified a group of 16 miRNAs that associate with bad 
prognosis in our breast cancer patient cohort (Relapse positive) and we revealed the 
function of miR-148b as a metastasis suppressor in mice as well as its molecular 
mechanism of action.  
 The identification of a group of miRNAs able to identify primary tumor 
subtypes is highly relevant for the clinics. In fact, it represents a potent molecular tool 
that clinicians can use at the time of surgery to attempt the most appropriate therapy for 
every patient. The strength of this tool is further marked by the fact that single 
components of the signature, for instance miR-148b, can predict tumor outcome 
individually. Relevantly, low levels of miR-148b were previously observed in Basal-
like [Enerly et al., 2011] and ERBB2+/ER-/PR- [Mattie et al., 2006] breast tumors 
suggesting its involvement in malignancy.  
 Our functional experiments with metastatic cells, strongly suggest that miR-
148b exerts its metastasis-suppressing role mostly by controlling cell movement. In 
fact, while it is true that ectopic expression of miR-148b in malignant tumor cells leads 
to decreased tumor growth, this effect is modest and not sufficient to justify the much 
more pronounced control of metastasis dissemination. On this line, increased miR-148b 
levels lead to stronger adhesion and anoikis and reduce invasion in vitro. Moreover, in 
vivo, miR-148b strongly reduces extravasation and lung colonization shortly after 
injection of the cells in the blood circulation, when proliferation has no time to play a 
major role. Overall, it is well accepted that miRNAs have pleiotropic functions and 
therefore can act in independent events such as tumor formation and progression via the 
activation/repression of a selective and rate-limiting cascade of specific genes 
[Blenkiron et al., 2007; Ma & Weinberg, 2008; Valastyan et al., 2010; Tavazoie et al., 
2008].  
 Of the over 130 genes modulated by miR-148b, many are known to be relevant 
in tumor progression; among them, cathepsin A (CTSA), neuropilin 1 (NRP1), colony 
stimulating factor 1 (CSF1), matrix metallopeptidase 15 (MMP15) and integrin alpha 5 
(ITGA5), all suppressed by miR-148b. By focusing on the ITGA5 signaling, we found 
that not only ITGA5, but also Rho-associated, coiled-coil containing protein kinase 1 
(ROCK1), PI3-kinase p110 subunit alpha (PI3KCA/p110α), Neuroblastoma RAS viral 
(v-ras) oncogene homolog (NRAS) are directly downregulated by miR-148b, 
	  66	  
	  
Discussion	  
	  
	   	  
suggesting a specific control for this miRNA on a pathway known to be involved in 
metastasis dissemination and chemotherapy response. In fact, ITGA5 and ROCK1 were 
previously found to be highly expressed in malignant breast tumors and are known to 
increase tumor growth or progression [Nam et al., 2009; Valastyan et al., 2009, Taverna 
et al., 2001; Liu et al., 2009; Lane et al., 2008; Zheng et al., 2011]. At the same time, 
PIK3CA/p110a is relevant for mammary tumorigenesis and angiogenesis [Renner et al., 
2008] as well as for resistance to endocrine or anti-HER2 therapies [Eichhorn et al., 
2008; Miller et al., 2010]. In addition, NRAS is a well known oncogene and its 
silencing in tumor cells leads to increased apoptosis [Eskandarpour et al., 2005]. 
Regarding chemotherapy response, elevated levels and activity of α5β1 have previously 
been implicated in drug-resistance [Nista et al., 1997] and inhibition of α5β1/fibronectin 
interactions promotes apoptosis in malignant cells and enhances radiation effects [Nam 
et al., 2009]. In addition, perturbations of the actin cytoskeleton integrity via ROCK1 
inhibition commit cells to apoptosis [Shi & Wei, 2007]. Remarkably, ITGA5 and its 
downstream player RHOA, a ROCK activator, have been previously found to be 
suppressed by miR-31, another small non-coding RNA that suppresses metastasis 
[Valastyan et al., 2009]. In addition, ROCK1 and RHOC are also directly targeted by 
two other miRs involved in tumor progression, miR-146a/b and miR-10b [Liu et al., 
2008; Ma et al., 2007]. The fact that CSF1 is also a direct target of miR-148b opens up 
a role for this small RNA in tumor-stroma cell interactions, which will be part of a 
future study. 
 In conclusion, our study unravels the association of a group of 16 miRNAs with 
bad prognosis tumors and identifies miR-148b as a suppressor of tumor progression and 
modulator of chemotherapy response acting via the integrin. 
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Figure S1. Differentially expressed miRNAs comparing estrogen receptor positive (ER+) and estrogen receptor negative (ER-) tumor samples. 
Table shows the levels of expression of the 29 most modulated miRNAs in ER+ (n=53) versus ER- (n=24) tumor samples. The averaged level of each 
miRNA in tumor samples versus mammoplastic reductions (controls) is shown as Log2. SAM two classes, False Discovery Rate (FDR): 14%. 
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Figure S2 – Differentially expressed miRNAs comparing progesterone receptor positive (PR+) and progesterone receptor negative (PR-) tumor 
samples. 
Table shows the levels of expression of the 56 most modulated miRNAs in PR+ (n=42) versus PR- (n=35) tumor samples. The averaged level of each 
miRNA in tumor samples versus mammoplastic reductions (controls) is shown as Log2. SAM two classes, False Discovery Rate (FDR): 9.30%. 
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Table S1. Cloning oligonucleotides employed in this study. 
Primer	  ID	   Sequence	  (5'→	  3')	  
miR-­‐148b_forw	  (miR-­‐148b	  overexpression)	   TTTCATAGGCACCACTCACTTTAC	  
miR-­‐148b_rev	  (miR-­‐148b	  overexpression)	   CCCTTTCCCCTTACTCTCCA	  
miR-­‐187_forw	  (miR-­‐187	  overexpression)	   GTCGAGTCCCTCAGGACAAG	  
miR-­‐187_rev	  (miR-­‐187	  overexpression)	   TTAGGCTGAACGACACGTAG	  
miR-­‐148b_sensor_forw	  (luciferase	  miR-­‐148b	  sensor)	   CTAGTCCACTGCCTGTCTGTGCCTGCTGTCGTAGGATCTACTGCCTGTCTGTGCCTGCTGTTGGACCTGACACTGCCTGTCTGTGCCTGCTGTCCCA	  
miR-­‐148b_sensor_rev	  (luciferase	  miR-­‐148b	  sensor)	   AGCTTGGGACAGCAGGCACAGACAGGCAGTGTCAGGTCCAACAGCAGGCACAGACAGGCAGTAGATCCTACGACAGCAGGCACAGACAGGCAGTGGA	  
ROCK1-­‐3’UTR_forw	  (ROCK1	  3’UTR	  cloning)	   GCACTAGTGTTCCATCTTCGGACGTTGA	  
ROCK1-­‐3’UTR_rev	  (ROCK1	  3’UTR	  cloning)	   ATACGCGTCTTCAACAGACCATGCTCCC	  
ITGA5-­‐3’UTR_forw	  (ITGA5	  3’UTR	  cloning)	   ATACTAGTAGGCTGACCGACGACTACTG	  
ITGA5-­‐3’UTR_rev	  (ITGA5	  3’UTR	  cloning)	   TAACGCGTTTTTGCATACAAACTGGGAGC	  
PIK3CA-­‐3’UTR_forw	  (PIK3CA	  3’UTR	  cloning)	   CTCGACTAGTATGATGCTTGGCTCTGGAAT	  
PIK3CA-­‐3’UTR_rev	  (PIK3CA	  3’UTR	  cloning)	   CTCGACGCGTATGCTGTTCATGGATTGTGC	  
CSF1-­‐3’UTR_forw	  (CSF1	  3’UTR	  cloning)	   CTCGACTAGTTGGACGCACAGAACAGTCTC	  
CSF1-­‐3’UTR_rev	  (CSF1	  3’UTR	  cloning)	   CTCGACGCGTTGTTCAGCAGGCAGGTACAG	  
NRAS-­‐3’UTR_forw	  (NRAS	  3’UTR	  cloning)	   CTCGACTAGTTAAGTTTTGTCAGAAAAGAGCCAC	  
NRAS-­‐3’UTR_rev	  (NRAS	  3’UTR	  cloning)	   CTCGACGCGTCAAAACAGGCCTCTGGAAAA	  
ITGA5-­‐3’UTR-­‐mut-­‐site	  a_forw	  (ITGA5	  3’UTR	  mutagenesis)	   CTGGGGATCCCTCCCCCCCACGTATTATGAAGGACCCTTGTTTA	  
ITGA5-­‐3’UTR-­‐mut-­‐site	  a_rev	  (ITGA5	  3’UTR	  mutagenesis)	   TAAACAAGGGTCCTTCATAATACGTGGGGGGGAGGGATCCCCAG	  
ITGA5-­‐3’UTR-­‐mut-­‐site	  b_forw	  (ITGA5	  3’UTR	  mutagenesis)	   GGGTTCTGCCTGCCAGCCGTAATTATGCTGCCCCTCATCTC	  
ITGA5-­‐3’UTR-­‐mut-­‐site	  b_rev	  (ITGA5	  3’UTR	  mutagenesis)	   GAGATGAGGGGCAGCATAATTACGGCTGGCAGGCAGAACCC	  
ROCK1-­‐3’UTR-­‐del_forw	  (ROCK1	  3’UTR	  mutagenesis)	   CATTAAGTTAACAAACATATAAGAAATGTATGTTTGAAATGTAAATTATTCTTAGAACACTTTC	  
ROCK1-­‐3’UTR-­‐del_rev	  (ROCK1	  3’UTR	  mutagenesis)	   GAAAGTGTTCTAAGAATAATTTACATTTCAAACATACATTTCTTATATGTTTGTTAACTTAATG	  
PIK3CA-­‐3’UTR-­‐mut_forw	  (PIK3CA	  3’UTR	  mutagenesis)	   GCTCACTCTGGATTCCACACGGTACGGTTAATAACTCTCAGCAGGC	  
PIK3CA-­‐3’UTR-­‐mut_rev	  (PIK3CA	  3’UTR	  mutagenesis)	   GCCTGCTGAGAGTTATTAACCGTACCGTGTGGAATCCAGAGTGAGC	  
NRAS-­‐3’UTR-­‐del_forw	  (NRAS	  3’UTR	  mutagenesis)	   GCCACTTTCAAGCTGTGACACCCTGGTCCT	  
NRAS-­‐3’UTR-­‐del_rev	  (NRAS	  3’UTR	  mutagenesis)	   AGGACCAGGGTGTCACAGCTTGAAAGTGGC	  
CSF1-­‐3’UTR-­‐del-­‐site	  a_forw	  (CSF1	  3’UTR	  mutagenesis)	   GACCTGCTGGTCTGTGACAGCCTGAAGG	  
CSF1-­‐3’UTR-­‐del-­‐site	  a_rev	  (CSF1	  3’UTR	  mutagenesis)	   CCTTCAGGCTGTCACAGACCAGCAGGTC	  
CSF1-­‐3’UTR-­‐del-­‐site	  b_forw	  (CSF1	  3’UTR	  mutagenesis)	   CATGAAGGAAGCCATTGTGTGAACACTGTACCTG	  
CSF1-­‐3’UTR-­‐del-­‐site	  b_rev	  (CSF1	  3’UTR	  mutagenesis)	   CAGGTACAGTGTTCACACAATGGCTTCCTTCATG	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Table S2. miR-148b modulated protein-coding genes 
MDAMB231 cells either transfected with miR-148b precursors or negative controls (pre-miR-
148b or control) were used to perform a microarray analysis (“Whole Human Genome Oligo 
Microarray”, Agilent). Up- and down-modulated protein-coding genes considering: minimum 
fold change (FC)=1.5; false discovery rate (FDR)=16%. 
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ABSTRACT Breast cancer is often fatal during its meta-
static dissemination. To unravel the role of microRNAs
(miRs) during malignancy, we analyzed miR expression
in 77 primary breast carcinomas and identified 16
relapse-associated miRs that correlate with survival
and/or distinguish tumor subtypes in different data-
sets. Among them, miR-148b, down-regulated in aggres-
sive breast tumors, was found to be a major coordinator
of malignancy. In fact, it is able to oppose various steps
of tumor progression when overexpressed in cell lines
by influencing invasion, survival to anoikis, extravasa-
tion, lung metastasis formation, and chemotherapy
response. miR-148b controls malignancy by coordinat-
ing a novel pathway involving over 130 genes and, in
particular, it directly targets players of the integrin
signaling, such as ITGA5, ROCK1, PIK3CA/p110,
and NRAS, as well as CSF1, a growth factor for stroma
cells. Our findings reveal the importance of the identi-
fied 16 miRs for disease outcome predictions and
suggest a critical role for miR-148b in the control of
breast cancer progression.—Cimino, D., De Pitta`, C.,
Orso, F., Zampini, M., Casara, C., Penna, E., Qua-
glino, E., Forni, M., Damasco, C., Pinatel, E., Pon-
zone, R., Romualdi, C., Brisken, C., De Bortoli, M.,
Biglia, N., Provero, P., Lanfranchi, G., Taverna, D.
miR148b is a major coordinator of breast cancer
progression in a relapse-associated microRNA signature by
targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.
FASEB J. 27, 000–000 (2013). www.fasebj.org
Key Words: microRNA profiling  malignancy  mammary
tumor  integrin signaling  prognosis
Breast cancer is the most common malignancy in
women worldwide, often fatal because of metastasis
dissemination (1). Clinical and pathological parame-
ters, including tumor size, lymph node involvement,
and histological grade and age (2), as well as molecular
tumor markers, such as estrogen receptor (ER) and
progesterone receptor (PR) or ERBB2, are routinely
employed to stratify patients with breast cancer accord-
ing to risk, assess prognosis, and define appropriate
therapies (3). However, since patients with similar
combinations of features may often have different
clinical outcomes, it is urgent to identify new ways to
classify the disease. More recently, protein-coding gene
expression profilings have been used to improve tumor
classifications (4) and expression of certain gene sets,
defined as “signatures,” were shown to have a prognos-
tic and/or predictive role for patients (5).
1 These authors contributed equally to this work.
2 Correspondence: MBC and Department Onc. Sci., Uni-
versity of Torino, Via Nizza, 52, 10126 Torino, Italy. E-mail:
daniela.taverna@unito.it
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This article includes supplemental data. Please visit http://
www.fasebj.org to obtain this information.
Abbreviations: 3=-UTR, 3= untranslated region; DFS, dis-
ease-free survival; ER, estrogen receptor; FDR, false discovery
rate; H&E, hematoxylin and eosin; IPA, Ingenuity Pathway
Analysis; miR, microRNA; PCA, principal component analysis;
PR, progesterone receptor; SAM, significance analysis of
microarray; TMRM, tetramethylrhodamine methyl ester
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MicroRNAs (miRs) are new players involved in the
establishment and progression of human tumors that
appear to be critical biomarkers of cancer with strong
classification power. miRs are a class of small noncod-
ing RNAs that negatively regulate protein-coding gene
expression post-transcriptionally by targeting mRNAs,
mostly at the 3= untranslated region (3=-UTR) and
triggering either translation repression or RNA degra-
dation (6). Investigations for miR levels in human
tumors showed that miR expression is altered in cancer
compared to normal tissues, and these changes can
help to classify tumors more accurately than mRNA
expression profiles according to developmental lineage
and differentiation status (7). Recent studies demon-
strated that breast cancers can be classified into specific
tumor pathological phenotypes (ER, PR, proliferation,
stage, metastasis, ERBB2) as well as subtypes (luminal A
or B, basal-like, ERBB2 and normal-like) based on
miR expression profiles (8, 9). Thus, it seems essential
to combine miR and protein-coding gene expression
analyses to obtain information for prognosis and can-
cer treatment. miRs such as let-7, miR-9, miR-10b,
miR-21, miR-31, miR-34, miR-126, miR-146, miR-155,
miR-200, miR-214, miR-221/222, miR-373, and 520c
have been proven to control tumor dissemination. In
fact, alterations of their expression in breast cancer
cells profoundly affect tumor dissemination (10–12).
In our work, we investigated the relationship between
altered miR expression and breast cancer metastasis by
analyzing miR levels in a cohort of patients with breast
cancer, grouped based on disease relapse. In particular,
we investigated the biological function and molecular
mechanism of a relapse-associated small noncoding
RNA, miR-148b.
MATERIALS AND METHODS
Cell culture
Human MDAMB231, 4175 TGL (13), MCF7, and T47D cells
and mouse 4T1 cells were maintained in standard conditions:
Dulbecco’s modified Eagle’s medium containing 10 mM
Glutamax and 4.5 mg/ml glucose(DMEM Glutamax; Gibco;
Invitrogen Life Technologies, Carlsbad, CA, USA), supple-
mented with 10% heat-inactivated FCS (Biochrom AG, Ber-
lin, Germany), 1 mM sodium pyruvate, 25 mM HEPES (pH
7.4), and 100 mg/ml gentamicin (all from Gibco).
Patients and samples
Frozen primary invasive ductal breast cancer specimens (77)
from 25- to 82-yr-old patients were selected from the Tumor
Bank of the Department of Obstetrics and Gynecology,
University of Torino (Turin, Italy; primary surgery: 1988–
2001) for a retrospective study. There was no distant metas-
tasis at diagnosis (M0). Complete clinical-pathological data
were updated by follow-up for 72 mo (up to 100 mo). All
patients were treated with radical modified mastectomy or
quadrantectomy and axillary dissection plus breast irradia-
tion. High-risk node-negative and node-positive patients re-
ceived adjuvant treatments (generally 6 cycles of CMF: 600
mg/m2 cyclophosphamide, 40 mg/m2 metotrexate, 600
mg/m2 5-fluorouracil), and/or 20 mg tamoxifen daily for 5 yr
in ER cases. Patient stage distribution was assessed as
prescribed by the Union for International Cancer Control
(UICC) clinical staging guidelines, and tumor grading was
performed as described previously (14). As normal breast
controls, 17 frozen mammoplastic reductions were included
in the screening. Appropriate ethical approval was obtained
for this study.
Reagents and antibodies
miR precursors and inhibitors
Pre-miR miRNA Precursor Molecules–Negative Control 1,
miRNA precursors hsa-miR-148b (PM10264) (000471), hsa-
miR-214 (PM12124), Anti-miR miRNA Inhibitor–Negative
Control 1, and miRNA inhibitor hsa-miR-148b (AM10264)
were from Ambion (Austin, TX, USA).
miR detection
TaqMan miRNA assays hsa-miR-148b (000471), hsa-miR-187
(000487), hsa-miR-365 (001020), hsa-miR-10a (000387), hsa-
miR-19a (000395), hsa-miR-342-3p (002260), hsa-miR-214
(002306), hsa-RNU44 (001094), and U6 snRNA (001973)
were from Applied Biosystems (Foster City, CA, USA).
ECM
Collagen IV and fibronectin were from Sigma-Aldrich (St.
Louis, MO, USA).
Apoptosis reagents
FITC-conjugated annexin V was provided by Boehringer
Mannheim (Indianapolis, IN, USA). PE-conjugated annexin
V was provided by BD Biosciences (Bedford, MA, USA).
Tetramethylrhodamine methyl ester (TMRM) was provided
by Molecular Probes (Invitrogen Life Technologies). Pacli-
taxel (Onco-Tain brand) was from Mayne Pharma (Mel-
bourne, Australia), cisplatin was from Ebewe Italia Srl.
(Rome, Italy), and doxorubicin was from Sigma-Aldrich.
RNAi
si ITGA5 (Hs_ITGA5_5 siRNA) and All Stars Negative Control
siRNA were purchased from Qiagen (Stanford, CA, USA).
Primary antibodies
Anti-N-RAS mAb F155, anti-hsp90 mAb F-8, anti-ROCK1 pAb
H-85, and anti-actin pAb I-19 were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Anti-PIK3CA (4255) was from
Cell Signaling Technology (Danvers, MA, USA). Anti-ITGA5
pAb RM10 was kindly provided by G. Tarone (University of
Torino, Turin, Italy; ref. 15). Anti-CSF1 mAb M01-1A9 was
from Abnova (Taipei, Taiwan), and anti--tubulin mAb B5-1-2
was from Sigma-Aldrich.
Secondary antibodies
Goat anti-mouse and goat anti-rabbit HRP-conjugated IgG were
from Santa Cruz Biotechnology. All antibodies were used at the
producer’s suggested concentrations. Matrigel used for in vivo
tumor growth experiments (BD Matrigel Basement Membrane
Matrix High Concentration) was from BD Biosciences.
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Primers
Cloning oligonucleotides employed in this study are listed in
Table 1. RT-PCR assays (Qiagen) employed in this study are
listed in Table 2.
Plasmid construction and lentiviral infections
Luciferase reporter vectors containing the partial 3=-UTR of
the indicated miR-148b target genes were generated follow-
ing PCR amplification of the 3=-UTR from human cDNA and
cloned into the firefly luciferase reporter pMIR-Report vector
(Ambion). When indicated, the 3=-UTRs were mutagenized at
miR-148b recognition sites using the QuickChange Site-Di-
rected Mutagenesis kit (Stratagene, Cedar Creek, TX, USA)
according to the manufacturer’s instructions. The miR-148b
sensor was obtained by annealing, purifying, and cloning
short oligonucleotides containing 3 perfect miR-148b binding
sites into the SpeI and HindIII sites of the pMIR-Report vector.
The human pre-miR-148b sequence (a 306-bp fragment con-
taining the pre-miR sequence) was amplified from genomic
DNA (MDAMB231) and cloned into pLemiR-tRFP (Open
Biosystems, Huntsville, AL, USA) vector to obtain pLemiR-
148b (still containing tRFP) vector. The human pre-miR-187
sequence (a 251-bp fragment containing the pre-miR se-
quence) was amplified from genomic DNA (MDAMB231)
and cloned into pWPT (Addgene, Cambridge, MA, USA)
vector to obtain pWPT-miR-187 vector. Stable cell lines were
generated by lentiviral infection. Lentiviruses were produced
by calcium phosphate transfection of 293T cells with 20 g of
specific vector together with 15 g packaging (pCMVdR8.74)
and 6 g envelope (pMD2.G-VSVG) plasmids, according to
D. Trono’s laboratory protocol (École Polytechnique Fé-
dérale de Lausanne, Lausanne, Switzerland; http://tronolab.
epfl.ch). Supernatant was harvested 48 h post-transfection,
filtered with 0.45-m filters, diluted, and used to infect 3.5 
105 cells in 6-well plates, in presence of 8 g/ml Polybrene
(Sigma-Aldrich). ITGA5 overexepression was obtained by
transfecting pEGFP-N3-ITGA5 expression vector (plasmid
15238; Addgene; ref. 16).
RNA isolation from tissues or cells
After surgical removal, tumor samples were macrodissected
by pathologists, quickly frozen, and stored at 80°C. Total
RNA was isolated with Concert cytoplasmic RNA reagent
(Invitrogen Life Technologies) from 20 to 50 mg tumor
tissues, according to the manufacturer’s guidelines. Frozen
tumors were then homogenized using a ball mill (MM200;
Retsch, Düsseldorf, Germany). The suspension was centri-
fuged at 14,000 g for 5 min at 4°C, and then lysed with 0.1 ml
of 10% SDS, followed by 0.3 ml of 5 M sodium chloride and
TABLE 1. Cloning oligonucleotides employed in this study
Primer ID Sequence, 5= ¡ 3=
miR-148b_forw (miR-148b overexpression) TTTCATAGGCACCACTCACTTTAC
miR-148b_rev (miR-148b overexpression) CCCTTTCCCCTTACTCTCCA
miR-187_forw (miR-187 overexpression) GTCGAGTCCCTCAGGACAAG
miR-187_rev (miR-187 overexpression) TTAGGCTGAACGACACGTAG
miR-148b_sensor_forw (luciferase miR-148b sensor) CTAGTCCACTGCCTGTCTGTGCCTGCTGTCGTAGGATCTACTG
CCTGTCTGTGCCTGCTGTTGGACCTGACACTGCCTGTCTGTGCC
TGCTGTCCCA
miR-148b_sensor_rev (luciferase miR-148b sensor) AGCTTGGGACAGCAGGCACAGACAGGCAGTGTCAGGTCCAACA
GCAGGCACAGACAGGCAGTAGATCCTACGACAGCAGGCACAGAC
AGGCAGTGGA
ROCK1-3=UTR_forw (ROCK1 3=-UTR cloning) GCACTAGTGTTCCATCTTCGGACGTTGA
ROCK1-3=UTR_rev (ROCK1 3=-UTR cloning) ATACGCGTCTTCAACAGACCATGCTCCC
ITGA5-3=UTR_forw (ITGA5 3=-UTR cloning) ATACTAGTAGGCTGACCGACGACTACTG
ITGA5-3=UTR_rev (ITGA5 3=-UTR cloning) TAACGCGTTTTTGCATACAAACTGGGAGC
PIK3CA-3=UTR_forw (PIK3CA 3=-UTR cloning) CTCGACTAGTATGATGCTTGGCTCTGGAAT
PIK3CA-3=UTR_rev (PIK3CA 3=-UTR cloning) CTCGACGCGTATGCTGTTCATGGATTGTGC
CSF1-3=UTR_forw (CSF1 3=-UTR cloning) CTCGACTAGTTGGACGCACAGAACAGTCTC
CSF1-3=UTR_rev (CSF1 3=-UTR cloning) CTCGACGCGTTGTTCAGCAGGCAGGTACAG
NRAS-3=UTR_forw (NRAS 3=-UTR cloning) CTCGACTAGTTAAGTTTTGTCAGAAAAGAGCCAC
NRAS-3=UTR_rev (NRAS 3=-UTR cloning) CTCGACGCGTCAAAACAGGCCTCTGGAAAA
ITGA5-3=UTR-mut-site a_forw (ITGA5 3=-UTR mutagenesis) CTGGGGATCCCTCCCCCCCACGTATTATGAAGGACCCTTGTTTA
ITGA5-3=UTR-mut-site a_rev (ITGA5 3=-UTR mutagenesis) TAAACAAGGGTCCTTCATAATACGTGGGGGGGAGGGATCCCCAG
ITGA5-3=UTR-mut-site b_forw (ITGA5 3=-UTR mutagenesis) GGGTTCTGCCTGCCAGCCGTAATTATGCTGCCCCTCATCTC
ITGA5-3=UTR-mut-site b_rev (ITGA5 3=-UTR mutagenesis) GAGATGAGGGGCAGCATAATTACGGCTGGCAGGCAGAACCC
ROCK1-3=UTR-del_forw (ROCK1 3=-UTR mutagenesis) CATTAAGTTAACAAACATATAAGAAATGTATGTTTGAAATGTA
AATTATTCTTAGAACACTTTC
ROCK1-3=UTR-del_rev (ROCK1 3=-UTR mutagenesis) GAAAGTGTTCTAAGAATAATTTACATTTCAAACATACATTTCT
TATATGTTTGTTAACTTAATG
PIK3CA-3=UTR-mut_forw (PIK3CA 3=-UTR mutagenesis) GCTCACTCTGGATTCCACACGGTACGGTTAATAACTCTCAGCAGGC
PIK3CA-3=UTR-mut_rev (PIK3CA 3=-UTR mutagenesis) GCCTGCTGAGAGTTATTAACCGTACCGTGTGGAATCCAGAGTGAGC
NRAS-3=UTR-del_forw (NRAS 3=-UTR mutagenesis) GCCACTTTCAAGCTGTGACACCCTGGTCCT
NRAS-3=UTR-del_rev (NRAS 3=-UTR mutagenesis) AGGACCAGGGTGTCACAGCTTGAAAGTGGC
CSF1-3=UTR-del-site a_forw (CSF1 3=-UTR mutagenesis) GACCTGCTGGTCTGTGACAGCCTGAAGG
CSF1-3=UTR-del-site a_rev (CSF1 3=-UTR mutagenesis) CCTTCAGGCTGTCACAGACCAGCAGGTC
CSF1-3=UTR-del-site b_forw (CSF1 3=-UTR mutagenesis) CATGAAGGAAGCCATTGTGTGAACACTGTACCTG
CSF1-3=UTR-del-site b_rev (CSF1 3=-UTR mutagenesis) CAGGTACAGTGTTCACACAATGGCTTCCTTCATG
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0.2 ml of chloroform per milliliter of reagent. The lysate was
centrifuged at 14,000 g for 15 min at 4°C, and the upper
aqueous phase was removed and combined with 0.8 vol of
isopropyl alcohol for 10 min at room temperature. Total RNA
was recovered by centrifugation, washed with 75% ethanol,
and finally dissolved in RNase-free water. Total RNA from
normal samples or cells in culture was isolated with TRIzol
reagent (Invitrogen Life Technologies). Frozen samples were
homogenized using an Ultra Turax T50 Basic homogenizer
(Bioclass, Pistoia, Italy) and extracted with an acid-phenol:
chloroform solution according to the manufacturer’s guide-
lines. RNA quantitation was performed using the NanoDrop
1000 spectrophotometer (Nanodrop, Wilmington, DE, USA).
Total RNA integrity and the percentage content of miRs in
each sample were assessed by capillary electrophoresis using
the Agilent Bioanalyzer 2100 with the RNA 6000 Nano and
the Small RNA Nano LabChips, respectively (Agilent Tech-
nologies, Palo Alto, CA, USA). Only total RNA samples with
an RNA integrity number (RIN)  6 and 30% of small
RNAs were used for miR microarray analysis.
miR and gene expression profilings
The miR and protein-coding expression profilings were car-
ried out using the Human MicroRNA Microarray kit (V2, 723
miRs) and the Whole Human Genome Oligo Microarray
(41,000, 60-mer oligonucleotide probes), respectively, both
from Agilent Technologies. For miR analysis, total RNA (200
ng) was labeled with pCp-Cy3, according to the Agilent
protocol (17), and probes were hybridized at 55°C for 22 h.
For protein-coding investigations, total RNA (800 ng) was
labeled by the Agilent One-Color Microarray-Based Gene
Expression protocol, according to the manufacturer’s instruc-
tions. The synthesized cDNA was transcribed into cRNA and
labeled with Cy3. Labeled cRNA (1.65 g) was used for
hybridization at 65°C for 17 h. Slides were scanned on an
Agilent microarray scanner. Raw miR and gene expression
data are available in the U.S. National Center for Biotechnol-
ogy Information Gene Expression Omnibus (GEO) database
(GSE26666; http:/www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token_jveltssyquiywvo&acc_GSE26666). Interarray normalization
was performed with cyclic Lowess for miRs and with quantile for
protein-coding expression profilings (18, 19), and the aver-
age of replicates was used. To perform differential gene
expression analysis, the level of each miR was calculated as
log2 of tumor sample/mammoplastic reduction median. The
identification of differential expression for miRs or protein-
coding genes was performed using the 2-class significance
analysis of microarray (SAM) algorithm (20). SAM uses a
permutation-based multiple testing algorithm and associates a
variable false discovery rate (FDR) to the significant genes. FDR
refers to the percentage of error that can occur in the identifi-
cation of the statistically significant differentially expressed
genes in multiple comparisons; it can be manually adjusted.
Statistical analysis of miR and gene expression data
For miRs, Feature Extraction software (Agilent Technologies)
was used to obtain spot quality measures in order to evaluate the
quality and the reliability of the hybridization. In particular, the
flag glsFound (set to 1 if the spot has an intensity value
significantly different from the local background, 0 otherwise)
was used to filter out unreliable probes: flag equal to 0 will be
noted as not available (NA). So, in order to perform a more
robust and unbiased statistical analysis, probes with a high
proportion of NA values were removed from the dataset. NA
(40%) was used as threshold in the filtering process, obtaining a
total of 237 available human miRs. Principal component analysis
(PCA), cluster analysis, and profile similarity searches were
performed with Multi Experiment Viewer 4.5.1 (TMev) of the
TM4 Microarray Software Suite (21). All heath maps were
obtained by TMeV software using an unsupervised 2-dimen-
sional hierarchical clustering approach with average linkage
method and Pearson correlation.
Statistical analyses of biological samples
Data are presented as means  sem or sd, and 2-tailed
Student’s t test was used for comparison analysis, with values
of P  0.05 considered to be statistically significant. Box and
whisker plots were prepared based on Liu (22). The bottom
and top of the box are, respectively, the first (bottom) and
third (top) quartile; the line in the middle corresponds to the
median, and circles label outliers.
Statistics for survival analysis
Survival association analyses were performed using the SPSS 18.0
statistical software (SPSS Inc., Chicago, IL, USA) and the Biocon-
ductor suite of software tools (http://www.bioconductor.org). The
receiver operating characteristic (ROC) method (23) was
used to categorize samples according to miR or mRNA
expression. Kaplan-Meier survival curves were used to esti-
mate time-to-event models in the presence of censored cases.
Risk differences between the two groups were assessed using
the Mantel-Haenszel log-rank test (24). Survival analysis was
carried out in both univariate and multivariate setting using
Cox’s proportional hazard model (25). ITGA5 survival asso-
ciation was evaluated in GSE2034 (26); gene expression
values were calculated as described previously (27), and
results were divided into two categories according to gene
expression levels.
Analysis of human breast cancer data sets
Blenkiron et al. (8) and Enerly et al. (9) miR expression values
and sample phenodata were obtained from GSE7842 and
GSE19536, respectively, and from the supplemental materials
of the publications.
Target prediction and pathway analysis
The TargetScan 5.1 algorithm (28) was used to predict miR
targets. The Ingenuity Pathways Knowledge Base (http://
www.ingenuity.com) is currently the world’s largest database
of knowledge on biological networks, with annotations orga-
TABLE 2. RT-PCR assays employed in this study
Primer ID Assay ID
COPZ1 QT00087024
CSF1 QT00035224
CTSA QT00087381
CXCL5 QT00203686
DYRK2 QT01011073
GRB2 QT00065289
ITGA5 QT00080871
MMP15 QT00014063
NRAS QT00076874
NRP1 QT00023009
PIK3CA QT00014861
ROCK1 QT00034972
RRN18S QT00199367
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nized by experts. We exploited this database to look for
enrichments in specific pathways among the relapse (or other
category)-associated miR putative targets. Enrichment signif-
icance in pathways analysis is shown as the negative log10 of
the P value. The P value is calculated with the right-tailed
Fisher’s exact test. Ingenuity networks are scored based on
the number of network eligible molecules they contain. The
network score is based on the hypergeometric distribution
and is calculated with the right-tailed Fisher’s exact test. The
score is the negative log of this P value.
Additional cell transfections and infections, qRT-PCRs,
apoptosis, luciferase assays, protein preparation, immuno-
blotting, and in vitro and in vivo biological studies were all
performed as indicated in detail in Penna et al. (12).
RESULTS
Sixteen relapse-associated miRs classify breast tumors
In a retrospective study, we analyzed miR expression in
77 primary human breast ductal tumors as well as 17
mammoplastic reductions (Table 3), using microarrays
(a 723-miR platform) and a 2-class SAM. In particular,
when we compared patients with relapse (n	41) or
without relapse (n	36), within 72 mo from surgery,
16 differentially expressed miRs were identified and
expressed as fold changes or levels, relative to the
median of the healthy controls, log2 tumors/controls
(Fig. 1). Within relapsing/nonrelapsing patients, vali-
dation of microarray data was performed by qRT-PCR
analysis for miR-148b, miR-365, and miR-10a using n 	
10/group (not shown). By using the 16 relapse-associ-
ated miRs together as a whole (as a group), we identi-
fied two groups of patients with different overall sur-
vival (OS; P	0.018) and disease-free survival (DFS;
P	0.016), independent of the lymph node status (Cox
proportional-hazards regression model; P	0.015) in
our study. The same was found when certain individual
specific miRs were used, for instance, miR-148b, down-
regulated in relapsing tumors (OS, P	0.027; DFS,
P	0.036). However, a correlation with survival was not
found when our 16 relapse-associated miRs were used
as a whole for two other available public datasets (8, 9).
These studies refer to 100 patients each; the primary
tumors were used to measure mRNA and miR expres-
sion with the goal of identifying tumor subtypes. Nota-
bly, in these datasets, our group of 16 relapse-associated
miRs could identify tumor subtypes and separate more
aggressive (ERBB2 or basal-like) vs. less aggressive (luminal
A/B) cancers (Fig. 1C, compare solid vs. shaded sym-
bols), based on the breast cancer classification in Sorlie
et al. (4). Moreover, our 16-miR signature could also
predict survival, in our cohort, when only luminal
tumors (n	53) were considered (DFS, P	0.0097). In
addition, some of the 16 miRs, such as miR10a, miR-
101, miR-142-5p, miR-148b, miR-342-3p, miR-342-5p,
miR-365, and miR-551b, could distinguish tumor sub-
types individually (8, 9 and data not shown). In sum-
mary, we identified 16 relapse-associated miRs that
could be used in the clinics to identify tumor subtypes
and to predict disease outcome.
miR-148b impairs tumor growth and suppresses
metastasis formation by altering extravasation
and survival
A detailed bioinformatics analysis was carried out for
the putative targets of the 16 relapse-associated miRs, as
predicted by TargetScan 5.1, using Ingenuity Pathway
Analysis (IPA) in order to identify pathways and func-
tions in which each miR was involved. This analysis,
together with literature searches, let us to conclude that
miR-148b has the potential to coordinate a very high
number of pathways relevant for breast cancer and that
its function has still to be elucidated. With this in mind,
we investigated the biological role of miR-148b in
TABLE 3. Clinical characteristics of the patients: summary
Characteristic Value %
Tumor samples
Patients (n) 77
Age (yr)
Median 54
Range 25–82
Tumor stage (n)
1 20 26.0
2 51 66.2
3 3 3.9
4 3 3.9
Tumor grade (n)
1 4 5.2
2 35 45.4
3 33 42.8
Unknown 5 6.5
LN (n)
Positive 44 57.1
Negative 33 42.9
ER (n)a
Positive 53 68.8
Negative 24 31.2
PR (n)a
Positive 42 54.5
Negative 35 45.4
Subtype (n)b
Luminal 53 68.0
ERBB2b 14 18.0
Basal 10 12.0
Relapse, 72 mo (n)
Yes 41 53.2
ER 25 61c
ER 16 39c
No 36 46.7
ER 28 78c
ER 8 22c
Normal samples
Patients (n) 17
Age (yr) 13
Median 43
Range 20–67
n, number; LN, lymph node status; ER, estrogen receptor status;
PR, progesterone receptor status. aER and PR are defined positive
when tumors contain 
10 fmol receptors/mg proteins or 10%
positive tumor cells. bSamples were classified according to ERBB2
mRNA level combined to ER and PR status. cPercentage refers to the
total of relapsing or nonrelapsing samples.
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neoplasia by modulating (up or down) its expression in
MDAMB231, 4175TGL, 4T1, T47D, and MCF7 mam-
mary tumor cell lines with a different level of malig-
nancy (independently of ER, PR, and ERBB2 expres-
sion) and of miR-148b, as measured by qRT-PCR
(Supplemental Fig. S1A). Transient modulations were
obtained using miR-148b precursors or inhibitors or
negative controls (pre-miR-148b, anti-miR-148b, or pre-
control or anticontrol) and evaluated 48 or 72 h
post-transfection for expression and biology (Supple-
mental Fig. S1B, C). Instead, for stable expression, cells
were transduced with pLemiR-empty or pLemiR-148b
overexpressing lentivirus vectors and selected with pu-
romycin as pools; expression evaluation is shown in
Supplemental Fig. S1C.
In vitro proliferation was not affected or only slightly
modulated up to 4 d for MDAMB231, 4175TGL, and
4T1 cells in stable or transient conditions (Supplemen-
tal Fig. S2A and data not shown). However, tumors
derived from transduced pLemiR-148b 4175TGL cells
grew significantly less compared to controls (pLemiR-
EV) when analyzed up to 12 d following injection in the
fat pad of immunocompromised NOD/SCID IL2Rnull
mice (see below). When invasion through fibronectin
or Matrigel was evaluated by transwell assays for the
same cell lines, reduced cell movement was observed in
the presence of miR-148b overexpression compared to
controls (Supplemental Fig. S2B and data not shown).
However, no effect was observed when cells were trans-
duced with pWPT-miR-187 (negative control) lentivirus
overexpression vectors compared to controls (pWPT-EV or
precontrol; Supplemental Fig. S2B and data not
shown). Instead, increased cell invasion was observed
when miR-214 was overexpressed in these cells (Sup-
plemental Fig. S2B, ref. 12, and data not shown). When
cell adhesion was investigated, increased adhesion on
fibronectin and collagen IV was found for MDAMB231
cells overexpressing miR-148b compared to controls.
Conversely, down-modulation of miR-148b in MCF7
and T47D cells led to decreased adhesion (Supplemen-
tal Fig. S2C).
To study the role of miR-148b in in vivo metastasis
formation, we injected miR-148b-overexpressing (pre-
miR-148b) 4T1 cells into the tail vein of female BALB/c
syngeneic mice, and analyzed dissemination in lungs. A
significant reduction in the number of lung colonies or
area occupied by the lesions was found 5 d postinjec-
tion compared with controls, as measured in hematox-
ylin and eosin (H&E)-stained sections (Fig. 2A). More
relevantly, when red fluorescent pLemiR-148b-trans-
duced, 4175TGL cells were injected orthotopically into
NOD/SCID/IL2Rnull mice and primary tumors formed, a
striking reduction of malignant cell dissemination from
the primary tumors to the lungs was observed com-
Figure 1. Expression of 16 miRs in relapse-positive (R) or relapse-negative (R) primary cancers and tumor subtype
identification. A) Clustering (Pearson correlation, average linkage) for the 16 most modulated miRs considering relapsing
(n	41) vs. nonrelapsing (n	36) tumors. Heatmap represents relative miR levels with reference to the median expression across
all samples; rows: miR; columns: tumors. B) Summary (left panel) and graph (right panel) showing the levels of expression of
the 16 most modulated miRs, expressed as fold change (FC) of relapsing/nonrelapsing median values (left panel) or averaged
levels (log2) in R
 or R tumor samples vs. mammoplastic reductions (controls). Two-class SAM, FDR 16%. C) PCA plots for
tumor subtypes using all 16 miRs in Blenkiron et al. (8) and Enerly et al. (9) datasets. Basal_like, basal; ERBB2, ERBB2 positive;
Lum_A, luminal A; Lum_B, luminal B; normal_like, normal-like breast cancer.
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pared to controls (Fig. 2B). Quantitations refer to the
red fluorescent metastatic foci (number/area) in the
lungs at 12 d postinjection (Fig. 2B); H&E sections are
shown (Fig. 2B). Similar results were obtained with
pLemiR-148b-transduced 4T1 cells (not shown). Nota-
bly, when similar experiments were previously per-
formed with miR-214-overexpressing 4T1 cells, in-
creased dissemination was observed (12).
Based on this, we assessed the involvement of miR-
148b in extravasation and survival in the blood circula-
tion, two essential steps of the metastatic dissemination.
To investigate extravasation in vivo, red fluorescent
pLemiR-148b-transduced MDAMB231 cells were in-
jected into the tail vein of immunocompromised mice,
and cell seeding and extravasation in the lung were
evaluated at 2 or 48 h postinjection. A high percentage
of cells lodged in the lung at 2 h (within the vessels or
outside) in the presence or absence of miR-148b.
However, extravasation was highly reduced for miR-
148b-overexpressing cells compared to controls, as
quantitation of the area occupied by metastatic cells
showed (Fig. 2C, D). Vessels were labeled for CD31
Figure 2. miR-148b impairs metastasis formation in mice by affecting extravasation and survival. A) 4T1 cells transiently
transfected with negative controls (pre-control; a) or miR-148b precursors (pre-miR-148b; b) were used to evaluate lung
colony formation in BALB/c mice at 5 d after tail vein injection. B) Alternatively, 4175TGL cells stably transduced with
pLemiR-EV (a, c) or pLemiR-148b (b, d) overexpression vectors were injected into the mammary gland fat pad of
NOD/SCID/IL2Rnull mice, and primary tumor growth as well as metastasis formation in the lungs were analyzed at 12 d
postinjection. A, B) Two independent experiments were performed, and results were pooled together (n	10 mice/group)
and shown as box and whisker plots for primary tumor weights (B) or number (or area) of microscopic colonies (A) or
metastasis (B) in the lungs. Tumor cell dissemination was evaluated in H&E-stained sections at d 5 (A) or as fluorescent
lesions in the whole lung at d 12 (B). Representative H&E stainings are shown. C, D) In vivo seeding/extravasation assays
following tail vein injections in nude mice of red fluorescent MDAMB231 cells, stably transduced with pLemiR-EV or
pLemiR-148b overexpression vectors. C) Representative fields of lung sections at 2 h (a) or 48 h (b) postinjection, stained
for CD31 (black) and containing red fluorescent MDAMB231 cells (here visible in light gray). No cells were found in the
vessels at 48 h. D) Left panels: red fluorescent cells in the whole lungs at 2 h (a, b) or 48 h (c, d) postinjection. Right panel:
quantitation of the red fluorescent cells (area) at 48 h for n 	 8 mice/group. E) MDAMB231 cells transfected with
miR-148b precursors or their negative controls (pre-miR-148b or control) were grown in presence or absence (anoikis) of
attachment and without serum for 48 h. Percentage of apoptotic cells was evaluated by TMRM and annexinV-FITC staining
in a FACS analysis. HighTMRM-LowAnnexinV, healthy cells; LowTMRM-HighAnnexinV, apoptotic cells. Three independent
experiments were performed in duplicate; pooled quantitations are shown as means  sem. Scale bars 	 60 m (A; Bc, d);
2 mm (Ba, b; D); 120 m (C). *P  0.05; **P  0.01; ***P  0.001.
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(Fig. 2C). To investigate survival in the blood circula-
tion, we evaluated apoptosis in miR-148b-overexpress-
ing MDAMB231 cells kept without serum and with or
without (anoikis) adhesion for 48 h by cytofluorimetric
analyses, and reduced survival was observed compared
to controls (Fig. 2E), which suggests a potential role for
miR-148b in tumor cell intraluminal viability and initial
survival. All these experiments strongly suggest that
miR-148b is involved in metastatic cell dissemination by
controlling tumor growth and cell survival in anoikis
but mostly by inhibiting cell escaping through the
endothelial cells of the vessels.
miR-148b expression enhances chemotherapy-induced
apoptosis
Considering the relevance of chemotherapy response
for tumor progression, we analyzed the response to
paclitaxel, doxorubicin, and cisplatin following 24 or 48
h treatment in miR-148b-overexpressing (MDAMB231,
4175TGL, 4T1) or down-modulated (T47D) cells by cyto-
fluorimetric analyses. A significant modulation in cell
survival was found for all cell lines and treatments
compared to controls (Fig. 3), favoring a positive role
for miR-148b in chemotherapy response.
miR-148b modulates multiple genes
To identify genes directly or indirectly modulated by
miR-148b, miR-148b-overexpressing MDAMB231 cells
were first used to perform whole human genome gene
expression analysis. A total of 129 differentially ex-
pressed genes (49 up-regulated; 80 down-regulated)
were found, considering a 1.5-fold change and a 16%
FDR (Supplemental Table S1). qRT-PCR analysis was
used to validate expression of the nonmodulated
NRAS, ROCK1, PI3KCA, COPZ1, GRB2, and CXCL5
and of the differentially expressed DYRK2, CSF1,
CTSA, ITGA5, MMP15, and NRP1 (not shown). By
crossing these results with putative miR-148b targets
(TargetScan 5.1), 20 common genes (19 down-regu-
lated; 1 up-regulated) were found (Fig. 4A), among
them ITGA5, known to modulate apoptosis, adhesion,
migration, and invasion (29, 30), and CSF1, involved in
tumor-stroma interactions (31, 32). Using TargetScan
predictions for an IPA, GM-CSF and integrin pathways
were identified as statistically significant (Supplemental
Fig. S3). Therefore, we investigated the plausible direct
regulation of these pathways by miR-148b and their
involvement in breast tumor progression. Protein ex-
pression was evaluated for ITGA5 and its downstream
players ROCK1, PI3KCA/p110, and NRAS (predicted
targets) and for CSF1 in miR-148b-overexpressing
MDAMB231 or 4175TGL cells by Western blot analysis.
Strong reductions were found compared to controls
(Fig. 4B). Instead, when miR-148b was down-modulated
in MCF7 cells, increased levels of ITGA5 proteins were
observed (Fig. 4B). Interestingly, ROCK1, PI3KCA/
p110, and NRAS were not modulated at the mRNA
level (not shown). Direct modulation of miR-148b on
its targets was proven by performing luciferase assays in
miR-148b-overexpressing or control MDAMB231 cells
transfected with reporter vectors containing wild-type
or mutated 3=-UTRs (Fig. 4C, D). As positive control, a
miR-148b-sensor construct was used (Fig. 4C). Notably,
when we evaluated miR-148b target expression on a
subset of relapsing/nonrelapsing human tumors, dif-
ferential expression was found (Fig. 5A). Relevantly,
when the 23 predicted and modulated miR-148b target
genes were used in IPA to look for gene connections,
cell-to-cell signaling and interaction, tissue develop-
ment, cellular movement network was identified (Inge-
nuity score	22; Fig. 5B). Given the relevance of the
integrin pathway in our investigations, we evaluated the
possibility that the upstream player ITGA5 can be used
to predict survival in a large microarray dataset of
human breast tumors (26). Performing hierarchical
clustering and Kaplan-Meier analyses and referring to
Figure 3. miR-148b affects chemotherapy-induced apoptosis. MDAMB231 (A), T47D
(B), or 4T1 (C) cells transfected with miR-148b precursors or inhibitors or their negative
controls (pre- and anti-miR-148b or control) or 4175TGL (D) cells stably transduced
with pLemiR-EV or pLemiR-148b overexpression vectors were grown in complete
medium with or without paclitaxel or doxorubicin or cisplatin for 24 or 48 h.
Percentage of apoptotic cells was evaluated by TMRM and annexinV-FITC stainings in
a FACS analysis. HighTMRM-LowAnnexinV, healthy cells; LowTMRM-HighAnnexinV,
apoptotic cells. Three independent experiments were performed in duplicate; pooled
quantitations are shown as means  sem. ns, not significant. *P  0.05; **P  0.01.
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ITGA5 median expression, we predicted DFS (Fig. 5C).
This, together with similar results reported previously
(33), suggests that repression of ITGA5 correlates with
better clinical outcome and can be used as a prognostic
marker.
Down-modulation of ITGA5 accounts for miR-148b
chemotherapy response
The effect of integrin signaling on cell survival and
chemotherapy response was evaluated in the absence of
serum and adhesion (anoikis) or in presence of pacli-
taxel. When ITGA5 was silenced with siRNAs in
MDAMB231 cells, reduction in cell survival was ob-
served in anoikis conditions and for paclitaxel-treated
cells vs. controls (Fig. 6A). Instead, when ITGA5 (cDNA
lacking its 3=-UTR) was overexpressed (pEGFP-ITGA5),
together with pre-miR-148b, in MDAMB231 or MCF7
cells (Fig. 6B), and with cells kept in the presence of
paclitaxel, the effect of miR-148b on cell death was
abolished (Fig. 3). Figure 6B considers only the differ-
ence () observed when comparing the presence or
absence of miR-148b. ITGA5 and miR-148b levels were
evaluated by qRT-PCR analysis (Fig. 6C–E). From these
results, we can conclude that ITGA5 directly controls,
at least partially, miR-148b-driven apoptosis in anoikis
conditions and in the presence of paclitaxel.
DISCUSSION
In this work, we identified a group of 16 miRs that are
associated with bad prognosis in our breast cancer
Figure 4. miR-148b modulates multiple genes. MDAMB231 or MCF7 cells transfected with miR-148b precursors or inhibitors or their
negative controls (pre- and anti-miR-148b or pre- and anti-control) analyzed at 48 or 72 h post-transfection or 4175TGL cells stably
transduced with pLemiR-EV or pLemiR-148b overexpression vectors were used to perform microarray analysis (A), Western blots (B), or
luciferase assays (C). A) Clustering (Pearson correlation, average linkage) was performed for 20 putative miR-148b targets. Heatmap
represents relative gene expression with reference to the median across all samples; row: protein-coding gene; column: cell preparation. B)
Western blot (WB) analysis was performed for 5 putative miR-148b targets: ITGA5, ROCK1, p110 (PIK3CA), NRAS, and CSF1. Protein
expression was calculated relative to controls, following miR-148b overexpression or down-modulation, normalized on the indicated loading
controls (hsp90/actin/tubulin) and expressed as repression percentages. C, D) Luciferase assays (C) in cells transfected with reporter
constructs containing wild-type or mutant 3=-UTRs (D) for the indicated genes or a synthetic sequence including 3 perfect miR-148b binding
sites (sensor). Results are shown as means sem of firefly luciferase activity relative to controls, normalized onRenilla luciferase activity. mut,
mutation; del, deletion; a/b, a and b binding sites; ns, not significant. Three independent experiments were performed with independent
protein (WB and luciferase) or RNA preparations. Representative results are shown in B; results are pooled in C. *P  0.05; **P  0.01.
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patient cohort, and we revealed the function of
miR-148b as a metastasis suppressor in mice, as well
as its molecular mechanism of action. The identifi-
cation of a group of miRs that could identify primary
tumor subtypes is highly relevant for the clinics. In
fact, it represents a potent molecular tool that clini-
cians can use at the time of surgery to attempt the
most appropriate therapy for every patient. The
strength of this tool is further marked by the fact that
single components of the signature, for instance
miR-148b, can predict tumor outcome individually.
Relevantly, low levels of miR-148b were observed
previously in basal-like (9) and ERBB2/ER/PR
(34) breast tumors, which suggests its involvement in
malignancy.
Our functional experiments with metastatic cells
strongly suggest that miR-148b exerts its metastasis-
suppressing role mostly by controlling cell move-
ment. In fact, while it is true that ectopic expression
of miR-148b in malignant tumor cells leads to de-
creased tumor growth, this effect is modest and not
sufficient to justify the much more pronounced
control of metastasis dissemination. On this line,
increased miR-148b levels lead to stronger adhesion
and anoikis and reduce invasion in vitro. Moreover, in
vivo, miR-148b strongly reduces extravasation and
lung colonization shortly after injection of the cells
in the blood circulation, when proliferation has no
time to play a major role. Overall, it is well accepted
that miRs have pleiotropic functions and therefore
can act in independent events, such as tumor forma-
tion and progression, via the activation/repression
of a selective and rate-limiting cascade of specific
genes (8, 35–37).
Figure 5. Analysis of miR-148b-modulated genes in human tumors and
by IPA. A) Proteins were extracted from relapsing or nonrelapsing
primary breast tumors, and Western blot (WB) analysis was performed
for the direct miR-148b targets, ITGA5, ROCK1, PIK3CA, NRAS, and
CSF1. miR-148b expression is indicated as low (L) or high (H),
according to previous microarray and/or qRT-PCR analyses. -Tubulin
or actin was used as loading control. B) Twenty miR-148b down-
modulated genes identified in the microarray analysis (Fig. 4A) plus the
3 direct targets, ROCK1, PIK3CA, and NRAS, were used to perform an
IPA searching for gene connections; the cell-to-cell signaling and
interaction, tissue development, cellular movement functional network
was generated. Ingenuity score: log10 P 	 22. Gene products are
represented as nodes and biological relationships between two nodes as
a line. Continuous lines indicate direct interactions; dashed lines
represent indirect connections. Shapes of nodes symbolize functional
classes of gene products (see legend in panel). Gray symbols indicate down-regulation; white symbols indicate genes absent
in the input but related with the dataset used. C) Kaplan-Meier analyses of the probability of DFS of breast cancer patients
based on ITGA5 expression (median) in Wang et al. (26) dataset for 286 breast tumor samples. P value was calculated using
the log-rank test.
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Among all the miR-148b-modulated genes identified
in this study, many are known to be relevant in tumor
progression, among them, CTSA, NRP1, CSF1, MMP15,
and ITGA5, all suppressed by miR-148b. By focusing on
the ITGA5 signaling, we found that not only ITGA5 but
also ROCK1, PIK3CA/p110, and NRAS are directly
down-regulated by miR-148b, which suggests a specific
control for this miR on a pathway known to be involved
in metastasis dissemination and chemotherapy re-
sponse. In fact, ITGA5 and ROCK1 were found previ-
ously to be highly expressed in malignant breast tumors
and are known to increase tumor growth or progres-
sion (33, 38–42). At the same time, PIK3CA/p110 is
relevant for mammary tumorigenesis and angiogenesis
(43), as well as for resistance to endocrine or anti-HER2
therapies (44, 45). In addition, NRAS is a well-known
oncogene, and its silencing in tumor cells leads to
increased apoptosis (46). Regarding chemotherapy re-
sponse, elevated levels and activity of 51 have previ-
ously been implicated in drug resistance (47), and
inhibition of 51/fibronectin interactions promotes
apoptosis in malignant cells and enhances radiation
effects (33). In addition, perturbations of the actin
cytoskeleton integrity via ROCK1 inhibition commit
cells to apoptosis (48). Remarkably, ITGA5 and its
downstream player RHOA, a ROCK activator, have
been previously found to be suppressed by miR-31,
another small noncoding RNA that suppresses metastasis
(36). In addition, ROCK1 and RHOC are also directly
targeted by two other miRs involved in tumor progres-
sion, miR-146a/b and miR-10b (49, 50). The fact that
CSF1 is also a direct target of miR-148b opens up a role
for this small RNA in tumor-stroma cell interactions,
which will be part of a future study. In summary, our
study unravels the association of a group of 16 miRs
with bad prognosis tumors and identifies miR-148b as a
suppressor of tumor progression and modulator of
chemotherapy response acting via the integrin.
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Abstract
Background: Ionizing radiation (IR) can be extremely harmful for human cells since an improper DNA-damage response
(DDR) to IR can contribute to carcinogenesis initiation. Perturbations in DDR pathway can originate from alteration in the
functionality of the microRNA-mediated gene regulation, being microRNAs (miRNAs) small noncoding RNA that act as post-
transcriptional regulators of gene expression. In this study we gained insight into the role of miRNAs in the regulation of
DDR to IR under microgravity, a condition of weightlessness experienced by astronauts during space missions, which could
have a synergistic action on cells, increasing the risk of radiation exposure.
Methodology/Principal Findings: We analyzed miRNA expression profile of human peripheral blood lymphocytes (PBL)
incubated for 4 and 24 h in normal gravity (1 g) and in modeled microgravity (MMG) during the repair time after irradiation
with 0.2 and 2Gy of c-rays. Our results show that MMG alters miRNA expression signature of irradiated PBL by decreasing
the number of radio-responsive miRNAs. Moreover, let-7i*, miR-7, miR-7-1*, miR-27a, miR-144, miR-200a, miR-598, miR-650
are deregulated by the combined action of radiation and MMG. Integrated analyses of miRNA and mRNA expression
profiles, carried out on PBL of the same donors, identified significant miRNA-mRNA anti-correlations of DDR pathway. Gene
Ontology analysis reports that the biological category of ‘‘Response to DNA damage’’ is enriched when PBL are incubated in
1 g but not in MMG. Moreover, some anti-correlated genes of p53-pathway show a different expression level between 1 g
and MMG. Functional validation assays using luciferase reporter constructs confirmed miRNA-mRNA interactions derived
from target prediction analyses.
Conclusions/Significance: On the whole, by integrating the transcriptome and microRNome, we provide evidence that
modeled microgravity can affects the DNA-damage response to IR in human PBL.
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Introduction
Eukaryotic cells have evolved efficient DNA-damage response
to genotoxic agents in order to eliminate any detrimental effect of
DNA lesions. Ionizing radiation (IR) in out-of Earth represents an
environmental mutagen to which humans are daily exposed on
Earth. Crewmembers of space mission are even more exposed to
IR because the cosmic radiation field is rather different from that
experienced on Earth, and fragmentation with spacecraft shielding
modifies the radiation quality spectrum, hence modifying the
biological effectiveness of IR in a manner that is still undeter-
mined. The cell response to the space environment, which is
characterized by a condition of weightlessness (i.e. microgravity,
1024–1026 g), includes immune cell function suppression [1,2],
skeletal muscle atrophy [3–5], cardiovascular disorders [6], loss of
bone [7,8], changes of gene expression [9,10], increase in
chromosomal aberrations and apoptosis [11,12]. Studies carried
out with systems simulating on Earth some aspects of microgravity,
such clinostats and Rotating Wall Vessel bioreactors, reported
similar results, indicating that the experiments performed with
modeled microgravity can be used as surrogate of space conditions
[13–20]. Despite the abundance of data about the biological
effects of space and simulated microgravity, it is still unclear
whether microgravity can affects the DNA-damage response
(DDR) to IR. DDR is a complex pathway addressed to maintain
genome integrity through the activation of proteins involved in
sensing, signaling, and transducing the DNA damage signal to
effector proteins of cell cycle progression/arrest, DNA repair and
apoptosis [21]. While several studies reported additive/synergistic
interactions of radiation and microgravity in different biological
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31293
systems [22–26], other studies did not report such interactions
[27–29]. In particular, the repair of radiation-induced DNA
damage seems to be unaffected by microgravity in bacteria and
human fibroblasts [30,31] and in yeast [32]. On the contrary, in
our previous work we detected a significant delay in the rejoining
of DNA double-strand breaks induced by IR in human peripheral
blood lymphocytes incubated in microgravity conditions [33].
Recent findings show the tendency of radioadaptation to DNA
damage when space flown cells recovered on Earth are exposed to
subsequent irradiation [34]. By considering the complexity of
DDR and the controversial impact of reduced gravity on radio-
sensitivity, we expected that the analysis of microRNA (miRNA)
profiles could contribute to increase our knowledge on the features
of space environment.
MiRNAs are endogenous small noncoding RNAs (18–24 nt),
acting as post-transcriptional modulators of gene expression, by
pairing to target mRNAs and leading to decreased translational
efficiency and/or decreased mRNA levels [35]. A single miRNA
can influence the expression of up to thousand genes, thus the
function of a miRNA is ultimately defined by the genes it targets.
Besides a physiological role of miRNAs in a variety of important
biological processes including differentiation, apoptosis [36], fat
metabolism [37], viral infection [38] and pathological processes,
such as tumorigenesis [39–43], the miRNA-mediated gene
regulation operates also in response to cellular stress. Ionizing
radiation induces changes in miRNA expression both in vitro and in
vivo, according to cell type, radiation dose and post-irradiation
time [44–49]. Several studies suggested that miRNA expression is
regulated in the DDR at the transcriptional level, in a p53-
dependent manner [50], and through modulation of miRNAs
processing and maturation steps [51]. Whilst miRNA-mediated
DDR has been studied after ionizing radiation, UV radiation and
hypoxic stress [52,53], the response to IR combined with
microgravity has not been studied yet, and should give important
information about the risk of the exposure to space environment.
In our previous studies carried out with peripheral blood
lymphocytes (PBL) incubated in modeled microgravity (MMG)
during the repair time after IR, we reported significant decrease of
cell survival, delay of double strand break repair, increase of
mutant frequency and apoptosis [33,54]. In the present study we
analyzed miRNA expression profile of human PBL irradiated in
vitro with 0.2 and 2Gy of c-rays and incubated for a short (4 h) and
medium-long (24 h) period in MMG and in parallel ground
conditions (1 g). The results obtained from this study show
differences in miRNA expression profile as a function of the dose
and the time after irradiation in both gravity conditions.
Interestingly, under MMG many miRNAs were not responsive
to radiation compared with 1 g-condition. Analysis of mRNA
expression profiles and further miRNA-mRNA anti-correlation
analyses allowed the identification of DDR genes differently
modulated in the two gravity conditions.
Methods
Ethics Statement
Human peripheral blood lymphocytes (PBL) were obtained
from freshly collected ‘‘buffy coats’’ of healthy donors at the
Blood Centre of the City Hospital of Padova (Italy). This study
obtained ethics approval from the Transfusion Medicine (TM)
ethics committee of Blood Centre of the City Hospital of
Padova. The informed consent from donors was not required by
the TM/ethics committee because PBL samples were analyzed
anonymously.
Cells, irradiation and microgravity simulation
PBL were isolated by separation on Biocoll (Biochrom KG,
Seromed) density gradient from freshly collected buffy coats from
12 healthy donors. After overnight incubation, PBL, consisting of
peripheral mononuclear cells depleted of monocytes, were
irradiated with c-rays (0.2 and 2Gy) at the Department of
Oncological and Surgical Sciences of Padova’s University with a
137Cs source (dose-rate: 2.8Gy/min). PBL from six donors (named
D, E, F, I, L, M) were irradiated with 0.2Gy whereas PBL from
other six donors (named A, B, C, G, H, P) were irradiated with
2Gy, for a total of 12 independent experiments. For each
experiment, irradiated and non-irradiated PBL of the same donor
were incubated in 1 g and MMG conditions for 4 and 24 h.
MMG was simulated by the Rotating Wall Vessel (RWV)
bioreactor (Synthecon, Cellon), as previously described [14,20].
PBL incubated in 1 g, irradiated and non, were kept in 75 cm2
flasks at the same density (Figure 1). In all experiments were used
unstimulated quiescent (G0) PBL.
Total RNA isolation
At the end of incubation time (4 and 24 h) in 1 g and MMG,
total RNA was isolated from 107 irradiated and non-irradiated
PBL, by using TrizolH Reagent (Invitrogen, CA), according to the
manufacturer’s protocol. Total RNA quantification was performed
using the ND-1000 spectrophotometer (Nanodrop, Wilmington,
DE); RNA integrity and the content of miRNAs were assessed by
capillary electrophoresis using the Agilent Bioanalyzer 2100, with
the RNA 6000 Nano and the small RNA Nano chips, respectively
(Agilent Technologies, Palo Alto, CA). Only total RNA samples
Figure 1. Experimental procedure of irradiation and micro-
gravity simulation.
doi:10.1371/journal.pone.0031293.g001
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with RNA Integrity Number (RIN) values $6 and with miRNA
,20% were used for microarray analysis.
MiRNA and gene expression profiling
MiRNA expression profiles were carried out in irradiated (0.2,
2Gy) vs. non-irradiated PBL, incubated for 4 and 24 h in 1 g and
MMG. Analyses were performed by using the ‘‘Human miRNA
Microarray kit (V2)’’ (Agilent Technologies), that allows the
detection of 723 known human (miRBase v.10.1) and 76 human
viral miRNAs. Total RNA (200 ng) was labeled with pCp Cy3,
according to the Agilent protocol and unincorporated dyes were
removed with MicroBioSpin6 columns (BioRad) [55]. Probes were
hybridized at 55uC for 22 hours using the Agilent’s Hybridization
Oven that is suited for bubble-mixing and microarray hybridiza-
tion processes. Then, the slides were washed by Agilent Gene
expression wash buffer 1 and 2 and scanned using an Agilent
microarray scanner (model G2565CA) at 100% and 5% sensitivity
settings. Agilent Feature Extraction software version 10.5.1.1 was
used for image analysis.
Gene expression profiling was carried out in 2Gy-irradiated vs.
non-irradiated PBL, incubated for 24 h in 1 g or MMG,
previously analyzed for miRNA profiling. We used the ‘‘Whole
Human Genome Oligo Microarray’’ (Agilent), consisting of
,41.000 (60-mer) oligonucleotide probes, which span conserved
exons across the transcripts of the targeted full-length genes.
800 ng of total RNA were labeled with ‘‘Agilent One-Color
Microarray-Based Gene Expression protocol’’ according to the
manufacturer’s instructions. 1.65 mg of labeled cRNA were used to
prepare the hybridization samples and the hybridization was
carried out at 65uC for 17 hours in a hybridization oven rotator
(Agilent). The arrays were washed by Agilent Gene expression
wash buffers and Stabilization and Drying Solution as suggest by
the supplier. Slides were scanned on an Agilent microarray
scanner (model G2565CA) and Agilent Feature Extraction
software version 10.5.1.1 was used for image analysis. Raw
data are available on the Gene Expression Omnibus (GEO)
website (http://www.ncbi.nlm.nih.gov/geo/) using accession number
GSE20120 for miRNA expression profiling (72 experiments) and
accession number GSE20173 for mRNA expression profiling (20
experiments).
Statistical analysis of miRNA and gene expression data
Inter-array normalization of expression levels was performed
with cyclic Lowess for miRNA experiments and with quantile for
gene expression profiling [56] to correct possible experimental
distortions. Normalization function was applied to expression data
of all experiments and then values of spot replicates within arrays
were averaged. Furthermore, Feature Extraction Software pro-
vides spot quality measures in order to evaluate the goodness and
the reliability of hybridization. In particular flag ‘‘glsFound’’ (set to
1 if the spot has an intensity value significantly different from the
local background, 0 otherwise) was used to filter out unreliable
probes: flag equal to 0 will be noted as ‘‘not available (NA)’’. So, in
order to make more robust and unbiased statistical analysis, probes
with a high proportion of ‘‘NA’’ values were removed from the
dataset. We decided to use the 40% of NA as threshold in the
filtering process obtaining a total of 270 available human miRNAs.
Principal component analysis, cluster analysis and profile similarity
searching were performed with tMev that is part of the TM4
Microarray Software Suite [57]. The identification of differentially
expressed genes and miRNAs was performed with one and two
class Significance Analysis of Microarray (SAM) program [58]
with default settings. The expression level of each miRNA and
mRNA was calculated as the log 2 (irradiated/non-irradiated) PBL
of the same donor.
Identification of miRNA target genes and anti-correlation
analysis of miRNA and mRNA expression data
To predict miRNA targets we have performed a computational
analyses using PITA algorithm based on thermodynamic stability
of the RNA-RNA duplex, considering free energy minimization
[59]. PITA algorithm was applied over up-to-date version 38 of
RefSeq transcript sequences and it used miRNAs sequences
downloaded from mirBase version 14. To identify the most likely
targets, we have integrated mRNA and miRNA expression data,
obtained on the same biological samples, using MAGIA web tool
[60]. We used a non-parametric index (Spearman correlation
coefficient), the most indicated statistical coefficient for a small
number of measures, to estimate the degree of anti-correlation
(e.g. up-regulated miRNA and corresponding down-regulated
mRNA target) between any putative pairs of miRNA and mRNA
[61,62] and we have selected as functional only those anti-
correlated less than 20.775. To identify biological processes most
involved in the biological phenomena under study we have
performed a Gene Ontology (GO) analysis, using DAVID tool
[63], on significant anti-correlated target genes identifying
biological pathways significantly enriched (P,0.05). Pathway
enrichment analysis was carried out by KEGG web tool [63]
whereas miRNA-mRNA anti-correlations were visualized by
Cytoscape software package [64].
Validation of miRNA and mRNA expression levels with
qRT-PCR
The data of miRNA expression analysis were validated by using
the TaqManH MicroRNA Assay kit (Applied Biosystems, Foster
City, CA), that incorporate a target-specific stem-loop reverse
transcription primer to provide specificity for the mature miRNA
target. In brief, each RT reaction (15 ml) contained 10 ng of total
purified RNA, 56 stem-loop RT primer, 16RT buffer, 0.25 mM
each of dNTPs, 50 U MultiScribeTM reverse transcriptase and
3.8 U RNase inhibitor. The reactions were incubated in a
Mastercycler EP gradient S (Eppendorf) in 0.2 ml PCR tubes for
30 min at 16uC, 30 min at 42uC, followed by 5 min at 85uC, and
then held at 4uC. The resulting cDNA was quantitatively
amplified in 40 cycles on an ABI 7500 Real-Time PCR System,
using TaqMan Universal PCR Master Mix and Taqman
MicroRNA Assays for miR-34a, miR-424*, miR-181a-2*, miR-
144, miR-598, miR-27a, and for U48 small nuclear (RNU48) as
endogenous control.
For mRNA detection, 1 mg of total RNA was retrotranscribed
with ImProm-II Reverse Transcription System (Promega). qRT-
PCR was performed with the GoTaq qPCR Master Mix
(Promega) and gene-specific primers for ATM, BAX, FANCF,
STAT5A, TNFRSF10B genes and for GADPH as reference.
qRT-PCR reactions were always performed in quadruplicates, in
PBL samples from 4–6 donors. The relative expression levels of
miRNAs and mRNAs between samples were calculated using the
comparative delta CT (threshold cycle number) method (2-DDCT)
implemented in the 7500 Real Time PCR System software [65].
Luciferase reporter assays
Luciferase reporter vectors containing the 39-UTR of miR-27a,
miR-144 and miR-424* target genes ATM, FANCF, STAT5A,
TNFRSF10B, BAX, were generated following PCR amplification
from human cDNA and cloned into the pmirGLO Dual-
Luciferase miRNA Target Expression Vector (Promega, Madison,
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WI), immediately downstream from the stop codon of the
luciferase gene. The sequence of each insert was confirmed by
sequencing. MiR-27a-sensor, miR-144-sensor and miR-424*-
sensor, were obtained by annealing, purifying and cloning short
oligonucleotides containing the perfect miRNA binding site into
the SacI and XbaI sites of the pmirGLO vector. A549 cells were
plated in 24-well plates (146105 cells/well) and 24 h later co-
transfected with 50 ng of the pmirGLO dual-luciferase constructs,
containing the indicated 39UTRs of target genes, and with 32 nM
pre-miRTM miRNA Precursor Molecules-Negative Control or
pre-miRTM miRNA Precursor hsa-miR-27a (PM10939), hsa-miR-
424*(PM12641), and hsa-miR-144 (PM11051) (all from Ambion,
Austin, TX), using Lipofectamine2000 (Invitrogen Life Technol-
ogies). Lysates were collected 24 h after transfection and Firefly
and Renilla Luciferase activities were consecutively measured by
using Dual-Luciferase Reporter Assay (Promega) according to
manufacturer’s instructions. Relative luciferase activity was
calculated by normalizing the ratio of Firefly/Renilla luciferase
to that of negative control-transfected cells. Transfections were
performed in triplicate and repeated 3–4 times.
Results
Radio-responsive miRNAs in static condition (1 g)
Human PBL were irradiated in vitro with c-rays (0.2Gy; 2Gy)
and incubated in normal gravity (1 g) and in MMG during the
post-irradiation time. Twelve total donors were analyzed, six for
each dose, by performing independent experiments, in which
irradiated and non-irradiated PBL of the same donor were
incubated in 1 g and in MMG for 4 and 24 h. MicroRNA
expression profiling was performed on total RNA extracted at the
end of incubation times (Figure 1), by comparing the expression
profile of irradiated vs. non-irradiated PBL of the same donor.
Data obtained from PBL incubated in 1 g allowed to identify 26
(0.2Gy) and 20 (2Gy) radio-responsive miRNAs at 4 h after
irradiation; miRNAs differentially expressed at 24 h after
irradiation were 17 (0.2Gy) and 52 (2Gy), (Figure 2A and
Table 1). Raw data and means of miRNA expression values are
available on Table S1. Besides a fraction of radio-responsive
miRNAs common between 0.2 and 2Gy (28% and 19% at 4 and
24 h after IR, respectively), most of miRNA species was activated
in a dose-related manner (Figure 2B). Our results showed that,
early after irradiation, both doses induced consistent changes in
miRNA expression, whereas late after irradiation, the effect of the
higher dose was predominant. Furthermore, most of radio-
responsive miRNAs showed a time-related expression pattern,
with a substantial down-regulation at 4 h and up-regulation at
24 h after IR (Figure 2C).
Radio-responsive miRNAs in modeled microgravity
(MMG)
To check whether the expression of radio-responsive miRNAs
was altered under modeled microgravity condition, we character-
ized the miRNA profile of PBL irradiated with 0.2 and 2Gy and
incubated in MMG. After 4 h of incubation in MMG we
identified 16 miRNAs responsive to 0.2Gy (vs. 26 in 1 g) and 22
miRNAs responsive to 2Gy (vs. 20 in 1 g). After 24 h of incubation
in MMG we identified only 4 miRNAs responsive to 0.2Gy (vs. 17
in 1 g) and 32 miRNAs responsive to 2Gy (vs. 52 in 1 g) (Figure 3
and Table S2). The dose- and time-effect of IR on miRNA profile
persisted in MMG, in spite of the decreased radio-responsiveness.
In Figure S1 we report miRNAs which changed their expression
level in a time-related pattern, showing the down-regulation at 4 h
and the up-regulation at 24 h after irradiation, in common with
1 g.
The Venn diagram in Figure 4A shows the number of shared
and exclusively modulated miRNAs as a consequence of radiation
alone (i.e. in 1 g) and radiation associated with MMG. Radio-
responsive miRNAs specific to 1 g condition were 15 (0.2Gy) and
29 (2Gy), whereas those specific to MMG condition were 2 in
0.2Gy PBL and 9 in 2Gy PBL. Except for miR-371-5p and miR-
886-3p, which were differently altered in 1 g at 24 h after
irradiation (Table 1), miR-99b, let-7i*, miR-144, miR-200a, miR-
27a, miR-598, miR-650, miR-7, miR-7-1* were activated by the
combined exposure to IR and MMG (Figure 4B).
Target prediction and integration analysis of miRNA and
mRNA expression profiles
To predict the target genes of differentially expressed miRNAs
we first performed a computational analyses using PITA algorithm
available on line [46,59]. However, all available softwares for
target prediction are characterized by a large fraction of false
positive, thus, the integration of target predictions with miRNA
and gene target expression profiles has been proposed to refine
functional miRNA-mRNA relationships. For this purpose, we
defined the gene expression signature on the same PBL samples
used to assess miRNA expression profile, and then we compared
miRNA and mRNA expression levels (Figure 5). Gene expression
profiles were carried out only in 2Gy PBL incubated for 24 h in
1 g or in MMG, since for this dose and this time point, several IR-
responsive genes involved in DDR pathway were previously
identified in human quiescent PBL [66] and in human peripheral
blood [67]. In addition, our previous results demonstrated that cell
survival, double-strand break (DSB) repair, mutant frequency and
apoptosis, were significantly altered when 2Gy PBL were
incubated for 24 h in MMG [33,54]. We did not perform gene
expression profiling in 0.2Gy PBL incubated 24 h in 1 g or in
MMG, since the number of miRNAs differentially expressed in
MMG was too small (n = 4, Figure 3) to obtain informative data
from the anti-correlation analysis. The 52 (in 1 g) and 32 (in
MMG) differentially expressed miRNAs in 2Gy PBL resulted anti-
correlated to a total of 379 and 391 transcripts, respectively. These
transcripts were then classified according to DAVID [63], to
determine which Gene Ontology (GO) terms were significantly
enriched in our set of genes, in relation to the different gravity
conditions. Biological categories common to 1 g and MMG were
those of ‘‘Immune response’’, ‘‘Leukocyte activation’’, ‘‘Cell
activation’’, ‘‘Regulation of cell proliferation’’, ‘‘Regulation of cell
cycle’’, ‘‘Positive regulation of apoptosis’’ (Figure 6). Biological
categories of ‘‘Response to DNA damage stimulus’’, ‘‘DNA
damage response, signal transduction by p53 class mediator’’,
‘‘Apoptotic mitochondrial changes’’ and ‘‘DNA metabolic pro-
cess’’ were enriched only when PBL were incubated in 1 g. In
MMG, instead were enriched categories of ‘‘Hemopoiesis’’,
‘‘Regulation of cytokine production’’, ‘‘Immune system develop-
ment’’ and ‘‘Lymphocyte differentiation’’, all characterized by a
general gene down-regulation of gene expression (not-shown). By
pathway enrichment analysis using the KEGG web tool [63] we
found that the p53-pathway was enriched in both gravity
conditions, but with some differences between 1 g and MMG
(Figure S2). Table 2 provides the identity and associated functions
of each altered gene belonging to p53 pathway, together with
additional DDR genes found deregulated from miRNA-mRNA
integrated analyses. Genes in italic are included in the GO
category ‘‘Response to DNA damage stimulus’’, which was
enriched in 1 g but not in MMG.
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Table 1. Differentially expressed miRNAs in c-irradiated versus non-irradiated human PBL.
4 h after irradiation 24 h after irradiation
miRNA name 0.2Gy 2Gy miRNA name 0.2Gy 2Gy
hsa-miR-21* 20.84 20.72 hsa-miR-1225-5p 0.44 0.60
hsa-miR-34b* 20.89 20.85 hsa-miR-135a* 0.48 0.67
hsa-miR-210 0.53 0.46 hsa-miR-152 20.43 20.41
hsa-miR-630 21.75 21.41 hsa-miR-181a-2* 20.57 20.99
hsa-miR-886-3p 20.59 20.91 hsa-miR-188-5p [46] 0.60 0.73
hsa-miR-199b-5p 0.58 0.39 hsa-miR-34a [44,48,52,70,71] 1.53 1.76
hsa-miR-582-5p 0.48 0.39 hsa-miR-34b* [68] 1.02 1.66
hsa-miR-378 20.71 20.46 hsa-miR-424* 1.00 2.08
hsa-miR-513b 20.96 20.65 hsa-miR-638 [49,70] 0.57 0.59
hsa-miR-923 20.99 20.53 hsa-miR-663 [46,49,68,70] 0.46 0.99
hsa-let-7e [45,47,49] 20.31 hsa-miR-765 0.63 0.71
hsa-miR-16 [52] 0.30 hsa-miR-1226* 0.76
hsa-miR-23a* 0.17 hsa-miR-150* 0.38
hsa-miR-34a 20.64 hsa-miR-202 0.43
hsa-miR-145 0.75 hsa-miR-601 0.78
hsa-miR-181b 0.30 hsa-miR-760 0.42
hsa-miR-196b 0.55 hsa-miR-886-3p 20.60
hsa-miR-202 0.49 hsa-miR-100 [72] 20.50
hsa-miR-221 [52,69] 0.51 hsa-miR-101* 20.37
hsa-miR-339-3p 20.34 hsa-miR-10a 20.57
hsa-miR-345 20.62 hsa-miR-141 20.38
hsa-miR-425* 0.43 hsa-miR-151-3p 20.32
hsa-miR-450a 0.52 hsa-miR-16-2* 20.66
hsa-miR-494 20.76 hsa-miR-17 [69,73] 20.22
hsa-miR-629* 0.71 hsa-miR-181a [44,69] 20.31
hsa-miR-801 20.85 hsa-miR-18b [52] 20.35
hsa-miR-223 0.47 hsa-miR-196a 20.91
hsa-miR-301a 0.45 hsa-miR-196b [70] 20.51
hsa-miR-513a-5p 21.19 hsa-miR-19b 20.25
hsa-miR-940 0.53 hsa-miR-200b [70] 20.24
hsa-miR-768-5p 20.38 hsa-miR-210 [44,53] 20.31
hsa-miR-146a 20.41 hsa-miR-221* 20.36
hsa-miR-575 20.47 hsa-miR-29b-1* 20.47
hsa-miR-378* 20.47 hsa-miR-30d [69] 20.18
hsa-miR-188-5p 20.59 hsa-miR-30e* 20.24
hsa-miR-126* [69] 20.60 hsa-miR-330-3p 20.34
hsa-miR-335 20.35
hsa-miR-345 [44,53,71] 1.16
hsa-miR-363 0.99
hsa-miR-371-5p 0.55
hsa-miR-421 0.50
hsa-miR-483-5p 1.33
hsa-miR-494 0.87
hsa-miR-505* 20.40
hsa-miR-513a-5p 1.06
hsa-miR-513b 1.19
hsa-miR-513c 1.22
hsa-miR-551b 20.40
hsa-miR-574-5p 0.97
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By using Cytoscape [64] we were able to visualize miRNA-
mRNA interactions of DDR pathway in the two gravity conditions
(Figure 7). Our results show that the same transcript deregulated in
both 1 g and MMG (i.e. PCNA, XPC, CDKN1C, BAX, BIRC5,
PHLDA3, TNFRSF10B, TRIAP1) was, in most cases, anti-
correlated to different miRNA species, according to the condition
of gravity.
The microarray data from miRNA and mRNA expression
profiling were validated by real time-qPCR experiments for six
miRNAs and four mRNAs, whose expression level was signifi-
cantly altered in response to radiation (Figure 8). MiR-27a, miR-
144, miR-598, together with ATM and STAT5A transcripts, were
down-regulated in 2Gy MMG samples. MiR-34a, miR-424*,
miR-181a-2*, together with BAX and TNFRSF10B transcripts,
were deregulated in 2Gy PBL incubated in both gravity
conditions.
Functional correlation between miRNAs and some of
their potential target mRNAs
The modulation of miRNAs involved in the DNA-damage
response to radiation showed some differences between samples
incubated in normal gravity and microgravity. To validate some of
the predicted miRNA-mRNA anti-correlations identified in 2Gy-
PBL incubated in 1 g and MMG, we selected three miRNAs
(miR-27a, miR-424*, miR-144) and at least 2 of their potential
targets, for functional testing in vitro with the luciferase reporter
assay. While miR-424* was up-regulated in response to radiation
in both gravity conditions, miR-27a and miR-144 were respec-
tively up-regulated and down-regulated, in 2Gy-PBL incubated in
MMG. A549 cells were co-transfected with the synthetic miRNA
precursors (pre-miRNA) of interest or miRNA precursor-negative
control (pre-control), and expression vectors containing the
39UTR of the target gene, cloned downstream of the luciferase
gene. The results show that pre-miR-27a reduced significantly the
luciferase activity from constructs containing the ATM 39UTR,
but not the FANCF and STAT5A 39UTR. Pre-miR-424* reduced
significantly the luciferase activity of both FANCF and STAT5A
39UTR containing vectors, whereas pre-miR-144 reduced signif-
icantly that from constructs containing the BAX 39UTR (Figure 9).
As positive controls were used miR-27a-sensor, miR-144-sensor,
and mR-424*-sensor constructs, containing the perfect binding site
for each miRNA.
Discussion
With the present study, carried out on human PBL, we
evaluated whether the expression of miRNAs involved in the
DNA-damage response to c-radiation was affected by modeled
microgravity incubation during the repair time, enhancing the
biological effects of ionizing radiation. In ground gravity the
exposure to c-radiation alters miRNA expression profile as a
function of the dose and the time after IR. These results are in
accordance with data from normal human fibroblasts [46,53] and
lymphoblastic IM9 cells [68], but not with those from lympho-
blastoid TK6 cells [44], and from human endothelial cells [69],
strengthening the existence of cell-specific miRNA radio-response.
Several of the radio-responsive miRNAs here identified have been
found deregulated in other cells types exposed to different kind of
stressors (Table 1), [44–49,52,53,68–73].
Also modeled microgravity alters miRNA expression profile of
irradiated PBL in a dose- and time-manner, but with a decreased
radio-responsiveness compared with in 1 g. Indeed, 15 and 29
miRNAs were not responsive to 0.2 and 2Gy, respectively, when
incubation occurred in MMG. Due to the decrease of radio-
responsiveness of miRNA expression, we believe that the DNA-
damage response to radiation might be affected by MMG
incubation during the repair time. From our analyses we
individuated common and distinct miRNAs differentially ex-
pressed in response to radiation alone (in 1 g) or associated with
MMG. Eight miRNAs (let-7i*, miR-7, miR-7-1*, miR-27a, miR-
144, miR-200a, miR-598, miR-650), were differentially expressed
only when PBL were incubated in MMG. Probably, they not
respond to the direct insult of c-radiation, but are instead altered
by the combined action of ionizing radiation and microgravity.
To improve the detection of functional miRNA-mRNA
relationships, we analyzed the gene expression profiles on the
same PBL samples used to assess miRNA expression levels. Then,
we integrated the transcriptome and microRNome and we
performed the anti-correlation analysis. Gene Ontology (GO)
analysis was conducted on significant anti-correlated target genes
to identify common and distinct biological categories significantly
over-represented in our set of anti-correlated transcripts. Our
results show that most genes were gravity-specific. While in PBL
incubated in 1 g a great number of hits were achieved by the
categories of DDR pathway, in PBL incubated in MMG these
4 h after irradiation 24 h after irradiation
miRNA name 0.2Gy 2Gy miRNA name 0.2Gy 2Gy
hsa-miR-630 [68,73] 0.96
hsa-miR-769-5p 20.34
hsa-miR-801 0.66
hsa-miR-873 20.64
hsa-miR-877* 0.72
hsa-miR-923 0.89
hsa-miR-940 0.49
hsa-miR-95 20.44
hsa-miR-99a 20.64
Irradiated and non-irradiated PBL of the same donors were incubated in static gravity (1 g) for 4 and 24 h, and miRNA expression profile was analyzed at the end of each
incubation time. The expression value of each radio-responsive miRNA is the mean of expression levels calculated as the log2 (irradiated/non-irradiated) PBL from six
donors/dose (see Table S1). References of miRNAs differentially expressed in other cell types following the exposure to different stressors are given in parentheses.
doi:10.1371/journal.pone.0031293.t001
Table 1. Cont.
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Figure 2. Differentially expressed miRNAs in irradiated PBL incubated in 1 g condition. (A) Number of radio-responsive miRNAs at 4 and
24 h after irradiation with 0.2 and 2Gy of c-rays. (B) Percentage of dose-responsive miRNAs at the same time points. The expression level of each
radio-responsive miRNA is the mean of expression values from six different donors/dose determined by the log2 (irradiated/non-irradiated) PBL. (C)
Dendrogram showing radio-responsive miRNAs common to 0.2 and 2Gy of c-rays, whose expression changed between 4 and 24 h after irradiation.
Six different donors were analyzed for each dose, as indicated by the capital letters. The range of expression value is from -3.0 (green, down-
regulation) to 3.0 (red, up-regulation). Grey boxes correspond to not available (N/A) fluorescent signal from the microarray platform.
doi:10.1371/journal.pone.0031293.g002
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categories were not enriched. We instead found enriched processes
involved in hemopoiesis, regulation of cytokine production,
immune system development and lymphocyte differentiation.
To investigate on the differences of DDR pathway between 1 g
and MMG conditions, we focused on p53-pathway, which is
pivotal in eliciting a complex DDR in response to genotoxic and
non-genotoxic stresses [74–77]. The ATM transcript resulted
down-regulated in MMG and anti-correlated to miR-27a, as
confirmed by functional validation with the luciferase reporter
assay. Mir-27a, which is activated by the combined action of IR
and MMG, is abnormally up-regulated in several types of cancers
and has been identified to play an oncogenic role in the
progression of cancers [78–81]. Moreover, miR-27a is a member
of the miR-24 cluster, whose over-expression enhances TNF-a
induced apoptosis in human embryonic kidney cells [82] and
affects DSB repair in terminally differentiated blood cells by
deregulating H2AX expression [83].
The results of anti-correlation analyses reported the down-
regulation of p53 transcript (TP53) and alterations in the
expression levels of several p53-related transcripts (BBC3,
CCNG1, CDKN1A, CDKN2A, DDB2, GADD45A, PPM1D,
RRM2B,SESN1,THBS1, TP53I3, ZMAT3), when 2Gy PBL were
incubated in MMG. PPM1D transcript encodes for the p53-
induced protein phosphatase 1 (WIP1), which modulates the
expression of H2AX, the histone with a key role in DNA damage
signaling and DSB repairing [84]. Since overexpression of WIP1
facilitates the clearance of IR-induced c-H2AX foci after DNA
repair is completed [85], the up-regulation of WIP1 transcript
observed in 1 g but not in MMG, is consistent with our previous
results, showing s slower disappearance of c-H2AX foci in
irradiated PBL incubated in MMG [33]. From our results the
extrinsic pathway of apoptosis appeared more targeted in MMG
than in 1 g. Indeed, miR-7, miR-7-1*, miR-144 and miR-650,
which were anti-correlated to pro-apoptotic TNFRSF10B, were
exclusively radio-responsive in MMG. The expression level of the
gene, which encodes the receptor for the cytotoxic ligand
TNFSF10/TRAIL, was 3.65-fold induced in MMG vs. 2.6-fold
in 1 g. Also PHLDA3, which contributes to p53/TP53-dependent
apoptosis by repressing AKT1 activity, showed a higher expression
level in MMG. This gene was anti-correlated to miR-200a, itself
activated by the associated action of IR and MMG. On the
contrary, the intrinsic apoptotic pathway appeared more targeted
in 1 g, with four up-regulated genes (BBC3, TP53I3, ZMAT3,
FDXR). Notably, pro-apoptotic BAX was anti-correlated to four
miRNAs (miR-144, miR-200a, miR-598,miR-650) deregulated in
only 2Gy MMG PBL. The luciferase assay confirmed the
functional interaction between miR-144 and BAX, suggesting
that this miRNA may contribute to, or amplify, IR-induced
apoptosis in MMG. Instead, the interaction between miR-144 and
miR-27a with their putative target genes involved in apoptosis
(respectively TNFRSF10B and STAT5A), diminished the lucifer-
ase activity, but not significantly. It should be noted that such
transcripts are anti-correlated to 4–6 different miRNAs that can
act together on individual mRNA to produce additive or
synergistic effects [86,87].
On the whole our results evidence that 1) many transcripts are
targeted by multiple miRNAs; 2) the same transcript can be targeted
by different miRNA species according to the gravity condition; 3)
miRNAs responsive to IR in both gravities not always target the
same transcript. The possibility that a single mRNA can be targeted
by multiple miRNAs has been reported [88,89] and recently
demonstrated by Wu et al. [86]. The reason why the same mRNA
could be anti-correlated to different miRNA species in relation to
the gravity condition, is not clear. We hypothesize that the reduced
number of radio-responsive miRNAs in MMG can operate an
unscheduled regulation of transcripts. Moreover, the dysregulation
of mRNAs caused by microgravity-mediated gene expression
changes, could impact on miRNAs recruitment. This idea is
consistent with the recent findings of Poliseno and co-authors [90]
which demonstrated that mRNAs introduced into a cell can
potentially perturb the interaction between miRNAs and their
multiple targets, thus having a biological activity independent of the
Figure 3. Effect of modeled microgravity on miRNA expression of irradiated PBL. Number of differentially expressed miRNAs in PBL
irradiated with 0.2 and 2Gy and incubated for 4 and 24 h in MMG and in 1 g condition.
doi:10.1371/journal.pone.0031293.g003
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Figure 4. miRNA changes in human irradiated PBL incubated 24 h in 1 g and in MMG. A) The Venn Diagram shows the number of
common and exclusively expressed miRNAs as a consequence of only radiation (0.2Gy 1 g, 2Gy 1 g) and radiation with microgravity (0.2Gy MMG, 2Gy
MMG). B) miRNAs differentially expressed in PBL incubated 24 h in 1 g or MMG after irradiation with 0.2 and 2Gy. The expression level is given as log
2 (irradiated/non-irradiated) PBL incubated in the indicated gravity condition.
doi:10.1371/journal.pone.0031293.g004
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Figure 5. The procedure of computational prediction of miRNA targets. miRNA and gene expression profiles were defined in PBL irradiated
with 2Gy versus non-irradiated PBL of the same donors, at the end of 24 h-incubation in 1 g and in MMG. Target prediction was first performed by PITA
algorithm, then expression data were integrated to improve the detection of functional correlation between miRNA and mRNA expression profiling.
doi:10.1371/journal.pone.0031293.g005
Figure 6. Gene Ontology (GO) analysis of anti-correlated target genes in 2Gy-irradiated PBL incubated 24 h in 1 g or MMG.
Biological processes found enriched from GO analysis are shown. For each functional category is shown the number of genes differentially expressed
in the two gravity condition.
doi:10.1371/journal.pone.0031293.g006
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translation of the protein they encode. These authors propose that
mRNAs could possess a regulatory role that relies on their ability to
compete for miRNA binding, independently of their protein-coding
function. Furthermore, it has been shown that miRNAs themselves
are subjected to post-transcriptional regulation. Various proteins
induce processing of specific pri-miRNAs into mature miRNAs by
influencing the Drosha-dgcr8 complex, while other proteins block
miRNAs maturation by binding to the pre-miRNA [91–93]. Thus,
microgravity could affect post-transcriptional regulation of miR-
NAs. In addition, since miRNA biogenesis is globally induced upon
DNA damage in an ATM-dependent manner and the loss of ATM
abolishes miRNA induction after DNA damage [94], we suggest
that ATM down-regulation in MMG could affect miRNA
biogenesis in response to radio-induced DNA damage.
Table 2. Significantly anti-correlated genes involved in the DNA-damage response to IR of human PBL.
Gene symbol Gene name Function 2Gy 1 g 2Gy MMG
F.C. F.C.
ATM Ataxia Telangiectasia Mutated DNA damage signal transduction; cell cycle
checkpoint
- - 21.42
BAX BCL2-associated X protein Apoptosis 3.40 3.22
BBC3 BCL2-binding component 3 (PUMA) Apoptosis 5.94 - -
CCND2 Cyclin D2 Cell cycle progression 21.81 21.59
CCNG1 Cyclin G1 Cell cycle progression/arrest 2.83 - -
CDC2 Cell division cycle 2 (CDK1) Cell cycle progression 21.94 22.48
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21) Cell cycle arrest 3.89 - -
CDKN2A Cyclin-dependent kinase inhibitor 2A (p14ARF) DNA damage sensor; cell cycle arrest;
apoptosis
21.61 - -
DDB2 Damage-specific DNA binding protein 2 (p48) DNA repair 4.89 - -
EI24 Tumor protein p53 inducible protein 8 (PIGs) Apoptosis p53-dependent 1.46 1.40
GADD45A Growth arrest and DNA-damage-inducible, alpha Growth arrest; DNA repair; apoptosis 6.23 - -
GADD45B Growth arrest and DNA-damage-inducible, beta Growth arrest; apoptosis - - 22.54
MDM2 Mdm2 p53 binding protein homolog Inactivation of tumour protein p53 3.75 2.86
PPM1D Protein phosphatase 1D magnesium-dependent (Wild type
p53-induced phosphatase,Wip1)
DNA damage sensor (phosphorylates H2AX) 1.49 - -
RRM2B p53-inducible ribonucleotide reductase small subunit (p53R2) DNA repair - - 1.76
SESN1 Sestrin 1 (Sestrins) Cell cycle arrest 2.56 - -
THBS1 Thrombospondin 1 (TSP1) Cell growth 2.44 - -
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b (DR5) Apoptosis 2.60 3.65
TP53 Tumor protein p53 Cell cycle arrest; DNA repair; apoptosis - - 21.73
TP53I3 Tumor protein p53 inducible protein 3 (PIGs) Apoptosis p53-dependent 1.72 - -
ZMAT3 Zinc finger, matrin type 3 (PAG608) Cell growth; apoptosis p53-dependent 4.60 - -
AEN Apoptosis Enhancing Nuclease Apoptosis 5.42 4.44
BIRC5 Baculoviral IAP repeat-containing 5 Apoptosis 22.90 23.43
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57) Cell cycle 2.11 4.22
FANCA Fanconi anemia, complementation group A DNA repair 21.56 - -
FANCF Fanconi anemia, complementation group F DNA repair - - 21.47
FDXR Ferrodoxin reductase DNA damage, apoptosis 10.20 - -
IER5 Immediate early response 5 Apoptosis 1.86 - -
LIG1 Ligase I DNA Repair 0.79 - -
MYC v-myc myelocytomatosis viral oncogene homolog Cell growth; apoptosis 22.48 22.88
PCNA Proliferating cell nuclear antigen DNA repair 2.41 2.60
PHLDA3 Pleckstrin homology-like domain, family A, member 3 Apoptosis 7.57 9.98
STAT5A Signal transducer and activator of transcription 5A Apoptosis - - 21.52
TNFRSF10D Tumor necrosis factor receptor superfamily, member 10d Apoptosis 1.75 - -
TRIAP1 TP53 regulated inhibitor of apoptosis 1 Apoptosis 2.34 2.88
XPC Xeroderma pigmentosum, complementation group C DNA repair 2.36 2.08
Significantly anti-correlated genes of DDR pathway in 2Gy PBL incubated for 24 h in 1 g or in MMG. Fold change (F.C.) is the mean of the expression values obtained
from the transformed log2 (irradiated/non-irradiated) PBL (see Table S5 and Table S6). Genes in bold belong to p53-pathway; genes in italic belong to the GO category
‘‘Response to DNA damage stimulus’’.
doi:10.1371/journal.pone.0031293.t002
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Figure 7. Visualization of functional miRNA-mRNA anti-correlation in the main pathways of DNA-damage response. Analyses were
carried out in 2Gy-irradiated PBL incubated for 24 hours in gravity 1 g or in MMG. Circles represent transcripts and triangles miRNAs; the expression
levels of each features are represented as color scale. The lists of significantly miRNA-mRNA anti-correlations are reported in Table S3 and Table S4.
doi:10.1371/journal.pone.0031293.g007
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Figure 8. Microarray data validation by quantitative real-time PCR (qRT-PCR). Validation of microarray data by qRT-PCR in irradiated (2Gy)
vs. non-irradiated PBL. A) Down-regulated miRNAs (miR-144, miR-598, miR-181a-2*) and mRNAs (ATM, STAT5A); B) Up-regulated miRNAs (miR-34a,
miR-424*, miR-27a) and mRNAs (BAX, TNFRSF10B). Values (fold change, dark grey bars) are means 6 S.E. of independent experiments performed in
quadruplicate on PBL samples from 4–6 different donors. The value ‘‘1’’ of control PBL (light grey bars) is arbitrarly given when no change is observed
(***P,0.001; **P,0.01, *P,0.05, t-test).
doi:10.1371/journal.pone.0031293.g008
Figure 9. Luciferase reporter assay. Transient transfection analysis for luciferase expression in A549 cells co-transfected with pre-miRNA
precursors (pre-miRNAs) miR-27a, miR-144, miR-424*, or pre-miRNA precursor-Negative Control (pre-control), and reporter constructs containing the
39UTR of the indicated target genes or synthetic sequence including the perfect miR-27a, miR-144 and miR-424* binding site (sensors). Results are
shown as mean 6 S.D. of Firefly luciferase activity relative to controls, normalized on Renilla luciferase activity, from 3–4 independent experiments
(***P,0.001, **P,0.01, t-test).
doi:10.1371/journal.pone.0031293.g009
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In conclusion, the miRNA-mRNA changes observed in 2Gy
PBL incubated in MMG conditions may translate into alterations
of DDR pathway, at the DNA level and/or in the processing of
IR-induced DNA damage, that could affect cell survival, mutation
rate and apoptosis induction.
Supporting Information
Figure S1 Radio-responsive miRNAs common to 1 g
and MMG, changed as a function of the time after
irradiation. Heatmap of differentially expressed miRNAs at 4
and 24 h after irradiation with 0.2Gy (A) and 2Gy (B), common to
1 g- and MMG-incubated PBL. Range of expression value
expressed as log2 (irradiated/non-irradiated) PBL is from 22.0
(green, down-regulation) to 2.0 (red, up-regulation).
(TIFF)
Figure S2 p53 regulatory pathway. Network diagram of
KEGG p53 signaling pathway in human PBL incubated 24 h in
1 g (A) or in MMG (B) after irradiation with 2Gy. Over-expressed
(red), under-expressed (dark green) and not significantly changed
(light green) transcripts are shown. The identity and associated
functions of each altered gene are given in Table 2 of the text.
(TIFF)
Table S1 miRNAs differentially expressed in 1 g-incu-
bated PBL. This table lists differentially expressed miRNAs in
human PBL at 4 and 24 h after irradiation with 0.2 and 2Gy and
incubation in ground condition (1 g). The table includes miRNA
ID and the expression value of each sample expressed as log2
(irradiated/non-irradiated) PBL.
(XLS)
Table S2 miRNAs differentially expressed in MMG-
incubated PBL. This table lists differentially expressed miRNAs
in human PBL at 4 and 24 h after irradiation with 0.2 and 2Gy
and incubation in modeled microgravity (MMG). The table
includes miRNA ID and the expression value of each sample
expressed as log2 (irradiated/non-irradiated) PBL.
(XLS)
Table S3 Functional anti-correlations in 1 g. List of the
most significant miRNA-mRNA relationships (Spearman index
,20.775) performed by MAGIA, in human PBL at 24 h after
irradiation with 2Gy and incubation in 1 g. The table includes
RefSeq ID, gene symbol, mRNA description, anti-correlated
miRNA, Spearman correlation index, gene and miRNA expres-
sion levels of each putative anti-correlated pairs of miRNA and
mRNA in the same sample.
(XLS)
Table S4 Functional anti-correlations in MMG. List of
the most significant miRNA-mRNA relationships (Spearman
index ,20.775) performed by MAGIA, in human PBL at 24 h
after irradiation with 2Gy and incubation in modeled micrograv-
ity. The table includes RefSeq ID, gene symbol, mRNA
description, anti-correlated miRNA, Spearman correlation index,
gene and miRNA expression levels of each putative anti-correlated
pairs of miRNA and mRNA in the same sample.
(XLS)
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Rhabdomyosarcoma (RMS) is the most common
childhood sarcoma and is identified as either the em-
bryonal or alveolar (ARMS) subtype. In approxi-
mately 75% of cases, ARMSs are characterized by spe-
cific chromosomal translocations that involve PAX
and FKHR genes. ARMS gene expression signatures
vary, depending on the presence or absence of the
translocations. Insulin-like growth factor–binding
protein 2 (IGFBP2) is strongly overexpressed in trans-
location-negative RMS. Because IGFBP2 is associated
with tumorigenesis, we investigated its functional
role in RMS. An analysis of IGFBP2 distribution in
RMS cell lines revealed a strong accumulation in the
Golgi complex, in which morphological characteris-
tics appeared peculiarly modified. After silencing
IGFBP2 expression, our microarray analysis revealed
mostly cell cycle and actin cytoskeleton gene modu-
lations. In parallel, IGFBP2-silenced cells showed re-
duced cell cycle and rates of invasion and decreased
seeding in the lungs after tail vein injections in im-
munodeficient mice. An analysis of IGFBP2mRNA and
protein localization in human tumors showed abnor-
mal protein accumulation in the Golgi complex,mostly in PAX/FKHR-negative RMS. Moreover, an
analysis of patients with RMS revealed the presence of
conspicuous circulating levels of IGFBP2 proteins in
children with highly aggressive RMS tumors. Taken
together, our data provide evidence that IGFBP2 con-
tributes to tumor progression and that it could be
used as a marker to better classify clinical and biolog-
ical risks in RMS. (Am J Pathol 2011, 179:2611–2624; DOI:
10.1016/j.ajpath.2011.07.018)
Insulin-like growth factor–binding proteins (IGFBPs) are a
family of six serum proteins that bind IGFs, thus modu-
lating the availability and interactions of these growth
factors with their receptors. The 36-kDa IGFBP2 is the
second most abundant IGF-binding protein, being highly
expressed in the fetus and in several tissues and biolog-
ical fluids of the adult.1 Both stimulatory and inhibitory
effects of IGFBP2 on IGF signaling have been reported,
but its biological pathways and mechanisms have not
been fully elucidated. IGFBP2 binds extracellular matrix
proteins, most likely via its heparin-binding domain or its
distinctive integrin-interaction arg-gly-asp motif.2 The as-
sociation of IGFBP2 with cell surface probably modulates
cell function in two ways: by affecting the bioavailability of
IGFs in the pericellular space, thereby regulating recep-
tor targeting of IGFs, and by a direct IGF-independent
action on cell signaling pathways.3,4
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model, this protein is involved in several important cellu-
lar processes, such as proliferation, cell migration, and
adhesion, all of which play key roles in cancer establish-
ment and progression.
Overexpression of IGFBP2 in neuroblastoma cells and
its interaction with components of the pericellular and
extracellular matrices result in local sequestration of IGF1
and then in a dramatic enhancement of cell proliferation.5
In contrast, the interaction of IGFBP2 with integrin 51
produces an antiproliferative effect.4 Pereira et al6 pro-
posed that the interaction between v3 integrin and
IGFBP2 negatively modulates IGF-mediated cellular mi-
gration responses.
The involvement of IGFBP2 in cell migration and ad-
hesion has been extensively studied in human gliomas
because consistent IGFBP2 overexpression was discov-
ered in this malignancy.7 Signatures of glioma cell lines
stably expressing IGFBP2 were compared with parental
cells revealing an increased expression of several inva-
sion-related genes, including matrix metalloproteinase
(MMP) 2.8,9 An independent study10 by which the IGFBP2
gene was inactivated in two glioma cell lines indicated
that the surface glycoprotein CD24 acted as a candidate
downstream target of IGFBP2, promoting invasiveness.
Furthermore, IGFBP2 directly interacts with IIp45, an in-
tracellular molecule that appears to antagonize the
IGFBP2-induced invasiveness of glioblastoma cells.11
Recent studies12,13 also suggested an inverse correlation
between IGFBP2 and tumor suppressor genes, such as
PTEN and p16/INK4, whose loss of function is frequently
observed in human cancer. PTEN induces the decrease
of IGFBP2 expression, and this effect is mediated by
phosphorylation of Akt.14
Overall, elevated expression of IGFBP2 has been re-
ported in a variety of tumors, such as glioma,15 prostate
cancer,16 ovarian cancer,17 breast cancer,18–20 and sar-
coma.21,22 In many instances, its expression correlates
with grade of malignancy. Taken together, these findings
suggest that IGFBP2 may participate in the regulation of
tumor growth and invasion.
Rhabdomyosarcoma (RMS) is the most common soft
tissue sarcoma of childhood, divided into two major his-
tological subtypes: alveolar RMS (ARMS) and embryonal
RMS (ERMS). ARMS shows a dismal prognosis, signifi-
cantly worse than ERMS.23 However, it is not known why
ARMSs have a greater aggressiveness and metastatic
potential than ERMSs. Cytogenetic and molecular analy-
ses have demonstrated that ARMSs frequently harbor the
reciprocal chromosomal translocation t(2;13) in which
PAX3 and FKHR genes are juxtaposed and, albeit less
commonly, the variant translocation t(1;13).24 There is
also some evidence that PAX3/FKHR-positive ARMSs
have a worse prognosis than the PAX3/FKHR-negative
counterpart.25,26
Knock-in mouse experiments demonstrated that the
expression of PAX3/FKHR fusion protein was not able to
generate histologically and immunohistochemically (IHC)
genuine ARMS at a high frequency, suggesting that
PAX3/FKHR protein is necessary, but not sufficient, for
tumor initiation.27 Moreover, expression profiling stud-ies28,29 have shown that the PAX/FKHR gene confers to
ARMS an expression signature that is distinct from trans-
location-negative ARMS and from ERMS. In whole, these
findings would suggest that ARMS differs from ERMS
and, despite the almost identical morphological appear-
ance, that ARMS is not a single biological, and possibly
clinical, entity.
We performed an expression study29 on RMS, identi-
fying a series of genes that were differentially expressed
in PAX3/FKHR-positive versus PAX3/FKHR-negative
ARMS. From a detailed analysis of these genes, IGFBP2
emerged as one of the most interesting overexpressed
genes in PAX/FKHR-negative ARMS compared with PAX/
FKHR-positive ARMS. Most RMS studies30 have focused
on the consequences of the PAX/FKHR fusion protein in
the activation of a myogenic program, transformation, or
cellular growth, but it is unclear which signaling pathways
are altered in PAX/FKHR-negative RMS. In the present
study, we focused on the role of IGFBP2 as a distinctive
overexpressed gene in ARMS and PAX/FKHR-negative
ERMS. From in vitro and in vivo experiments using RMS
cell lines, we demonstrated the positive role of IGFBP2 in
cell cycle progression and invasiveness. A study on a
cohort of patients with RMS suggests that IGFBP2 could
be used as an IHC marker to distinguish between PAX/
FKHR-positive and PAX/FKHR-negative RMS and as a
plasma marker with potential prognostic impact in pa-
tients with RMS.
Materials and Methods
Cell Culture
Human ARMS cells (RH4, RH28, RH30, and RH18), hu-
man ERMS cells (RD, RH36, and SMS-CTR), and mouse
C2C12 myoblast cells were maintained in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf se-
rum, penicillin (100 U/mL), and streptomycin (100 g/mL)
(Invitrogen Life Technologies, Carlsbad, CA) at 37°C in
5% CO2 in a humidified incubator.
The human RMS cell lines RH30 and RD and C2C12
control cells were obtained from American Type Culture
Collection (Manassas, VA); RH4 and RH18 were a gift
from Dr. Peter J. Houghton (St Jude Children’s Hospital,
Memphis, TN); and SMS-CTR, RH36, CCA were obtained
from Dr. Maria Tsokos (National Cancer Institute, Be-
thesda, MD).
Tumor Samples
Selected clinical parameters of patients with RMS used
for this analysis are available (see Supplemental Tables
S1 and S2 at http://ajp.amjpathol.org).
RNA Interference
RH36 cells at 50% to 70% confluence were transfected
with SMARTpool small-interfering RNA (siRNA) for target
gene IGFBP2 (siIGFBP2) or with nontargeting siRNA pool
(siCONTROL) using Dharmafect 3 transfection reagent
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formed preliminary experiments to achieve the highest
efficiency and reproducibility. The efficacy of gene
knockdown was evaluated at the mRNA or protein level
by using RT-PCR and Western blot analysis after 48
hours.
Real-Time RT-qPCR
Total RNA was isolated using the TRIzol reagent (Invitro-
gen Life Technologies) and reverse transcribed using
Super-Script II (Invitrogen Life Technologies), according
to the manufacturer’s instructions. Each total RNA sample
was analyzed for quality control by capillary electropho-
resis using the RNA 6000 Nano LabChip and the Agilent
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).
An aliquot of first-strand cDNA was PCR amplified using
SYBR Green chemistry (Finnzymes, Espoo, Finland).
Quantitative RT-PCR (RT-qPCR) was performed in the
Applied Biosystems SDS-7500 thermal cycler (Applied
Biosystems, Life Technologies, Foster City, CA). Gene-
specific primers were designed using Primer3 software
(http://frodo.wi.mit.edu/primer3, last accessed July 20,
2008) or Application Design Tools (Roche Applied
Science, Monza, Italy). The sequences used are as fol-
lows: IGFBP2, 5=-ACTCCCTGCCAACAGGAAC-3= (for-
ward) and 5=-GTTGGGGTTCACACACCAG-3= (reverse);
glyceraldehyde-3-phosphate dehydrogenase (GADH),
5=-TCCTCTGACTTCAACAGCGA-3= (forward) and 5=-
GGGTCTTACTCCTTGGAGGC-3= (reverse); and guan-
ine nucleotidebinding protein, beta-peptide 2-like 1
(GNB2L1), 5=-GGGTCTTACTCCTTGGAGGC 3= (forward)
and 5=-GCTTGCAGTTAGCCAGGTTC-3= (reverse).
By using SYBR Green chemistry, we performed the
dissociation curve to confirm the specificity of the ampli-
con. Cycling parameters consisted of an initial denatur-
ation step at 95°C for 15 minutes; followed by 40 cycles
of denaturation at 95°C for 25 seconds, annealing, and
elongation steps at 59°C for 1 minute; and a final elon-
gation step at 72°C for 3 minutes. To evaluate differences
in gene expression, we chose a relative quantification
method in which the expression of target gene is stan-
dardized by one or two nonregulated reference genes
(ie, GADPH or GNB2L1). The mathematical method pre-
sented by Pfaffl,31 which calculates the efficiency of each
PCR using a standard curve, was applied. To calculate
the relative expression ratio, we used the CT method
implemented in the software of the Applied Biosystems
thermal cycler.32
Gene Expression Experiments
Control RNA pool and RNA samples obtained from three
different silencing experiments were linearly amplified with
the MessageAmp amplified RNA (aRNA) amplification kit
(Ambion, Austin, TX), labeled with Cy3 and Cy5 dye (Am-
ersham Biosciences, Chandler, AZ) and competitively hy-
bridized to oligonucleotide microarray platforms (GeneEx-
pression Omnibus ID: GPL2136). For each sample, we
performed at least two microarray experiments. Array fluo-
rescence was quantified with ScanArray Express software(PerkinElmer Inc, Wellesley, MA), and data were normalized
with MIDAS tool.33 All experiments were analyzed by the
SAM program,34 implemented in tMEV software.35 The list
of differentially expressed genes was functionally classified
using Gene Ontology (GO) criteria, as implemented in
DAVID.36 The data discussed in this publication have been
deposited in the National Center for Biotechnology In-
formation’s GeneExpression Omnibus37 database (http://
www.ncbi.nlm.nih.gov/geo, last accessed July 27, 2010)
and are accessible through accession number GSE23196.
Western Blot Analysis
Cells cultured under desired conditions were lysed in
buffer (50 mmol/L Tris-HCI, pH 7.5; 150 mmol/L sodium
chloride; 2 mmol/L EDTA; 1% Triton; 0.5% sodium deoxy-
cholate; and 0.1% SDS) containing protease inhibitors
(Sigma-Aldrich, St Louis, MO). Lysates were incubated
on ice and centrifuged for 30 minutes at 13,000  g, and
supernatants were removed and stored at 20°C until use.
Conditioned medium for analysis of secreted proteins
was concentrated using a Centricon filter (Millipore, Bil-
lerica, MA). Equal amounts of secreted or whole-lysate
proteins (30 g of protein per lane) were separated by
4% to 12% SDS-PAGE (Invitrogen Life Technologies) and
transferred to nitrocellulose membranes (Amersham Bio-
sciences). Membranes were blocked for 1 hour at room
temperature with 3% nonfat milk in PBS and then incu-
bated with diluted goat polyclonal anti-IGFBP2 (1:1000,
C-18; Santa Cruz Biotechnology, Santa Cruz, CA) or with
anti--actin (1:3000; Sigma-Aldrich) in PBS containing
0.1% (v/v) Tween 20 overnight at 4°C. After washing three
times for 5 minutes each with PBS containing 0.1% (v/v)
Tween 20 at room temperature, membranes were incu-
bated at room temperature for 1 hour with a diluted per-
oxidase-labeled secondary antibody. The membranes
were then washed three times for 5 minutes with PBS
containing 0.1% (v/v) Tween 20 at room temperature, and
immunopositive signals were visualized using an en-
hanced chemiluminescence detection kit (Cyanagen,
Bologna, Italy). The protein levels were quantified using
Quantity One software (ChemiDoc-Bio-Rad, Hercules,
CA). The control sample was set to one, and all RMS cell
results were related to this value. -Actin was used as an
internal reference for data normalization.
Immunofluorescence Assays
Cells cultured on glass coverslips in six-well dishes were
washed in PBS, fixed with 4% paraformaldehyde, and
permeabilized in 50 mmol/L NH4Cl and 0.2% Triton X-100
in PBS. After fixation, the cells were blocked with 1%
bovine serum albumin in PBS for 30 minutes at room
temperature. Cells were incubated with primary antibod-
ies (IGFBP2, 1:50, and GM130, 1:500; BD Biosciences,
San Jose, CA), diluted in 1% bovine serum albumin in
PBS for 1 hour in a humidified incubator at 37°C. After
washing with PBS, cells were incubated for 30 minutes in
a dark chamber with the corresponding secondary goat
fluorochrome-conjugated antibodies. Alexa Fluor 488
(green) or 568 (red) secondary antibodies were obtained
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slides were washed three times with PBS, and cell nuclei
were counterstained with DAPI mounted with gel Mount
Aqueous Mounting medium (Sigma-Aldrich) and exam-
ined using an 40 or 63 objective of a Leica 5000B
microscope (Leica Microsystems, Newcastle upon Tyne,
UK). Controls with no or only one primary antibody or
both secondary antibodies alone or in combination were
used to exclude nonspecific background staining. In
case of treatment with brefeldin A (BFA) before fixation
for staining, the culture medium was replaced with se-
rum-free medium containing BFA (Sigma-Aldrich) to a
final concentration of 10 g/mL, and the cells were cul-
tured for 1 hour.
Aequorin Measurements
All measurements were performed as previously de-
scribed.38 Briefly, for reconstituting with high efficiency
the aequorin chimera targeted to the Golgi apparatus
(GoAEQ), the luminal Ca2 concentration of this com-
partment must be reduced first. This was achieved by
incubating cells for 1 hour at 4°C in Krebs-Ringer buffer
(125 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L Na3PO4, 1
mmol/L MgSO4, 5.5 mmol/L glucose, 20 mmol/L HEPES,
pH 7.4, at 37°C) supplemented with 5 mol/L coelentera-
zine, 5 mol/L Ca2 ionophore ionomycin, and 600
mol/L EGTA. After this incubation, cells were extensively
washed with Krebs-Ringer buffer supplemented with 2%
bovine serum albumin and then a 13-mm round coverslip
with the transfected cells was placed in a perfused ther-
mostatic chamber placed in close proximity to a low-
noise photomultiplier, with a built-in amplifier-discrimina-
tor. The output of the discriminator was captured by a
Thorn-EMI photon counting board (Torn-EMI Ltd, Hayes,
Middlesex, UK) and stored in a computer for further anal-
yses. When the EGTA of the perfusion buffer was re-
placed with 1 mmol/L CaCl2, Ca
2 concentration Golgi
rapidly increased. Then, the addition of ATP, an ago-
nist coupled to inositol 1,4,5-trisphosphate production,
caused a rapid and extensive decrease in the Golgi Ca2
concentration.
The aequorin luminescence data were calibrated off-
line into Ca2 concentration values, using a computer
algorithm based on the Ca2 response curve of wild-type
and mutant aequorins, as previously described.39
VSVG Imaging
C2C12, RH30, and RH36 cells were seeded on 25-mm
coverslips previously coated with 0.01% poly-D-lysine
(for 1 hour at 37°C). At 48 hours after plating, cells were
transfected with the temperature-sensitive variant of the
G protein of vesicular stomatitis virus (VSVG), tagged
with green fluorescent protein (GFP; provided from Dr.
Jennifer Lippincott-Schwartz, NIH, Bethesda, MD) using
Lipofectamine 2000 (Invitrogen Life Technologies). In de-
tail, a Lipofectamine-DNA mix was prepared in Optimem
(Invitrogen Life Technologies) with a ratio of 8 L/1 g.
After 30 minutes, the mixture was placed on cells growing
in Dulbecco’s modified Eagle’s medium plus 10% fetalbovine serum. At 48 hours after transfection, the cells
were shifted to 15°C for 3 hours to accumulate cargoes in
the intermediate compartments. Then, cargoes were re-
leased to proceed into the Golgi complex by shifting the
temperature back to 37°C. Cells were then imaged with
Nikon Swept Field Confocal equipped with CFI Plan Apo
VC60XH objective (numerical aperture, 1.4) (Nikon In-
struments, Melville, NY) and an Andor DU885 electron
multiplying charge-coupled device (EM-CCD) camera
(Andor Technology Ltd, Belfast, Northern Ireland). Cov-
erslips were placed in an incubated chamber with a
controlled temperature, CO2, and humidity; then,
z-stacks were acquired by 21 planes with a 0.6-m dis-
tance, to allow acquisition of the whole cell. Intensity
measurements and three-dimensional rendering were
obtained by using open source software Fiji (http://fiji.sc/
wiki/index.php/Fiji, last accessed June 20, 2011). In detail,
membrane regions were obtained by generating a
threshold-based mask of the whole cell; then, with the
edge detection and dilated functions, a region for mea-
suring the membrane signal was obtained. A higher
threshold was used to detect Golgi aggregates (because
of the distribution of the signal) and vesicles with VSVG-
GFP localization. Golgi aggregates were then filtered
from vesicles using the analyzed particle function; ob-
jects 100 pixels2 were excluded.
Electron Microscopy
C2C12 and RMS cells were grown to 70% confluence.
After washing with PBS, cells were fixed with 4% para-
formaldehyde in PBS for 1 hour, embedded in 12% gel-
atin, infiltrated with 2.3 mol/L sucrose, and then frozen in
liquid nitrogen. Ultrathin cryosections were obtained with
Leica Ultracut UCT microtome, with a Leica EM FCS
cryoattachment and collected on copper-formavar car-
bon-coated grids (Leica Microsystems). Double-immuno-
gold labeling was performed as previously described.40
Briefly, the sections were incubated with goat anti-
IGFBP2 antibody. Rabbit anti-goat 10-nm gold-conju-
gated protein A was used to reveal the primary antibody
staining. Then, sections were incubated with rabbit anti-
giantin, followed by 15-nm gold-conjugated protein A as
the secondary antibody. The samples were examined
using an FEI CM10 and Tecnai G12 electron microscope
(FEI company, Eindhoven, The Netherlands).
Flow Cytometric Analysis of the Cell Cycle
After transfection, IGFBP2-silenced (siIGFBP2) and con-
trol (siCONTROL) cells were harvested. For each sample,
1  106 cells were fixed with 70% cold ethanol, washed
with PBS, and incubated with propidium iodide (50 g/
mL) and RNase (100 g/mL) for 60 minutes at 37°C.
Samples were run in a BD FACScan (Becton Dickinson,
Labware, Bedford, MA), and data were analyzed with
ModFitLT V3.0 software (Verity Software House, Top-
sham, ME). Two independent samples were analyzed for
each cell type.
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Migration was tested using cell culture inserts (Transwell)
with an 8-m pore size membrane (24-well format; Bec-
ton Dickinson). Chemoinvasion was measured using 24-
well BioCoat Matrigel invasion chambers (Becton Dickin-
son) with an 8-m pore polycarbonate filter coated with
Matrigel. The lower compartment contained 0.5 mL of 1%
serum medium conditioned by the NIH3T3 cell line as a
chemoattractant or serum-free Dulbecco’s modified Ea-
gle’s medium as a control. In the upper compartment, 105
RH36 cells per well were placed in triplicate wells and
incubated for 18 hours at 37°C in a humidified incubator
with a 5% CO2 atmosphere. After incubation, the cells on
the upper surface of the filter were wiped off with a cotton
swab, whereas the cells on the lower surface were fixed
in 2.5% glutaraldehyde, stained with 0.2% crystal violet in
20% methanol, and then photographed using a stereomi-
croscope (model MZ16; Leica Microsystems) equipped
with a CCD camera. Images were elaborated with Corel-
Draw software (Corel, Ottawa, Canada), and the area
occupied by the migrated cells was measured by using
ImageJ software (http://rsbweb.nih.gov/ij, last acces-
sed September 4, 2009).
Lentiviral Infections and Gene Silencing with
shRNAs
The lentiviral expression vectors were obtained from
Sigma-Aldrich, and cells were infected as previously
described.41
Seeding Assay
All animal experiments were conducted in compliance
with national legislation on ethical animal care. Female
CD1 nude mice, aged 7 weeks (Charles River Laborato-
ries, Wilmington, MA), were injected in the tail vein with
1.6  106 RH36 IGFBP2-silenced or control RH36 cells,
previously labeled with CellTracker Orange CMRA (Mo-
lecular Probes, Invitrogen Life Technologies), and resus-
pended in PBS. After 48 hours, mice were sacrificed and
4% paraformaldehyde was injected into the trachea.
Lungs were dissected and photographed using a Leica
MZ16F fluorescence stereomicroscope (Leica Microsys-
tems), and the mean of the total red fluorescent (CMRA)
tumor cells present in three representative pictures per
lungs per animal was evaluated using ImageJ software.
Twelve mice per group were used.
IHC Analysis
Sections (4-m thick) from paraffin-embedded tissues
were dewaxed in xylene, rinsed in graded ethanol, and
rehydrated in distilled water. For antigen retrieval, slides
were pretreated by steaming in EDTA citrate buffer (pH
9.0) for 15 minutes at 100°C. Then, the sections were
treated with 3% H2O2 for 5 minutes at room temperature
to block endogenous peroxidase activity. After washing
with PBS, the sections were manually immunostained
with anti-IGFBP2 antibody at 1:100 dilution. For mousemonoclonal anti-58k antibody (GeneTex, Irvine, CA), the
IHC stain was performed using a Bond MaX automated
immunostainer (Leica Microsystems). The 58k primary
antibody was used at 1:1000 dilution for 15 minutes.
IGFBP2 was detected using the ABC Elite method
(Vector Laboratories, Burlingame, CA), whereas mouse
monoclonal anti-58K was detected using the polymer
Refine detection kit (Leica Microsystems), according to
the manufacturer’s instructions. Hematoxylin was used
for counterstaining. Specimens were then dehydrated
with alcohol. The sections were analyzed with a Leica
DM4000B-M microscope at either 20 or 40 amplifica-
tion (Leica Microsystems). A human placenta tissue sec-
tion was used as the positive control.
ELISA Assays
IGFBP2 plasma levels were determined by using the
IGFBP2 enzyme-linked immunosorbent assay (ELISA) kit
(RayBiotech, Inc., Norcross, GA), according to the man-
ufacturer’s instructions. Each assay was repeated three
times, and the mean concentration of IGFBP2 was used
for further statistical analysis.
Statistical Analysis
Microarray
All microarray experiments were analyzed by the SAM
program implemented in tMEV software. SAM uses a
permutation-based multiple testing algorithm and identi-
fies significant genes with variable false-discovery rates.
The list of differentially expressed genes presenting a
false-discovery rate of 0 was classified in terms of bio-
logical functions using DAVID, a functional annotation
tool. This type of analysis was aimed at identifying func-
tional categories from the GO and public gene annotation
databases that are present in the IGFBP2-silenced ex-
pression signature more frequently than expected by
chance alone. The Group Enrichment Score is used to
rank their biological significance. Thus, the top ranked
annotation groups most likely have consistent lower P
values for their annotation members.
Seeding
Data are calculated as mean  SEM number of
seeded cells 48 hours after injections for 12 mice per
group, and the two-tailed Student’s t-test was used for
comparisons, with P  0.05 considered a statistically
significant value.
ELISA Data
Two or three independent experiments were per-
formed in triplicate for each sample. Significance was
evaluated using the Student’s t-test or an F test that does
not assume equal variances, and P  0.05 was consid-
ered statistically significant. We performed the nonpara-
metric U-test and the Wilcoxon signed rank test. An anal-
ysis of variance multiway analysis was used to correlate
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0.05 was considered statistically significant.
Results
Analysis of IGFBP2 in RMS Cell Lines
The presence or absence of the PAX/FKHR fusion gene
identifies two different gene expression signatures in
RMS.28,29 Because IGFBP2 emerged as one of highly
overexpressed genes in PAX/FKHR-negative RMS, we
hypothesized that it may play a role in growth and differ-
entiation of this tumor. To test this, we first studied the
expression of IGFBP2 in eight RMS cell lines and in the
myoblast C2C12 cell line as a control. We found that
IGFBP2 expression in cell lines mirrors the expression pat-
tern of the histologically related RMS samples analyzed in
our previous microarray study.29 In fact, IGFBP2 mRNA
(Figure 1A) and both the intracellular and secreted protein
fractions (Figure 1B) were significantly more abundant in
most PAX/FKHR fusion-negative cell lines. The higher con-
centration of secreted IGFBP2 in culture medium of fusion-
negative cells was also confirmed by ELISA (see Supple-
mental Figure S1 at http://ajp.amjpathol.org).
An analysis of the intracellular localization of IGFBP2
revealed that the protein was concentrated in a perinu-
clear region of RMS cells (Figure 1C). IGFBP2 was more
abundant in the embryonal RH36 cell line compared withthe alveolar PAX3/FKHR-positive RH30 cell line (Figure
1D). The differential expression of IGFBP2 between
ARMS and ERMS was confirmed in other RMS cell lines
(data not shown). In the cytoplasm of the control cell line
C2C12, the IGFBP2 signal was low (Figure 1E). Co-im-
munostaining with an antibody directed against the cis-
Golgi matrix protein GM130 demonstrated the concen-
tration of IGFBP2 in the Golgi apparatus. This finding was
confirmed by treatment of RMS cells with BFA, a fungal
metabolite that inhibits protein secretion in eukaryotic
cells by interfering with the function of the Golgi appara-
tus.42 On BFA treatment, we observed a redistribution of
IGFBP2 in the cytoplasm of RMS cells (Figure 1F). Inter-
estingly, IGFBP2-expressing RMS cells showed an un-
usual modification of the Golgi morphological features
that appeared condensed in a juxtanuclear position and
without their typical stack organization. This peculiar or-
ganization appears to depend on the level of accumu-
lated protein, as shown in the different cell lines analyzed
(Figure 1, C and D).
RMS Cells Show Morphological and Functional
Alterations of Golgi Apparatus
We analyzed whether the conspicuous morphological
changes in the Golgi apparatus complex, seen in RMS
cells by immunofluorescence experiments, were accom-
Figure 1. IGFBP2 accumulates in the Golgi of
RMS cell lines. A: RT-qPCR evaluation of IGFBP2
expression in different RMS cell lines classified
as indicated. Results are shown as relative ex-
pression ratio obtained with the CT method.
GADH and G2BNL1 were used as reference
genes. Vertical bars indicate 95% confidence in-
terval. B: IGFBP2 protein content was measured
in whole-cell lysate (dark gray bars) and in me-
dium (light gray bars) of the same RMS cell lines
as in A by using Western blot analysis. Quantity
One software was used for quantitation. Values
are calculated as fold changes relative to C2C12
control cells and normalized to -actin level.
Vertical bars indicate 95% confidence interval.
The trend line (red) was calculated by adding
the lysate and medium protein values. C–F: Im-
munostaining of ERMS cell line RH36 (C), PAX3/
FKHR-positive ARMS cell line RH30 (D), and
control cell line C2C12 (E) with DAPI for nuclei
(blue), anti-GM130 antibody for Golgi (green),
and anti-IGFBP2 antibody (red). The pictures of
the last column are obtained by merging the
GM130 and IGFBP2 antibody signals. F: Immu-
nostaining of RH36 cells after BFA treatment
shows the simultaneous releasing of GM130 an-
tigen and IGFBP2 from Golgi into the cytoplasm.
The image is restricted to few cells to highlight
the distribution of Golgi marker protein, but all
of the cells show the same staining pattern.panied by functional alterations of this organelle. The
larged v
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AJP November 2011, Vol. 179, No. 5Golgi apparatus acts as Ca2 store, and changes in
calcium concentration within the Golgi lumen regulate
Golgi function, controlling some of the key processes of
cell biology, such as protein trafficking and sorting.38
Therefore, we assayed the dynamic variations of Ca2
concentration homeostasis within the Golgi apparatus
using the recombinant Ca2-sensitive bioluminescent
protein aequorin, modified with a specific tag for lo-
calization in this organelle (Golgi aequorin protein
[GoAEQ]).38 To obtain reliable quantitative estimates of
Ca2 concentration in the lumen of the Golgi apparatus,
its Ca2 concentration needs to be decreased during
both the reconstitution of aequorin with coelenterazine
and the subsequent initial phase of perfusion with Krebs-
Ringer buffer–EGTA in the luminometer (seeMaterials and
Methods). After Ca2 depletion of the organelle, we in-
vestigated the characteristics of the Ca2 uptake and
release after agonist stimulation. When the EGTA in the
perfusion buffer was replaced with 1 mmol/L CaCl , Golgi
Figure 2. Morphological and functional alterations of Golgi apparatus in RM
cells. Where indicated, cells were treated with CaCl2 to assess the filling of th
the organelle. RMS cells showed a deregulation of Golgi Ca2 homeostasis, i
accumulate and release Ca2 after agonist stimulation. B: Analysis of VSVG
intensity at plasma membrane compared with overall signal. A significant (*P
with control cells. Vertical bars represent the confidence interval of single-cell
compartment at 37°C (D) and at 15°C (E) revealed a more fragmented Golgi a
F and G: Ultrathin cryosections of C2C12 (F) and RMS (G) cells were double
IGFBP2 (10-nm gold, arrowhead). IGFBP2 colocalizes in giantin-labeled en
G). g, Golgi; N, nuclei.2
Ca2 rapidly increased up to a concentration of approx-imately 300 mol/L (Figure 2A) in C2C12 cells. Produc-
tion of inositol 1,4,5-trisphosphate activates channels on
the Golgi membrane, resulting in Ca2 release from the
apparatus. Indeed, when C2C12 cells were stimulated
with ATP (an agonist of inositol 1,4,5-trisphosphate pro-
duction), a release of Ca2 from the Golgi membrane was
observed (Figure 2A). On the contrary, a deregulation of
Golgi Ca2 homeostasis was detected in two different
RMS cell lines. The Golgi apparatus of RH30 cells
showed a normal Ca2 uptake, reaching the same
steady state observed in C2C12 but a completely com-
promised Ca2 release after ATP treatment (Figure 2A).
The alteration is more evident in RH36 cells, in which the
Golgi apparatus apparently failed to both accumulate
and, in turn, release Ca2 after agonist stimulation (Fig-
ure 2A). These data suggest that RMS cells have a de-
fective Ca2 homeostasis in the Golgi apparatus.
To investigate whether the deregulation of Ca2 can
affect protein sorting and trafficking from Golgi to the
A: Golgi Ca2 homeostasis measurements with aequorins in C2C12 and RMS
compartments and with ATP, as agonist, to analyze the release of Ca2 from
lar RH36 (gray line), in which the Golgi apparatus apparently failed to both
tribution in C2C12 and RMS cell lines at 37°C. C: Percentage of VSVG-GFP
ncrease in VSVG-GFP at the cell surface of RMS cells was observed compared
of three independent experiments.D and E: VSVG-GFP signal from the Golgi
s with clear morphological changes in RMS cells compared with C2C12 cells.
with antibodies against giantin (15-nm gold, arrows), a Golgi marker, and
esicles at the edge of Golgi cisterns in RH36 cells. Scale bars: 192 nm (F andS cells.
e Golgi
n particu
-GFP dis
0.05) i
signals
pparatu
labeledplasma membrane, we used the viral glycoprotein VSVG,
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sis in control C2C12 cells showed that, at 37°C, VSVG-
GFP moves from the Golgi to the plasma membrane
(Figure 2B). An analysis of VSVG-GFP protein distribution
in RMS cells at 37°C revealed significant accumulation of
protein at the cell surface compared with control cells
(P  0.05, Figure 2C). These data suggest an active
production of secreted proteins in RMS cells, probably
linked to the deregulation of protein transport. A colocal-
ization experiment, using GM130 as a specific Golgi
marker, confirmed that VSVG-GFP transits through Golgi
in control and RMS cells during its secretory process (see
Supplemental Figure S2 at http://ajp.amjpathol.org).
Therefore, by focusing on the VSVG-GFP signal from the
Golgi compartment, in C2C12 cells, we observed normal
morphological features of the Golgi apparatus that ap-
peared with its stacking organization (Figure 2D). In con-
trast, in RMS cells, the distribution of VSVG-GFP protein
revealed a more fragmented Golgi, with clear morpho-
logical changes (see Supplemental Videos S1, S2, and
S3 at http://ajp.amjpathol.org).
The use of a mutant gene encoding a temperature-
sensitive VSVG-GFP allowed us to localize the protein in
different cellular compartments. At temperatures as low
as 15°C, mutant VSVG-GFP accumulates in intermediate
structures called pre-Golgi apparatus that appeared
markedly enlarged and accumulate secretory prod-
ucts.44 Indeed, at 15°C, we observed an altered distribu-
tion of VSVG-GFP in C2C12 cells with accumulation of the
protein in Golgi structures that appear more fragmented,
similar to RMS cells (Figure 2E). However, VSVG-GFP
protein localization in RH30 and RH36 cells was not af-
fected by temperature, indicating that, in these cells,
there is a continuous accumulation of secretory products
in an altered Golgi compartment.
This hypothesis was confirmed by electron microscopy
analysis. Cryosections of C2C12 control cells and
IGFBP2-overexpressing RH36 cells were immunolabeled
with specific antibodies against IGFBP2 and giantin, a
Golgi apparatus marker. In C2C12 cells, the distribution
of IGFBP2 in the Golgi apparatus was as expected for a
typical secreted protein (Figure 2F). In ERMS cell RH36,
some normal Golgi apparatus stacks were found, but the
IGFBP2 pattern was peculiar because the protein accu-
mulated at the edge of membrane-bound cisterns, reac-
tive with Golgi-specific marker, that appeared less de-
fined than normal Golgi apparatus cisterns (Figure 2G).
Taken together, these data suggest that, in RMS cells, the
morphological alterations are likely involving only a se-
lected portion of the Golgi apparatus that appears to be
made up of structures resembling altered and enlarged
vesicles, possibly because of abnormal accumulation of
secreted proteins.
Gene Expression Modification in RMS Cells after
Silencing IGFBP2
We used siRNA to examine the effects of IGFBP2 sup-
pression in the IGFBP2-overexpressing ERMS cell line
RH36. As a result, IGFBP2 abundance was dramaticallyreduced at both the mRNA and protein levels after 48
hours of siRNA treatment (Figure 3, A and B). Moreover,
a low level of IGFBP2 protein positively correlated with a
change of Golgi shape that appears less condensed,
probably because of a decrease of secretory vesicles
(Figure 3C).
To identify the networks of genes whose expression
was influenced by and functionally related to IGFBP2
reduction, we obtained the profiles of RMS cells from
three independent experiments of IGFBP2 silencing and
compared them with RMS cells treated with a pool of
nontargeted siRNAs, used as controls. A total of 603
genes were differentially expressed in silenced RMS
cells, equally distributed between up- and down-regu-
lated genes (see Supplemental Table S3 at http://ajp.
amjpathol.org). A functional annotation web tool (DAVID)
was used to analyze the biological meaning of the differ-
entially expressed genes. This type of analysis was
aimed at identifying functional categories from the GO
and public gene annotation databases that are present in
the IGFBP2-silenced expression signature more fre-
quently than expected by chance. The Group Enrichment
Score was used to rank their biological significance.
Thus, the top-ranked annotation groups most likely have
consistently lower P values for their annotation members.
As a result, we observed that GO functional categories
overrepresented in the up-regulated component of the
expression signature included protein transport and
Golgi-vesicle transport; in contrast, the down-regulated
component showed an overrepresentation of GO catego-
ries (ie, regulation of the cell cycle, cell adhesion, and cell
motility or migration) (Figure 3, D and E). Among the
deregulated genes, cyclin D1 (CCND1), MMP2, and
minichromosome maintenance protein (MCM) family ex-
pression levels were remarkable. Cyclin D1 and the
MCMs are implicated in tumorigenesis because of their
involvement in the regulation of cell cycle progression.
Moreover, correlation of IGFBP2 expression and MMP2
expression was reported. Metalloproteinase proteins act
in the modeling of extracellular matrix and are implicated
in the acquisition of invasive potential and in tumor pro-
gression. Microarray results were validated by RT-qPCR
for a sample of 12 genes belonging to different annota-
tion clusters (see Supplemental Figure S3 at http://
ajp.amjpathol.org).
IGFBP2 Silencing Reduces Cell Cycle
Progression, Migration, and Invasiveness of
RMS Cells in Vitro
The signatures of IGFBP2-silenced cells showed the in-
volvement of IGFBP2 in cellular pathways generally as-
sociated with cancer growth and progression. To validate
this observation, cell cycle progression of the IGFBP2-
silenced cell line (siIGFBP2) was compared with control
cells (siCONTROL) by flow cytometry. Cells with reduced
levels of IGFBP2 showed a decreased proliferation rate
and G0/G1 phase arrest (P  0.05, Figure 4A). Moreover,
we tested whether IGFBP2 suppression affected RMS
cell migration and invasion in vitro. Both assays revealed
here re
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ity of IGFBP2-silenced cells compared with parental cells
(P  0.05, Figure 4B). Altogether, these results suggest
that a high level of IGFBP2 facilitates RMS tumor cell
Figure 3. Altered gene pathways in IGFBP2-silenced RMS cells. A: IGFBP2 m
for IGFBP2 (siIGFBP2) or with the nontargeted siRNA pool (siCONTROL). A
B: IGFBP2 protein content measured by immunoblotting of whole cell lysate
mRNA and protein after 48 hours of silencing (siC, siCONTROL; siI, siIGFB
Treatment shows that low levels of IGFBP2 correlate with change of Golgi sha
DAPI for nuclei (blue), anti-GM130 antibody for Golgi (green), and anti-I
up-regulated (red) or down-regulated (green) genes in IGFBP2-silenced RH3
(Group Enrichment Score). E: Heat map representing a selection of der
IGFBP2-silenced RH36-infected cells. Globally, the microarray data analyzed
genes. A color-coded scale for the normalized expression values was used, w
RH36 cells transfected with the siRNA pool (siCONTROL).invasion and cell cycle progression in vitro.IGFBP2 Silencing Reduces Seeding of RMS
Cells in Vivo
To assess whether IGFBP2 influenced tumor progres-
el (RQ) measured by RT-qPCR in RH36 cells transfected with the siRNA pool
nt (*P  0.05) decrease of IGFBP2 mRNA level was observed after silencing.
6 cells treated as in A. Both assays indicate a significant reduction of IGFBP2
Immunostaining of RMS cell line RH36 after IGFBP2 silencing (siIGFBP2).
appears less condensed, possibly because of a decrease of secretory vesicles.
antibody (red) were used. D: GO functional categories were enriched in
ata were obtained by DAVID and are plotted by the negative log of P value
transcripts involved in cell cycle regulation, common to three different
tMEV tool and the SAM algorithm have identified 603 differentially expressed
d represents up-regulation and green represents down-regulation relative toRNA lev
significa
of RH3
P2). C:
pe that
GFBP2
6 cells. D
egulated
with thesion in vivo, we measured the lung seeding ability of
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line was transduced with five lentiviral vectors contain-
ing different IGFBP2 short hairpin RNA (shRNA) se-
quences. Control cells were transduced with empty
pLKO.1 lentiviral vectors or with the same vectors ex-
pressing IGFBP2-mutated shRNAs. Specific, strong,
and stable IGFBP2 gene silencing was obtained with
two shRNA sequences (ie, sh6575 and sh6577), as
demonstrated by using RT-qPCR and Western blot as-
says (Figure 4, C and D). Cells expressing either the
sh6575 or the sh6577 sequence showed defects in
migration, invasion, and cell cycle compared with con-
trol (pLKO.1) cells (see Supplemental Figure S4 at
http://ajp.amjpathol.org), as also observed for cells
transiently transfected with siIGFBP2 (Figure 4B).
CMRA-labeled (red) control (pLKO.1) or IGFBP2
sh6577-expressing RH36 cells were tail vein injected in
nude mice, and their ability to seed in the lung paren-
chyma was evaluated 2 and 48 hours later. Two hours
after injection, many cells were still associated with the
lung blood vessels, although some cells already
crossed the endothelial barrier and were already visi-
ble in the lung parenchyma (data not shown). No dif-
ference in lodging was observed between IGFBP2
sh6577 and control cells. When cells were counted 48
hours after injection, a reduced seeding ability was
observed for IGFBP2 sh6577 cells compared with con-
trols (Figure 4E). These results indicate a positive role
for IGFBP2 in early lung colonization events of tumor
cells that could depend on intraluminal viability or ex-
travasation or early growth capabilities.IGFBP2 Expression and Distribution in Patients
with RMS Resemble Those of RMS Cell Lines
The data obtained from both in vitro and in vivo experiments
using RMS cell lines indicate IGFPB2 as a protein that plays
an important role in RMS tumor progression, proliferation,
and invasiveness. Thus, we determined whether these find-
ings could be extended to patients with RMS. Our previous
gene expression profiling study,29 using patient samples,
showed that IGFBP2 is an important discriminating tran-
script between PAX3/FKHR-positive ARMS and PAX3/
FKHR-negative RMS. To confirm and extend these obser-
vations, we tested IGFBP2 mRNA expression in tumor
specimens of a novel cohort of patients with RMS using
RT-qPCR and demonstrated that PAX/FKHR-positive ARMS
expressed significantly less IGFBP2 than PAX/FKHR-nega-
tive RMS (Figure 5A).
Subsequently, we assessed the pattern of cellular
IGFBP2 distribution in tumor specimens. Thus, we stud-
ied paraffin-embedded biopsy specimens of patients
with RMS by IHC using anti-IGFBP2 and anti-58k Golgi
marker antibodies. Of 13 RMS samples studied (seven
ERMS, four PAX3/FKHR positive, and two ARMS nega-
tive), all PAX/FHKR-positive ARMS samples showed ab-
sent or low IGFBP2 expression (Figure 5B). Six of seven
ERMS specimens and all PAX/FHKR fusion-negative
ARMSs analyzed were positive for IGFBP2. In the
IGFBP2-positive RMSs, we observed a specific staining
pattern ranging from diffuse cytoplasmic staining to a
Figure 4. IGFBP2 silencing reduces proliferation,
cell migration, and invasion of RMS cells in vitro and
lung seeding ability in vivo. A: Mean percentages of
cells in different cycle phases in RH36 cells silenced
with siRNA for IGFBP2 (siIGFBP2, light gray boxes)
or with nontargeted siRNA (siCONTROL, dark gray
boxes), as measured by flow cytometry. Vertical bars
represent the confidence interval among two inde-
pendent experiments, each performed in triplicate. A
significant (*P 0.05) increase in G0/G1 cells is seen
in IGFBP2-silenced cells, accompanied by a decrease
in S and G2/M cells. B: Mean area fractions covered
by siIGFBP2 (light gray boxes) and siCONTROL-
transfected RH36 cells (dark gray boxes) after Trans-
well migration (Migration) and Matrigel invasion (In-
vasion) assays. Vertical bars represent the confidence
interval among three independent experiments, each
performed in triplicate. Significant (*P  0.05) de-
clines in both parameters are evident after IGFBP2
silencing. C: RT-qPCR measurements of IGFBP2
mRNA (RQ) in RH36 cells stably transduced with
lentiviral vectors expressing different IGFBP2-silenc-
ing shRNAs (ie, sh6575 and sh6577) or with empty
vector controls (pLKO.1). Expression values are cal-
culated as relative expression ratio obtained with the
CTmethod. Vertical bars represent the confidence
interval of at least three experiments. The data dem-
onstrate a significant (***P  0.01) stable down-reg-
ulation of the IGFBP2 gene in the two different
IGFBP2-silenced RMS cells. D: IGFBP2 protein con-
tent of the same transfected RH36 cells described in
A, measured by immunoblotting of whole cell lysate
with anti-IGFBP2 antibody. IGFBP2 is reduced in
both stably silenced cells. E: In vivo seeding analysis
after tail vein injections in nude mice of CMRA-la-
beled RH36 cells, infected as in C and D. Data are
presented as the mean SEM of the number of cells
seeding the lungs, 48 hours after injections for 12
mice per group (see also Materials and Methods).
The two-tailed Student’s t-test was used for statistics.
*P  0.05.more intense signal in the perinuclear region (Figure 5, C
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cell lines. Moreover, the staining of the 58k Golgi marker
was superimposable to the signals of IGFBP2 antibody,
confirming that IGFBP2 localized and accumulated in the
Golgi apparatus of RMS cells in vivo (Figure 5, E–G).
Figure 5. Evaluation of IGFBP2 status in patients with RMS. A: RT-qPCR
quantitation of IGFBP2 mRNA in tumor biopsy specimens from 16 patients
affected by different subtypes of RMS (ARMS translocation positive and
negative and ERMS). Values are calculated as the ratio to the IGFBP2
mRNA content of fetal skeletal muscle (black box) with the CT method
using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the refer-
ence transcript. Vertical bars are the 95% confidence interval among at
least three measurements. B–G: Immunodetection of IGFBP2 (B–D) and a
58K cis-Golgi protein marker (E–G) in paraffin-embedded sections of
tumor samples from the three RMS subtypes described in A. PAX/FKHR-
positive ARMS shows a negative signal for IGFBP2 (B) and positive
staining for 58K protein (E). Original magnification, 20. Instead, PAX/
FKHR-negative ARMS shows positive IGFBP2 staining that resembles that
of cis-Golgi marker (F). ERMS sections show similar results as PAX/FKHR-
negative ARMS for both IGFBP2 (D) and 58K cis-Golgi (F) proteins, even
though the number of stained cells appears to be reduced. Original
magnification: 40; 63 (zoomed images). Arrows, peculiar perinuclear
accumulation of IGFBP2 and condensed Golgi apparatus (in IGFBP2- and
58k-stained sections, respectively), already seen in RMS cell lines (see
Figure 1, C and D). Hematoxylin was used as a counterstain. H: Plasma
levels of IGFBP2 evaluated by ELISA assay are significantly higher in
patients with RMS (*P  0.001) versus healthy controls (CTRs). I: Plasma
levels of IGFBP2 in translocation-negative RMS are significantly higher
than in translocation-positive RMS. J: The plasma level of IGFBP2 is
markedly higher (P  0.05) in the group of patients with RMS who have
advanced stage tumors (IRS stage IV). Box, interquartile range; center bar,
median; whiskers, data range; and lines, outliers.Overall, the expression and staining patterns of IGFBP2differed between PAX/FKHR-positive and PAX/FKHR-
negative patients with ARMS (Figure 5, B–D).
Elevated IGFBP2 in Plasma Correlates to RMS
Severity
To test whether IGFBP2 protein was present in the
plasma of patients with RMS and to assess whether its
concentration was associated with aggressiveness, we
used ELISA assays to detect plasma IGFBP2 in 41 pa-
tients with RMS before any therapy and in 15 healthy
subjects as controls. Plasma levels of IGFBP2 were sig-
nificantly higher in patients with RMS than in controls:
median levels of 362.42 ng/mL in RMS patient samples
and 60.11 ng/mL in controls (P  0.001, Figure 5H).
Moreover, we found that the IGFBP2 plasma level varies
significantly between PAX/FKHR fusion-positive and PAX/
FKHR fusion-negative patients (P  0.030, Figure 5I).
To assess whether IGFBP2 correlated with RMS sever-
ity, we compared IGFBP2 plasma levels of nonmetastatic
with metastatic RMS based on the Intergroup Rhabdo-
myosarcoma Study (IRS) grouping. Comparing nonmeta-
static (IRS I-II-II) with metastatic (IRS IV) patients with
RMS, we found that IGFBP2 levels were significantly
higher in group IV patients with advanced-stage tumors
(P  0.05), demonstrating a positive correlation between
IGFBP2 and tumor invasiveness (Figure 5J). Moreover, an
analysis of variance multiway analysis was performed to
evaluate if the combination of IRS group and the presence
of the PAX/FKHR fusion gene were related to IGFBP2
plasma level. This analysis confirmed and validated that an
elevated plasma concentration of IGFBP2 positively corre-
lated with higher aggressiveness of tumor (P  0.024) and
with PAX/FKHR-negative subtype (P  0.001).
Discussion
Our previous studies29,45 on the human RMS transcrip-
tome indicated that IGFPB2 was one of the genes that
may play an important role in the biological characteris-
tics of this pediatric cancer because it is differentially
expressed in different RMS subtypes. To analyze the
IGFBP2-induced signaling pathway in RMS, we studied
gene expression profiling of RMS cells undergoing
forced inhibition of IGFBP2 expression. In the signature of
these cells, we observed a significant deregulation of
transcripts belonging to protein transport and Golgi ves-
icle-mediated transport. At the same time, RMS cells
showed packaging of IGFBP2 in the Golgi apparatus that
appeared morphologically altered.
These results were confirmed by immunogold labeling
of ultrathin cryosections showing that, in RMS cells,
IGFBP2 associates with unusual perinuclear Golgi struc-
tures that resemble enlarged vesicles. The Golgi luminal
Ca2 concentration and variations may be key controllers
of the function of this organelle.38 By using a Ca2-sen-
sitive photoprotein to investigate the Ca2 homeostasis in
RMS cells, we showed a marked deregulation of the
Golgi Ca2 cycle, suggesting a functional alteration. Be-
cause depletion of Ca2 from the Golgi organelle has
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VSVG-GFP mutant protein to study protein transport. We
found that the characteristic rearrangement of Golgi com-
plex was associated with increased VSVG transport to
the cell surface in RMS cells. Babiá et al46 observed that
transformation of a murine cell line with the oncogenic
N-Ras caused a rearrangement of the Golgi complex into
collapsed morphological features, similar to that caused
by IGFBP2. Furthermore, in agreement with our findings,
they reported an increase in protein transport from the
trans-Golgi network to the cell surface, suggesting an
alteration in membrane trafficking.
Our hypothesis is that IGFBP2 is produced in abnormal
amounts and accumulates in atypical Golgi structures.
Subsequently, the unusually high quantity of IGFBP2
moves from the Golgi apparatus to the cell surface, en-
tering in a defective secretory pathway, as suggested by
VSVG-GFP results. In cell tumor ultrathin sections, we
observed that the organelle was rearranged only in part.
RMS cells showed normal Golgi stacks, and this is ex-
pected given that the cells have an active secretion of
proteins. However, cells also showed atypical Golgi
structures that probably function as storage of an abnor-
mal amount of secreted proteins and that could be re-
sponsible for the strong signal observed in immunofluo-
rescence experiments.
Gene expression profiling of IGFBP2-silenced cells
also revealed an alteration of transcripts involved in the
regulation of the cell cycle and in cell migration and
adhesion, such as MCMs and cyclin D1. The MCMs are
a family of highly conserved proteins, playing an essen-
tial role in the early stages of eukaryotic genome replica-
tion. The requirement for MCM proteins in cycling cells
and their absence in quiescent cells have led to their
potential clinical application as proliferation markers,
useful in cancer diagnosis. Microarray analyses and IHC
studies47,48 have shown increased mRNA and protein
levels of MCMs in many different tumor cells and in car-
cinomas with a clinically aggressive phenotype. Typi-
cally, cyclin D1 acts together with their CDK partners to
control G1-S–phase progression through the inactivation
of retinoblastoma protein and the release of the E2F tran-
scription factor. The protein is frequently overexpressed
in a large spectrum of human cancers, such as breast,
lung, and bladder cancers, in which it may contribute to
tumorigenesis.49 We found that IGFBP2-silenced cells
showed a significant, but not dramatic, decrease of the
proliferation rate, paralleled by an enrichment of cells in
the G1 phase, probably because of weak involvement of
IGFBP2 in this specific cellular process. Literature
data15,17 are conflicting regarding the role of IGFBP2 on
cell cycle progression. Moreover, recent studies50 re-
vealed a role of cyclin D1 in cell migration, correlating its
overexpression with cellular metastasis. Cell migration is
essential for the invasion of tumor cells into the surround-
ing tissues. This coordinated migration process leads to
tumor metastasis. An important contribution to cell motil-
ity depends on several changes in actin cytoskeletal
structures.51 Our microarray results confirmed that many
transcripts involved in cytoskeleton remodeling are cor-
related to IGFBP2 expression.Another interesting finding that supports a key role of
IGFBP2 in the invasiveness of RMS cells is the deregu-
lation of MMP2 as a consequence of IGFBP2 silencing.
Several studies52 have shown that an increased level of
MMP2 expression is associated with an aggressive phe-
notype and poor prognosis in various human cancers,
indicating MMP2 as a biomarker useful for stratifying
patients with cancer into different risk groups. Moreover,
a gene expression analysis in gliomas revealed a con-
sistent induction of MMP2 by IGFBP2.8 In our study, we
demonstrated that IGFBP2 silencing in RMS cells affects
migration and invasion.
Taken together, our results show that the strong silenc-
ing of IGFBP2 results in a complex phenotype and, the-
refore, we suggest that IGFBP2 may modulate an
integrated network of genes involved in proliferation, cy-
toskeleton rearrangement, and tumor progression. This
conclusion is further supported by our in vivo experiments
demonstrating that stably IGFBP2-silenced cells showed
reduced seeding ability in the lungs. Although we do not
have sufficient experimental data to discuss a direct link
between the accumulation of IGFBP2 in the Golgi appa-
ratus, increase of IGFBP2 at the cell surface, and its
prometastatic roles, we can speculate that the proinva-
sive effect is amplified by an alteration of Golgi protein
trafficking.
To define the possible role of IGFBP2 in RMS in vivo, we
determined IGFBP2 expression in tumor specimens. Only
RMS fusion-negative patients were positive for IGFBP2
staining. Thus, IGFBP2 could reliably distinguish PAX/
FKHR-positive from PAX/FKHR-negative tumors and, con-
sequently, may represent a useful marker in clinical prac-
tice. Furthermore, we confirmed a perinuclear IGFBP2
staining pattern in PAX/FKHR-negative tumor biopsy
specimens that overlapped a Golgi marker distribution.
Thus, IGFBP2 accumulation appears to also correlate
with a morphological modification of the Golgi apparatus
in vivo. The immunostaining pattern of IGFBP2 has been
studied by Makawita et al,53 who assayed the level of all
IGF pathway proteins in an RMS group of 29 patients
belonging to different subtypes. They found an IGFBP2
expression pattern similar to our results but that focused
on differences between ARMS and ERMS independently
of the PAX3/FKHR fusion gene status. They reported that
IGFBP2 did not differ significantly (P  0.052) between
the two major subgroups of RMS, although a study of a
larger cohort of patients was warranted to draw definitive
conclusions.
Finally, we tested IGFBP2 plasma levels in patients
with RMS. The IGFBP2 plasma level was significantly
higher than in healthy subjects, and IGFBP2 plasma lev-
els discriminated between PAX/FKHR-positive and PAX/
FKHR-negative patients, similar to IHC findings. Interest-
ingly, when the levels of IGFBP2 were considered in
relation to the aggressiveness of the tumor, we found that
higher IGFBP2 levels were present in patients belonging
to the high-risk group with metastatic disease at diagno-
sis. Further studies are needed to correlate the levels of
IGFBP2 with different clinical characteristics of patients
with RMS and with response to treatment. High plasma
levels of IGFBP2 were associated with tumor progression
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recent study56 revealed that plasma concentrations of
IGFBP2 were elevated in patients with high-grade glioma.
Moreover, plasma levels of IGFBP2 and low levels of
IGFBP3 at diagnosis correlated with a high risk of relapse
or a lack of remission in childhood acute lymphoblastic
leukemia.57 These studies disclose the involvement of
IGFBP2 in tumorigenesis and may lead to the discovery
of new and specific treatments. In fact, the heat shock
protein-90 inhibitors, including the geldanamycin deriva-
tive 17-AAG, decrease plasma IGFBP2 in patients with
cancer.19 It would be interesting to determine whether
treatments of RMS-overexpressing IGFBP2 with such
drugs would influence growth and differentiation of RMS
cells. In conclusion, our results provide evidence that
IGFBP2 is overexpressed in PAX/FKHR fusion-negative
RMS and could promote cancer progression by aug-
menting cell invasiveness and cell proliferation. More-
over, we have identified IGFBP2 as a marker that may
contribute to refine a clinical and biological classification
of patients with RMS.
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Malignant melanoma is fatal in its metastatic stage. It is
therefore essential to unravel the molecular mechanisms
that govern disease progression to metastasis. MicroRNAs
(miRs) are endogenous non-coding RNAs involved in
tumourigenesis. Using a melanoma progression model, we
identified a novel pathway controlled by miR-214 that co-
ordinates metastatic capability. Pathway components include
TFAP2C, homologue of a well-established melanoma tumour
suppressor, the adhesion receptor ITGA3 and multiple sur-
face molecules. Modulation of miR-214 influences in vitro
tumour cell movement and survival to anoikis as well as
extravasation from blood vessels and lung metastasis forma-
tion in vivo. Considering that miR-214 is known to be highly
expressed in human melanomas, our data suggest a critical
role for this miRNA in disease progression and the establish-
ment of distant metastases.
The EMBO Journal advance online publication, 5 April 2011;
doi:10.1038/emboj.2011.102
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Introduction
The ability of tumours to acquire malignancy and spread in
their host organism is one of the main issues in cancer
treatment, as metastasis formation accounts for 490% of
human cancer deaths. Nevertheless, the understanding of the
molecular mechanisms that regulate metastatic dissemina-
tion remains fragmentary. The cascade of events that lead to
metastasis is a complex multi-step process by which primary
tumour cells acquire the ability to detach and invade adjacent
tissues, intravasate, survive in the systemic circulation and
translocate through the vasculature, adhere to the walls of
capillaries of distant organs, extravasate in the parenchyma
and finally proliferate in secondary tumours (Gupta and
Massague, 2006). It is urgent to identify and characterize
the genetic and epigenetic changes occurring during tumour
progression. Several protein-coding genes involved in
malignancy have been identified and characterized (Steeg,
2006; Nguyen et al, 2009). More recently, abnormalities in
non-coding genes, such as microRNAs (miRs), have also
been found to contribute to tumourigenesis (Croce, 2009;
Valastyan and Weinberg, 2009). miRs are small endogenous
non-coding RNAs able to post-transcriptionally downregulate
expression of specific target genes by binding to the 30UTRs of
their mRNAs causing destabilization, degradation or transla-
tion inhibition (Filipowicz et al, 2008; Bartel, 2009). The
ability of miRs to achieve simultaneous fine tuning of numer-
ous different target genes makes them fundamental regula-
tors of cellular signalling and implicates them in tumour
progression (Inui et al, 2010). Several miRs, such as miR-21,
miR-10b, miR-373 and 520c, miR-126, miR-335, miR-31, miR-
200, miR-151 and miR-9, have already been reported to
regulate tumour progression and metastasis (Valastyan and
Weinberg, 2009; Ma et al, 2010).
Malignant melanoma is one of the most aggressive human
cancers (Parkin et al, 2005) which progresses very rapidly via
specific steps characterized by defined molecular alterations.
Melanomas arise when the melanocytes of the epidermis
become transformed and start to proliferate abnormally,
leading to radial and vertical growth phases and subsequent
spreading all over the body (Melnikova and Bar-Eli, 2008).
The transition from the non-invasive to the invasive and
metastatic stage is accompanied by gain of function of
a number of transcription factors such as CREB/ATF-1,
ATF-2, NFkB, SNAIL and STATs, while the loss of the
AP-2 transcription factors (TFAP2) positively correlates with
malignancy. At the same time, alterations in the repertoire
of adhesion molecules, including MCAM-MUC18, E-cadherin,
N-cadherin and several integrins, as well as changes in
genes involved in angiogenesis, invasion and survival, such
as VEGF, bFGF, IL-8, c-KIT, EGFR, MMP2 and PAR-1, are
linked to the acquirement of higher metastatic potential
(Melnikova and Bar-Eli, 2008). Several miRs, including
miR-137, miR-221/222, miR-182 and miR-34a, have already
been found to be involved in melanoma progression by
regulating key genes such as c-KIT, MITF, FOXO3, ITGB3,
CCND1 and p27Kip1 (Mueller and Bosserhoff, 2009). It now
becomes fundamental to unravel how miRs control mela-
noma aggressiveness.
We identified a new pathway, coordinated by miR-214
and including TFAP2C, ITGA3 as well as multiple surfaceReceived: 17 September 2010; accepted: 9 March 2011
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molecules, which controls melanoma metastasis dissemina-
tion by increasing migration, invasion, extravasation and
survival of melanoma cells.
Results
miR-214 is upregulated in a metastatic melanoma
model
To assess a potential correlation between deregulation of
miRs and melanoma malignancy, a miR profiling, which
will be presented elsewhere (Cimino et al, unpublished),
was performed in a melanoma progression model (Xu et al,
2008). The model consisted of a poorly metastatic A375
parental cell line (A375P) and its four highly metastatic
variants, MA-1, MA-2, MC-1 and MC-2 derived by repeated
passages in mice. Among the modulated miRs, miR-214 was
found to be differentially expressed comparing metastatic
(high) versus parental (low) cells in culture, as shown by
qRT–PCR (Figure 1A and B). miR-214 showed a very strong
enhancement of expression in samples derived from in vivo
lung metastases following tail vein injections of MA-2 cells in
immunodeficient mice (Figure 1B), suggesting an influence of
the microenvironment for high expression. Induction of miR-
214 expression in vivo was also observed in subcutaneous
tumours derived from different melanoma cell lines expres-
sing low miR-214 in culture (WK-Mel, GR4-Mel, 1300-Mel,
Dett-Mel, SK-Mel-173, SK-Mel-197) (Supplementary Figure S1A).
Other miRs, previously found to be involved in melanoma,
such as miR-34a, miR-221, miR-222 and miR-137, also
showed some differential expression in this system, however,
not as pronounced as miR-214 changes (Figure 1A). When we
extended expression analysis for miR-137 to other melanoma
malignant cell lines it resulted to be overexpressed in some of
them, such as WK-Mel, GR4-Mel, SK-Mel-173 and SK-Mel-197
compared with A375P. Instead no expression was detected in
1300-Mel, Dett-Mel and SK-Mel-187 cells (Supplementary
Figure S1B). Some miRs were poorly expressed or did not
show differential expression in our A375P isogenic model,
including miR-210, which we used as a control (Figure 1C).
miR-210 was expressed to some extent in most of the mela-
noma cells analysed although often at a low level (Supple-
mentary Figure S1C). Importantly, miR-214 copy number gain
was found in the genome of A375P, its MA-2 and MC-1
variants and in other melanoma cells, such as GR4-Mel,
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Figure 1 miR-214 modulates cell migration and invasion. (A–C) Expression levels of the indicated miRs were evaluated in A375P cells or in its
metastatic variants MA-1, MA-2, MC-1, MC-2 or in a pool of MA-2-derived lung metastases (MA-2 mets) by qRT–PCR. Results are shown as fold
changes (mean±s.e.m.) relative to A375P cells, normalized on U44 RNA level. (D–M) Wound healing motility (D, E) or transwell migration or
matrigel invasion (F–K) or adhesion on fibronectin, laminin or collagen (L, M) assays for cells either transfected with the indicated miR
precursors or inhibitors or their negative controls (pre- and anti-miR or control) or stably transduced with pWPT-empty or miR-214
overexpression vectors. Results are shown as mean±s.e.m. of the reciprocal of the wound size (motility assay) or of the area covered by
migrated or adherent cells (migration, invasion and adhesion assays). Two or three independent experiments were performed in triplicate and
results were either shown as representative ones (A–C) or pooled together (D–M). *Po0.05; **Po0.01; ***Po0.001.
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Dett-Mel, SK-Mel-103 and SK-Mel-187, as measured by geno-
mic qRT–PCR (Supplementary Figure S1D) and SNP (not
shown) analyses.
miR-214 expression enhances cell movement
The more pronounced expression of miR-214 in metastatic
cells prompted us to investigate the potential pro-metastatic
role of miR-214 by analysing cell movement following
miR-214 expression modulations.
We stably or transiently overexpressed miR-214 in the
miR-214-empty, poorly motile A375P cells and in the MA-2
metastatic variant, expressing an intermediate endogenous
level of miR-214 (see Figure 1B), as well as in other melano-
ma cells, such as 1300-Mel, SK-Mel-187, WK-Mel and GR4-
Mel, expressing low to undetectable miR-214 in culture
(see Supplementary Figure S1A), by lentiviral infections
with miR-214 expression or empty vectors (pWPT-miR-214
or pLemiR-214 or empty) or by transfections with miR-214
precursors or negative controls (pre-miR-214 or control).
Conversely, we silenced miR-214 in the highly motile and
invasive MC-1 and MC-2 variants following transfection with
specific miR-214 antisense inhibitors or negative controls
(anti-miR-214 or control). The efficacy of miR-214 modulations
was tested by qRT–PCRs; miR-214 expression was increased up
to 200000- or 500-fold, respectively, in pre-miR-214 transiently
transfected cells and stable infected cells (Supplementary Figure
S2A–C) and almost completely silenced following miR-214
inhibition (Supplementary Figure S2D).
Significantly, miR-214 overexpression by pre-miR-214
transfection in MA-2 cells enhanced cell motility, migration
and invasion as evaluated by wound healing assays
(Figure 1D) or transwell assays in presence or absence of
matrigel (Figure 1F and G) compared with negative controls.
Migration and invasion were also increased 2–3-fold in stable
miR-214-overexpressing MA-2 cells compared with cells con-
taining the empty vector (Figure 1H and I). Moreover, miR-
214 overexpression was sufficient to promote a significant
increase in migration and/or invasion in poorly motile A375P
cells (pWPT-miR-214, Supplementary Figure S3A) and in
other unrelated melanoma cell lines, such as 1300-Mel,
SK-Mel-187, WK-Mel and GR4-Mel (pre-miR-214, Supplemen-
tary Figure S3E–J). The effects observed on cell movement in
the A375P isogenic model were specific for miR-214, since no
significant variation in migration or invasion was observed
following transient miR-210 overexpression (Figure 1F and
G). In line with these results, transient miR-214 downregula-
tion in MC-1 or MC-2 cells, following transfection with
anti-miR-214, led to a 50% reduction in motility in a wound
healing assay (Figure 1E, MC-1) and a 40–80% decrease
in migration and matrigel invasion in transwell assays
(Figures 1J and K, MC-1; Supplementary Figure S3B and C,
MC-2). miR-214 functions were also evaluated by stable
silencing in MC-1 cells using miR-214-specific sponges cloned
in the 30UTR of the green fluorescent protein (GFP) gene
(see Materials and methods). MC-1 cells were transduced
with pLenti-CMV-GFP-Puro-sponge1 (pLenti-sponge1) or
pLenti-CMV-GFP-Puro-sponge3 (pLenti-sponge3) or pLenti-
CMV-GFP-Puro (pLenti-empty) vectors and the efficacy of
each sponge was evaluated by measuring the expression of
the GFP in a western blot (WB) analysis (Supplementary
Figure S2E). In presence of pLenti-sponge1 or pLenti-sponge3
GFP expression was highly decreased, indicating the efficient
binding of miR-214 on the complementary sequences in the
30UTR of the GFP. As shown in Supplementary Figure S3D,
stable miR-214 silencing by sponge1 or sponge3 resulted in
impairment of MC-1 cell migration in vitro (transwell assays),
compared with control cells. Interestingly, miR-214 over-
expression (pre-miR-214) was also able to significantly in-
crease cell migration and matrigel invasion in other tumour
cells, including human MDA-MB-231 or murine 4T1 mam-
mary epithelial cancer cell lines (Supplementary Figures S2A
and S3K–N). When we looked for the involvement of
miR-214 in cell adhesion we observed significant adhesion
alterations on different extracellular matrices (ECMs). In
particular, transient miR-214 overexpression in A375P cells
improved adhesion on fibronectin, laminin and collagen
(1.5–3-fold increase), while miR-214 silencing in MC-1 cells
consistently resulted in comparable adhesion defects on these
matrices (Figure 1L and M).
Taken together, these results show that miR-214 signifi-
cantly enhances in vitro cell movement and modulates adhe-
sion, suggesting that it might facilitate metastasis formation
by favouring tumour cell invasion and adhesion to the
surrounding ECM.
miR-214 expression enhances metastasis formation
in vivo
Because of its ability to induce motility and invasion in vitro,
we asked whether miR-214 could influence cell movement
and metastasis formation in vivo. Thus, miR-214-overexpres-
sing MA-2 cells or miR-214-silenced MC-1 cells were injected
into the tail vein of immunodeficient SCID mice and the
number of lung metastases was evaluated 7 weeks later. A
significantly higher number of macroscopic lung metastases
could be observed for miR-214-overexpressing (pWPT-miR-
214) MA-2 cells when compared with control (pWPT-empty)
cells (Figure 2A). To investigate whether miR-214 was able
to promote or regulate metastasis formation in the poorly
metastatic parental cells, miR-214-overexpressing (pWPT-
miR-214) or control (pWPT-empty) A375P cells were injected
into SCID mice. Metastasis formation was analysed 9 weeks
later and no macroscopic metastases were found on the lung
surface for the two groups of mice. However, histological
analyses revealed that 3 out of 10 mice injected with miR-214-
overexpressing cells contained small metastatic formations in
their lungs, while no micrometastases were found in control
mice (Supplementary Figure S4). In contrast, miR-214-
silenced MC-1 cells (by anti-miR-214 transfection) were signi-
ficantly impaired in their ability to seed lung metastases and
formed fewer lesions than the control (anti-control) cells
(Figure 2B). High miR-214 expression levels were also able
to enhance lung metastasis formation from a primary tumour.
In fact, when the 4T1 mammary epithelial cancer cells,
transduced with a lentiviral vector encoding for the turbo
red-fluorescent protein (tRFP) alone (pLemiR-empty) or for
miR-214 plus tRFP (pLemiR-214), were injected in mammary
fat pad of female BALB/c mice, a significantly higher dis-
tribution of red-fluorescent micrometastasis in the lungs was
observed for miR-214-overexpressing cells compared with
controls, 20 days after injection (Supplementary Figure S2C;
Figure 2C). However, miR-214-overexpressing cells gave rise
to similar sized primary tumours as control cells (not shown).
miR-214 enhancement effects on in vitro cell movement and
in vivo metastasis formation are directly ascribed to the
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metastatic ability of the cells and not to proliferation effects.
In fact, miR-214 overexpression (pre-miR-214) in A375P and
MA-2 cells or miR-214 silencing (anti-miR-214) in MC-1 cells
did not influence in vitro proliferation compared with con-
trols (Figure 3A and B). Moreover, anchorage-independent
growth in soft agar was not affected, since the number and
the size of colonies for stable miR-214-overexpressing (pWPT-
miR-214) A375P and MA-2 cells were comparable with con-
trols (pWPT-empty) (Figure 3C and D). Furthermore, miR-214
did not influence primary tumour growth. In fact, when miR-
214-overexpressing (pWPT-miR-214) or control (pWPT-
empty) A375P or MA-2 cells were subcutaneously injected
in the flanks of nude mice, the final tumour weight was
similar for the different samples (Figure 3E and F).
miR-214 modulates extravasation and survival
To assess the involvement of miR-214 in extravasation and
survival, we combined in vitro and in vivo experiments. We
first simulated transendothelial migration in vitro by seeding
CMRA-labelled (red) miR-214-overexpressing (pre-miR-214)
or control (pre-control) A375P or MA-2 cells in the upper
chambers of fibronectin-coated transwells, covered by a
confluent GFP-transduced human umbilical vein endothelial
cell (HUVEC) monolayer. The remodelling of the endothe-
lium and the consequent migration of melanoma cells in the
lower chamber of the transwell were then evaluated
(Figure 4A). The interaction of melanoma and endothelial
cells induced the formation of fenestrations in the HUVEC
monolayer. In the absence of melanoma cells (panel a) or
in the presence of melanoma cell-conditioned medium
(not shown), the HUVEC monolayer remains intact, suggest-
ing the requirement of a direct cell–cell contact. Interestingly,
the spaces formed in the endothelium were larger in the
presence of miR-214-overexpressing A375P or MA-2 cells,
compared with those formed with control cells (panels b, c,
f and g) and, consequently, an increased number of cells
migrated through the endothelial cells (panels d, e, h and i).
In conclusion, miR-214 overexpression in A375P and MA-2
cells resulted in a 2–3-fold more efficient transendothelial
migration. To evaluate the ability of miR-214 to influence
extravasation in vivo, we first demonstrated that cell extra-
vasation in the mouse lungs occurs within 48 h following
injection of any metastatic variant in the blood circulation.
For this, CMRA-labelled (red) negative control-transfected
MC-1 (Figure 4B) or MA-2 (not shown) cells were injected
in the tail vein of nude mice and their localization in the
lungs was evaluated at different times. Two hours after
injection, a high percentage of cells was located inside or
associated with the lung blood vessels (Figure 4B, panel a),
although some cells were already visible in the parenchyma
(not shown). Forty-eight hours after injection, most of the
cells present in the lungs appeared to be dispersed in the
parenchyma (Figure 4B, panel b). To evaluate the role of miR-
214 in the regulation of extravasation, CMRA-labelled miR-
214-overexpressing A375P or MA-2 cells (pLemiR-214 or pre-
miR-214, respectively) or silenced (anti-miR-214) MC-1 cells
were injected via tail vein in nude mice and their ability
to persist in the lungs was quantitated 48 h later. Two- or four-
fold increased extravasation was observed, respectively,
for miR-214-overexpressing A375P and MA-2 cells (Figure
4C, panels c, d, g and h), while about a 50% reduction in
extravasation ability was observed for miR-214-silenced
MC-1 cells (Figure 4C, panels k and l), compared with
controls. This was not the consequence of a different lod-
ging in the lung microvasculature, evaluated 2 h post-
injection, since no difference was observed between
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Figure 2 miR-214 enhances metastasis formation in vivo. (A, B) Metastasis formation in the lungs of SCID mice, 7 weeks after tail vein
injection of MA-2 or MC-1 cells, stably transduced with pWPT-empty or miR-214 overexpression vectors (A) or transfected with miR-214
inhibitors or negative controls (anti-miR-214 or control) (B). Total number of macroscopic metastases per lung is shown as box and whiskers
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mice. Number of red-fluorescent micrometastasis per lung is shown as mean±s.e.m. for n¼ 10 mice per group. Representative whole lung (a,
b, e, f, i and j) and H&E staining (c, d, g, h, k and l) pictures are shown; bar¼ 1mm and 100 mm, respectively. Two independent experiments
were performed and representative ones are shown (A, B) or results were pooled together (C). *Po0.05; **Po0.01.
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miR-214-modulated cells and negative controls (Figure 4C,
panels a, b, e, f, i and j). In vivo extravasation experiments
were also performed with CMRA-labelled MC-1 cells stably
transduced with specific miR-214 sponge (pLenti-sponge3)
or empty (pLenti-empty) vectors as in Supplementary
Figure S2E. In line with transient anti-miR-214 experiments,
MC-1 cells expressing pLenti-sponge3 showed a highly
reduced (80–90%) ability to extravasate compared with con-
trol cells, 48 h post-injection, as measured in the red (CMRA)
or green (GFP) channel (Supplementary Figure S5A and B).
No difference in lodging was observed at 2 h. In addition
to transendothelial migration and extravasation ability,
resistance to apoptosis was evaluated following miR-214
expression modulation in cells kept in the absence of
adhesion (anoikis) and serum for 72 h, by AnnexinV–FITC
and TMRM staining and cytofluorimetric analyses. miR-214-
overexpressing (pre-miR-214) A375P cells showed a 20–30%
reduction in cell death versus controls (Figure 4D, left);
consistently, miR-214 silencing (anti-miR-214) in MC-1
cells led to 20–30% increased cell death (Figure 4D, right)
compared with controls, suggesting a miR-214-driven
cooperative role between extravasation ability and resistance
to anoikis.
miR-214 regulates the expression of a panel of target
genes
miR-214’s ability to coordinate the various steps of metastasis
formation can be attributed to multiple direct and indirect
regulation of target genes. To identify direct targets of miR-
214, we first used different algorithms such as miRecords
(Xiao et al, 2009), miRanda (John et al, 2004) and TargetScan
5.1 (Friedman et al, 2009) and obtained 42000 predicted
genes containing one or more putative binding sites for
this miR. Then, genes were functionally classified using the
Ingenuity Systems Analysis software and a large number of
genes involved in Cancer (557 genes; P from 5.96E-13 to 9.7E-
04) and Cellular Movement (302 genes; P from 7.82E-11 to
1.05E-03) were identified. A panel of 11 putative targets
predicted by at least one algorithm and present in one or
both of the functional categories were selected for experi-
mental validation. For this purpose, the 30UTRs of these 11
genes were cloned into a reporter vector and luciferase assays
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performed in MA-2 and/or MC-1 cells transfected with
miR-214 precursors or negative controls (pre-miR-214 or
control). As shown in Figure 5A, luciferase expression driven
by the 30UTRs of integrin a3 (ITGA3) or transcription factor
AP-2g (TFAP2C) was significantly repressed. No effect was
revealed in the presence of the 30UTRs of integrin b8 (ITGB8),
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microphthalmia-associated transcription factor (MITF), neuro-
pilin 1 (NRP1), plexinA1 (PLXNA1), phosphatase and tensin
homologue (PTEN) and transcription factor AP-2a (TFAP2A)
(Figure 5A). A slight luciferase repression was also observed
in the presence of the p21 protein (Cdc42/Rac)-activated
kinase 2 (PAK2) 30UTR while, surprisingly, a strong induction
of luciferase activity occurred in the presence of met proto-
oncogene (MET) and Rho GTPase activating protein 12
(ARHGAP12) 30UTRs (Supplementary Figure S6A). To assess
if the ITGA3 and TFAP2C luciferase expression regulation
depended on the binding between miR-214 seed and
the complementary sequence present on the 30UTRs of
ITGA3 or TFAP2C, a four nucleotide deletion or three point
mutations were inserted in the ITGA3 or TFAP2C 30UTRs,
respectively, as indicated in Figure 5B, left. Both 30UTR
alterations completely abrogated the effect of miR-214 over-
expression on luciferase expression in MC-1 (Figure 5B,
right), A375P and MA-2 cells (not shown) indicating the
specific and direct regulation of miR-214 on ITGA3 and
TFAP2C 30UTR binding sites in our A375P isogenic model.
Similar results were obtained also in unrelated melanoma cell
lines such as WK-Mel (Supplementary Figure S7A) or GR4-
Mel (not shown) transfected with miR-214 precursors or
negative controls. As a positive control, a miR-214-sensor
construct, containing three perfect bindings for miR-214,
was used for each experiment (Figure 5A and B;
Supplementary Figures S6A and S7A). ITGA3 and TFAP2C
modulations in luciferase activity corresponded to fluctua-
tions of endogenous protein levels following transient miR-
214 overexpression (pre-miR-214) in MA-2, WK-Mel, GR4-Mel
(Figure 5C; Supplementary Figure S7C and D) or A375P and
1300-Mel (not shown) cells or miR-214 inhibition (anti-miR-
214) in MC-1 cells (Figure 5C), as measured by WB analyses
48 h (not shown) or 72 h post-transfection. miR-214 over-
expression led to a 30–90% and 40–80% protein decrease in
ITGA3 and TFAP2C, respectively (Figure 5C; Supplementary
Figure S7C and D). Reduction of protein expression was also
observed in stable miR-214-overexpressing (pWPT-miR-214)
MA-2 cells (10 and 15% decrease) compared with con-
trols (Supplementary Figure S7B). Consistently, ITGA3 a
nd TFAP2C proteins were upregulated (20 and 40%,
respectively) in miR-214-silenced MC-1 cells (Figure 5C).
Additionally, following transient miR-214 overexpression
(pre-miR-214) in MA-2 cells, TFAP2C mRNAwas significantly
reduced, while ITGA3 mRNA showed a non-statistically sig-
nificant decrease, as measured by qRT–PCR analyses 48 h
post-transfection (Figure 5D).
Consistent with the luciferase results, MET protein levels
showed a 60 or 10% induction, respectively, following
transient or stable miR-214 overexpression (Supplementary
Figure S6B and D), which corresponded to mRNA fluctua-
tions (Supplementary Figure S6E) and a 60% reduction
following miR-214 silencing (Supplementary Figure S6C).
Slight changes were also detected for PAK2 or PTEN protein
expression following miR-214 overexpression or downmodu-
lation, but no mRNA modulations were observed (Supple-
mentary Figure S6B, C and E). Similarly, no mRNA changes
were observed for ARHGAP12, ITGB8, MITF and NRP1, while
a slight PLXNA1 mRNA decrease was found (Supplementary
Figure S6E). On the contrary, TFAP2A was well modulated
both at the protein and at the mRNA level (Supplementary
Figure S6B and E); however, considering that TFAP2A is only
slightly expressed in these melanoma cells.
In parallel, we used a proteomic approach to identify miR-
214-modulated surface proteins. The expression profile for
119 surface molecules involved in cell adhesion and move-
ment was evaluated in MA-2 cells 72 h after transfection with
miR-214 or control precursors; 65 differentially expressed
molecules were found, 36 upregulated and 29 downregu-
lated, following miR-214 overexpression (Table I; Figure 5E).
Twenty-five modulated genes were predicted targets of miR-
214 (Table I) and 17 genes, miR-214 predicted targets or not,
were previously proven to be transcriptionally regulated by
members of the AP-2 transcription factor family (TFAP2) or to
contain TFAP2 binding sites in their promoters (Table I),
suggesting a possible TFAP2-driven modulation in our mela-
noma model. Since it is well established that TFAP2 proteins
contribute to melanoma progression via transcriptional reg-
ulation of key genes, we evaluated the expression of known
TFAP2-activated or -repressed transcriptional targets by
qRT–PCR, following miR-214 overexpression in MA-2 cells
(pre-miR-214) compared with negative controls (pre-control).
As shown in Figure 6A, the TFAP2-activated genes, ERBB2,
IGFBP5 and TGFB, were found to be downregulated in the
presence of miR-214, while the TFAP2-repressed genes,
MCAM-MUC18 and VEGFA, but not MMP2, were upregulated
(eight-fold and two-fold, respectively). Taken together, the
direct or indirect TFAP2-dependent protein or mRNA modu-
lations suggest that TFAP2 family members could have a
relevant role in miR-214-dependent enhancement of mela-
noma malignancy.
Connections between 70 protein-coding genes found to be
modulated in a direct or indirect manner by miR-214 (65
surface molecules in addition to ITGA3, MET, PAK2, TFAP2A
and TFAP2C; Figure 5; Supplementary Figure S6; Table I)
were searched using the Ingenuity Systems Analysis. Two
main networks were identified, such as Tissue Development,
Cellular Movement, Cell Cycle (Supplementary Figure S8A)
Figure 4 miR-214 promotes extravasation and cell survival. (A) Transendothelial migration assays of CMRA-labelled (red) cells, through a
fibronectin-coated transwell membrane covered by a confluent monolayer of HUVECs–GFP. Upper panels: HUVECs–GFP monolayer on the upper
side of the transwell at time 0h (a) or 18h following the seeding of A375P (b, c) or MA-2 (f, g) cells transfected with miR-214 precursors or
negative controls (pre-miR-214 or control). Lower panels: transmigrated A375P (d, e) or MA-2 (h, i) cells transfected as indicated, on the lower
side of the transwell. (B, C) In vivo extravasation assays following tail vein injections in nude mice of CMRA-labelled (red) A375P cells stably
transduced with pLemiR-empty or pLemiR-214 vectors, or MA-2 cells transfected as in (A) or MC-1 cells transfected with miR-214 inhibitors or
negative controls (anti-miR-214 or control). (B) Representative fields of murine lung sections 2 h (a) or 48 h (b) post-injections, stained for
VonWillebrandt factor (green) and counterstained with DAPI (blue). (C) CMRA-labelled cells in whole lungs 2 h (a, b, e, f, i and j) or 48 h (c, d,
g, h, k and l) post-injections. Results are shown as mean±s.e.m. of the area covered by migrated cells (A) or of the number of extravasated
cells at 48 h for n¼ 10 (A375P), 7 (MA-2) or 5 (MC-1) mice per group (C). Two independent experiments were performed (in triplicate for (A))
and representative ones are shown. Bar¼ 30 mm (A), 10mm (B) or 500mm (C). (D) Anoikis assays for A375P or MC-1 cells transfected as in (C).
Cell death percentage was evaluated by TMRM and AnnexinV–FITC stainings, displayed in bidimensional plots. HighTMRM–LowAnnexinV gate:
healthy population; LowTMRM–HighAnnexinV gate: apoptotic population. Four independent experiments were performed in duplicate and
pooled quantitations refer to fold increased or decreased cell death versus controls, shown as mean±s.e.m. *Po0.05; ***Po0.001.
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Figure 5 miR-214 downregulates TFAP2C and ITGA3 target genes and modulates multiple surface proteins. (A) Luciferase assays in MA-2 or
MC-1 cells cotransfected with reporter constructs containing the 30UTR of the indicated genes or a synthetic sequence including three perfect
miR-214 binding sites (miR-214-sensor), cloned downstream of the luciferase coding sequence, together with miR-214 precursors or negative
controls (pre-miR-214 or control). (B) Left panel: wild-type and miR-214 binding site mutant or deletant (ITGA3del, TFAP2Cmut) ITGA3 or
TFAP2C 30UTRs paired with miR-214 seed (respectively at positions 624 and 1071 of their 30UTRs). Right panel: luciferase assays in cells
cotransfected with wild-type or mutant 30UTR reporter constructs, together with miR-214 precursors or negative controls (pre-miR-214 or
control). Results are shown as mean±s.e.m. of Firefly luciferase activity relative to controls, normalized on Renilla luciferase activity.
(C) Western blot (WB) analysis of ITGA3 and TFAP2C protein levels in MA-2 or MC-1 cells 72 h after transfections with miR-214 precursors or
inhibitors or their negative controls (pre- and anti-miR-214 or control). Protein modulations were calculated relative to controls, normalized on
the hsp90 loading control and expressed as percentages. (D) ITGA3 and TFAP2C mRNA levels measured by qRT–PCR in MA-2 cells 48 h after
transfection as in (C, top). Results were calculated as fold changes (mean±s.e.m.) relative to controls, normalized on GAPDH. Three
independent experiments were performed (in triplicate for (A, B); with independent protein or RNA preparations for (C, D)) and representative
ones are shown. (E) Representative protein expression obtained for MA-2 cells 72 h after transfection with miR-214 precursors or negative
controls (pre-miR-214 or control) by Proteome Profiler Human Soluble Receptor Antibody Arrays. Transferrin R was used as loading control.
Doublets are shown. Two independent experiments were performed, a representative one is shown. Refer to Table I. *Po0.05; **Po0.01;
***Po0.001.
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Table I miR-214 modulates multiple surface molecules involved in cell movement and adhesion
Protein Gene symbol Pre-miR-214/control FC Up/down miR-214 target TFAP2-dependent modulations
ADAM15 ADAM15 1.6 Up
ADAM8 ADAM8 1.6 Up Y
ADAM9 ADAM9 2.5 Up
ALCAM/CD166 ALCAM 6.0 Up
APP (pan) APP 1.8 Up Provenzano et al (2007)
BCAM BCAM 1.9 Up Y
bIG-H3 TGFBI 2.3 Up Orso et al (2008)
BMPR-IB/ALK-6 BMPR1B 1.8 Down Y
Cadherin-11 CDH11 1.2 Down Y Borchers et al (2001)
Cadherin-4/R-Cadherin CDH4 1.8 Down Y
Cathepsin D CTSD 1.2 Down Y Redecker et al (1991)
CD155/PVR PVR 1.4 Up Solecki et al (1999)
CD23/FcRII FCER2 3.1 Up
CD36/SR-B3 CD36 1.7 Up
CD40 Ligand/TNFSF5 CD40LG 1.3 Up
CD40/TNFRSF5 CD40 1.5 Down
CD44H CD44 1.7 Up
CD9 CD9 2.4 Up
CD90/Thy1 THY1 1.6 Up
CD99 CD99 1.8 Up
CEACAM-1/CD66a CEACAM1 1.4 Up
CEACAM-5/CD66e CEACAM5 2.0 Down
Clusterin CLU 2.0 Down Bayon et al (2004)
Coagulation factor II/Thrombin F2 2.1 Down
CX3CL1/Fractalkine CX3CL1 1.7 Up Y
CXCL8/IL-8 IL8 1.4 Up Y
E-Cadherin CDH1 1.7 Down Y Schwartz et al (2007)
EGF R/ErbB1 EGFR 1.6 Down Y Wang et al (2006)
EMMPRIN/CD147 BSG 1.8 Up Y
Endoglin/CD105 ENG 1.6 Up Y Rı`us et al (1998)
Endoglycan PODXL2 1.4 Down
EpCAM/TROP-1 EPCAM 1.5 Down
Epiregulin EREG 1.2 Up Orso et al (2008)
ErbB2/HER2 ERBB2 1.4 Down Y Bosher et al (1996)
ErbB3/HER3 ERBB3 1.7 Down
E-Selectin/CD62e SELE 1.9 Down
Galectin-3BP/MAC-2BP LGALS3BP 2.7 Up
HB-EGF HBEGF 1.7 Up
HPRG HRG 1.2 Up
ICAM-2/CD102 ICAM2 1.6 Up Grether-Beck et al (1996)
IL-1 RII IL1R2 2.2 Up
Integrin a6/CD49f ITGA6 1.5 Down
Integrin aV/CD51 ITGAV 1.4 Down Kambe et al (1998)
Integrin b1/CD29 ITGB1 1.7 Up
Integrin b3/CD61 ITGB3 1.6 Up
JAM-A JAM1 1.6 Down Y
JAM-B JAM2 1.5 Down
JAM-C JAM3 1.4 Down Y
Jagged 1 JAG1 1.2 Down Y
Lipocalin-2/NGAL LCN2 1.5 Up
LRP-6 LRP6 1.5 Down Y
MMP-2 (total) MMP2 1.5 Up Y Nyormoi et al (2003)
MUCDHL CDHR5 1.4 Up
N-Cadherin CDH2 1.5 Down Y
NCAM-1/CD56 NCAM1 1.6 Up Y
Nectin-2/CD112 PVRL2 2.1 Up Y Lui et al (2007)
Periostin/OSF-2 POSTN 1.3 Down
Podocalyxin PODXL 1.5 Down Y
Semaphorin 3A SEMA3A 1.6 Down
TIMP-1 TIMP1 2.0 Up Clark et al (1997)
TIMP-2 TIMP2 2.2 Up Y Hammani et al (1996)
TIMP-3 TIMP3 1.4 Up Y
VCAM-1 VCAM1 1.2 Down
VEGF R1/Flt1 FLT1 1.3 Down
VEGF R2/KDR2/Flk-1 KDR 1.5 Down Y
Expression modulation of 65 out of 119 surface proteins in MA-2 cells 72 h after transfection with miR-214 precursors or negative controls (pre-
miR-214 or control), obtained by Proteome Profiler Human Soluble Receptor Antibody Arrays (see also Figure 5E). Modulations are expressed
as fold change (FC) referring to miR-214-overexpressing cells versus controls, normalized on Transferrin R expression levels. Y, predicted
miR-214 target. Literature references indicate previously demonstrated TFAP2 family members-mediated gene regulation (see references
in Supplementary data).
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Figure 6 miR-214-mediated downmodulation of TFAP2C accounts for miR-214 functions. (A) mRNA levels for the indicated genes measured
by qRT–PCR in MA-2 cells 48 h after transfection of miR-214 precursors or negative controls (pre-miR-214 or control). Results were calculated as
fold changes (mean±s.e.m.) relative to controls, normalized on GAPDH. (B, D) Transwell migration assays for cells stably transduced with
TFAP2C-targeting or negative control scramble shRNA vectors (pLKO-shTFAP2C or SCR) (B) or first transduced with pLemiR-214 and then
transfected with either pSP(RSV)-empty or TFAP2C expression vectors (D). In the boxes: western blot (WB) showing TFAP2C protein levels.
(C, E) In vivo extravasation assays 2 h (a, b) or 48 h (c, d) following tail vein injection in nude mice of the cells described in (B, D), previously
labelled with CMRA (red). Representative pictures of the lungs are shown; bar¼ 500 mm. Results are presented as mean±s.e.m. of the area
covered by migrated cells (B, D) or of the number of extravasated cells at 48 h for n¼ 10 (C) or 5 (E) mice per group. Two to three independent
experiments were performed (in triplicate for (A, B, D)) and results were either shown as representative ones or pooled together (C). *Po0.05;
**Po0.01; ***Po0.001.
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and Cell-To-Cell Signalling and Interaction, Tissue Develop-
ment, Embryonic Development (Supplementary Figure S8B).
A top pathway was also identified, Leukocyte Extravasation
Signalling (not shown), including CD44, CD99, ITGB1, MMP2,
JAM2, JAM3, VCAM1 and TIMPs, genes potentially involved
in tumour cell movement and blood vessel extravasation.
miR-214-mediated downmodulation of TFAP2C and
ITGA3 controls miR-214 functions
As presented above, miR-214 is able to modulate TFAP2C and
genes known to be transcriptionally regulated by the TFAP2
family members. To investigate if the metastatic effects
of miR-214 in this melanoma model could be explained, in
part, via its TFAP2C target we first analysed how TFAP2C
silencing affected in vitro and in vivo cell movement. MA-2
cells were transduced with either specific TFAP2C or scram-
ble negative control (pLKO-shTFAP2C or SCR) shRNA lenti-
viral vectors, leading to almost complete silencing of TFAP2C
expression as measured by WB analysis (Figure 6B, top).
TFAP2C-silenced cells were used for in vitro cell migration
and in vivo extravasation experiments leading to results that
phenocopied miR-214 overexpression. Indeed, 41.5-fold in-
creased in vitro cell migration (Figure 6B) and extravasation
in the lungs 48 h following tail vein injections (Figure 6C,
panels c and d) were observed. No effect on the initial lodging
of silenced cells in the lung vasculature 2 h post-injection
was observed (Figure 6C, panels a and b). Hence, we
asked whether the pro-metastatic phenotype associated
with miR-214 overexpression could be rescued by TFAP2C
overexpression in miR-214-overexpressing cells. For this pur-
pose, a TFAP2C expression construct lacking its 30UTR
(pSP(RSV)-TFAP2C) was transiently transfected in stable
miR-214-overexpressing MA-2 cells (Supplementary Figure
S2C), as shown by WB in Figure 6D, top. Remarkably, a
40% decrease in in vitro cell migration (Figure 6D) and a
significant impairment of in vivo lung extravasation at 48 h
(Figure 6E) were observed compared with pSP(RSV)-empty
controls. In conclusion, these experiments proved that
TFAP2C is a major functional player downstream of miR-
214, in fact, its direct repression by miR-214 contributes to
increased melanoma pro-metastatic traits.
The functional impact of ITGA3 modulation via miR-214
was evaluated with similar approaches, by in vitro migration
and in vivo extravasation assays. For this purpose, ITGA3 was
silenced in MA-2 cells following transfections with specific
siRNAs (si-ITGA3), leading to strong protein downregulation
compared with negative control cells (si-control), as evalu-
ated by WB (Supplementary Figure S9A, top). In parallel,
ITGA3 overexpression was obtained in miR-214-overexpres-
sing MA-2 cells following transfection with a 30UTR-deprived
ITGA3 expression construct (pCMVzeo-ITGA3), compared
with control (pCMVzeo-empty) cells (Supplementary Figure
S9C, top). A significant increase in cell migration (Supple-
mentary Figure S9A) was found in ITGA3-silenced cells,
compared with controls, while decreased cell migration
(Supplementary Figure S9C) was found for miR-214/ITGA3-
overexpressing cells compared with controls. In contrast,
lung extravasation of CMRA-labelled cells, 48 h post-injection
as well as the lodging in the lung vasculature 2 h post-
injection were not affected by ITGA3 silencing or overexpres-
sion (Supplementary Figures S9B and D). This observation is
reinforced by the fact that long-term metastasis formation,
7 weeks following tail vein injection, was also not affected by
ITGA3 overexpression in miR-214-overexpressing MA-2 cells
(not shown).
Finally, the effect of TFAP2C on ITGA3 and MET protein
expression was evaluated in MA-2 cells following TFAP2C
silencing or overexpression. As shown in Supplementary
Figure S10, only a slight protein modulation was observed
for ITGA3 following TFAP2C silencing (10% reduction, left)
or overexpression (10% increase, right). In contrast, MET
protein expression strongly increased (over 100%) following
stable TFAP2C silencing and decreased (20% reduction)
when TFAP2C was transiently overexpressed (Supplemen-
tary Figure S10). These data suggest that the miR-214-depen-
dent regulation of METand ITGA3 is at least in part mediated
by TFAP2C.
Expression of miR-214 and its modulated genes in
human melanoma tumours
qRT–PCR analysis was used to assess miR-214 expression in
human primary melanocytes (two preparations), in situ
melanomas, confined into the basal membrane (n¼ 13),
primary invasive melanomas (n¼ 57) and cutaneous metas-
tases (n¼ 18). As shown in Figure 7A, miR-214 was highly
expressed in primary and metastatic melanomas, compared
with in situ tumours and normal melanocytes. Instead, miR-
210 expression, which we used as control, did not vary
significantly among tumour samples; however, low miR-210
levels were found in primary melanocytes (Figure 7B).
Considering the elevated levels of miR-214 in invasive mela-
nomas and in metastases, we investigated the expression of
over 70 miR-214-modulated genes (Figures 5 and 7C; Supple-
mentary Figure S6; Table I) in a human protein-coding gene
expression data set available in GEO, referring to mRNA
expression in normal skin, nevi and primary melanomas
(Talantov et al, 2005). Differential expression was observed
for several of these genes relative to the three groups of
samples analysed (Supplementary Figure S11), underlying
the relevance of this gene group for melanoma progression.
In agreement with our findings, TFAP2C mRNA was down-
regulated in melanoma but expressed in skin as well as nevus
samples; in contrast, ITGA3 mRNA was upregulated in
this cohort of melanomas, suggesting different or additional
regulations.
Discussion
Our work led to the identification of a novel functional
pathway (Figure 7C), controlled by miR-214 and including
its direct targets TFAP2C and ITGA3 as well as multiple
surface proteins, that coordinates metastasis formation in a
melanoma progression model, represented by the A375P
poorly metastatic parental cell line and its derived metastatic
variants. This pathway can be considered of general rele-
vance for melanoma progression since it was also studied
and validated in a panel of unrelated human melanoma cell
lines. Importantly, overexpression of miR-214 or silencing
of TFAP2C in melanoma cells enables them to acquire or
increase invasive and metastatic behaviour. On the other
hand, miR-214 silencing or concomitant miR-214 and TFAP2C
(lacking its 30UTR) overexpression impairs the establishment
of a metastatic phenotype, suggesting a major role for miR-214
and TFAP2C in controlling melanoma tumour progression.
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In agreement with our findings, also high-throughput
screenings showed that miR-214 is strongly expressed in
malignant cutaneous and ocular melanomas (Worley et al,
2008; Segura et al, 2010) as well as in various solid tumours,
such as pancreas, prostate, gastric, breast and ovary cancers
(Volinia et al, 2006; Blenkiron et al, 2007; Sempere et al, 2007;
Yang et al, 2008; Ueda et al, 2010); thus, it will be funda-
mental to understand the mechanism of miR-214 overexpres-
sion in tumours. We showed that gene amplification for miR-
214 locus occurs in A375P, MA-2 and MC-1 variants as well as
in other melanoma cells. In addition, a main study of
Comparative genomic hybridization demonstrated copy num-
ber gain in miR-214 locus for various melanomas, ovarian
and breast cancer samples (Zhang et al, 2006). However, it
was previously demonstrated that miR-214 is transcription-
ally regulated by Twist-1 (Lee et al, 2009; Yin et al, 2010) and
by Polycomb protein complex (Juan et al, 2009), suggesting
important transcriptional controls for miR-214. The fact that
miR-214 expression is generally low or undetectable in cul-
ture while it increases dramatically when cells are injected in
vivo, i.e., tumours or lung metastases, suggests an essential
regulation by the microenvironment, possibly involving se-
creted growth factors or cytokines or cell-to-cell contacts,
currently under investigation.
So far, miR-214 was proposed to be mostly involved during
differentiation and morphogenesis of tissues and organs
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Figure 7 miR-214 is expressed in human melanomas and modulates multiple genes. (A, B) miR-214 (A) and miR-210 (B) expression levels were
evaluated by qRT–PCR in human primary melanocytes (two independent preparations), in situ melanomas (n¼ 13), primary melanomas
(n¼ 57) and cutaneous metastases (n¼ 18). miR levels are shown as box and whisker plots; the bottom and the top indicate the 25th and 75th
percentile (the lower and upper quartile, respectively), the band inside the box is the 50th percentile and the dots represent the outliers.
Relative expression was calculated using the healthy skin miR median expression as reference and normalized on U44 RNA level. Statistical
analysis was performed with the Mann–Whitney non-parametric statistical test. (C) Drawing summarizing the miR-214-modulated genes
identified in this study and their connections. Continuous lines: miR-214 direct (luciferase proven) regulations; dashed lines: indirect
regulations. *Po0.05; **Po0.01.
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(Flynt et al, 2007; Decembrini et al, 2009) and disruption of
the mouse genomic locus including miR-214, Dnm3os, deter-
mined death within 1 month of birth with skeletal abnorm-
alities (Watanabe et al, 2008). Considering that genetic
programs controlling embryonic development are often
reactivated during tumour progression, a role for miR-214
in tumourigenesis is expected. High levels of miR-214 in
human tumours suggest an oncogene-like function, but we
and others (Fei et al, 2008) did not find any positive regula-
tion of cell growth for miR-214. Instead, increased levels of
miR-214 could induce chemotherapy resistance in ovarian
tumours via the direct downregulation of PTEN and conse-
quent upregulation of the Akt pathway (Yang et al, 2008);
however, we were not able to see any strong miR-214-
dependent downmodulation of PTEN, suggesting a cell
context role in PTEN targeting by miR-214.
The spread of melanoma cells from the primary lesion to
the sites of metastasis formation involves multiple steps
(Melnikova and Bar-Eli, 2008) that are coordinated by miR-
214. Other miRs were previously found to be involved in
some aspects of melanoma tumourigenesis: miR-221/222
and let7b mostly control proliferation and survival, while
miR-182, miR-137, let7a and miR-34a affect migration and
invasion as well as cell growth (Mueller and Bosserhoff,
2009). miR-214 exerts pleiotropic roles in our melanoma
model due to its ability to directly or indirectly modulate
the expression of many genes. We were able to identify over
70 miR-214-modulated genes that were previously found to
be involved in cell movement and metastasis formation,
some specifically in melanoma. Examples are integrins
(Desgrosellier and Cheresh, 2010), cadherins (Jeanes et al,
2008), cell adhesion molecules (Kobayashi et al, 2007), the
tyrosine kinase receptor MET (Benvenuti and Comoglio,
2007), MMP2 (Hornebeck et al, 2002), ADAMs (Duffy
et al, 2009), TIMPs (Cruz-Munoz and Khokha, 2008),
Semaphorin3A (Neufeld and Kessler, 2008) and PAK2
(Gadea et al, 2008). In addition to cell migration and inva-
sion, we showed, for the first time, that a miR promotes
transendothelial migration and extravasation of melanoma
cells via direct tumour-endothelial cell interactions, as proven
by the fact that melanoma cells but not conditioned medium
are able to induce endothelial cell reorganization. Based on
the extravasation experiments, we suggest that miR-214 pro-
metastatic effect is mainly due to the earlier steps of the
metastatic process, such as the passage through the endo-
thelial barrier, more then post-colonization events. In fact, we
observed a significant reduction in both extravasation (48 h)
and long-term metastasis formation following transient
silencing of miR-214 in cells, a condition in which we
expected miR-214 levels to remain low only in the first 48 h
post-transfection, as observed in in vitro experiments (not
shown). Considering that extravasation data were confirmed
by permanent knockdown of miR-214 via specific sponges
and that miR-214 did not influence tumour cell growth, we
can conclude that high levels of miR-214 favour extravasation
and survival in the blood circulation but do not control later
tumourigenesis steps. Heterotypic interactions are known to
occur between endothelial and melanoma cells during extra-
vasation involving, for instance, the CAM family molecules,
such as ALCAM (Swart et al, 2005) and MCAM-MUC18
(Xie et al, 1997), or tetraspanin CD9 and ITGB1 complexes
at the melanoma-endothelial cell contact regions (Longo et al,
2001), or IL-8 secretion, ICAM-1 expression and E-selectin
reduction, as a consequence of B-Raf mutation in melanoma
cells (Liang et al, 2007). Interestingly, these molecules are
modulated by miR-214 in our cells (see Table I). Given that
B-Raf is mutated in our melanoma model (Eskandarpour
et al, 2005), a possible cooperation between B-Raf and miR-
214 could occur during extravasation. Moreover, functional
classification of miR-214-modulated molecules revealed an
enrichment of genes involved in the leukocyte extravasation
pathway, suggesting a common mechanism of migration
through the endothelial walls for melanoma cells and leuko-
cytes. Since miR-214 reduces anoikis in cell culture, we
speculate that miR-214 also helps the tumour cells to survive
in the blood circulation. Similar functions were shown for
miR-31 in breast cancer (Valastyan et al, 2009). We found that
miR-214 was able to confer various pro-metastatic traits also
to the A375P parental cells; however, we observed only a
slight effect on lung colonization in our experimental condi-
tions. No macrometastases were found when miR-214-over-
expressing or control A375P cells were injected. Nevertheless,
micrometastases were detected exclusively for miR-214-over-
expressing cells. These results suggest that miR-214 facilitates
metastasis formation but it is not a strong metastasis inducer
per se and that its role depends on the cellular context
in which it operates. In any case, we cannot exclude
that different experimental settings were needed for these
investigations.
Based on bioinformatic predictions we looked for direct
miR-214 targets and among various genes tested, we were
able to prove that TFAP2C and ITGA3 are directly and
specifically repressed via miR-214 binding on their 30UTRs
in melanoma cells. At the same time, we observed that miR-
214 was able to induce MET overexpression. TFAP2C is a
member of the AP-2 transcription factor family involved,
together with TFAP2A, in the activation or repression
of various genes implicated in tumourigenesis (Hilger-
Eversheim et al, 2000; Eckert et al, 2005). Melanoma progres-
sion is clearly associated with loss of expression of total or
nuclear TFAP2 proteins and this correlates with poor prog-
nosis and advanced stages of the disease (Bar-Eli, 2001;
Berger et al, 2005). Loss or deletions of the TFAP2 family
member genomic loci were found in some, but not all,
melanomas, suggesting other mechanisms for control of
gene expression (Karjalainen et al, 2000). We were able to
demonstrate that miR-214 downregulates expression of
TFAP2C directly and TFAP2A indirectly in melanoma cells.
We need to underline that only low TFAP2A protein expres-
sion was detected in the melanoma progression model we
used, consistent with the fact that A375P cells were derived
from a metastatic melanoma with low TFAP2A amount
(Huang et al, 1998). Instead, TFAP2C is well expressed in
our system, although at reduced levels in the most invasive
variant MC-1 compared with the parental A375P cells due to
miR-214 higher expression. Reduction of TFAP2A is, at least
in part, due to direct control by TFAP2C, since TFAP2C
silencing reduces TFAP2A protein levels partially (Orso
et al, unpublished), which is in line with the fact that
TFAP2 family members are able to regulate each other
transcriptionally (Bauer et al, 1994). It is known that elim-
ination of TFAP2A from non-metastatic primary melanoma
cells increases malignancy (Gershenwald et al, 2001), while
re-expression abrogates it (Huang et al, 1998), by controlling
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transcription of genes such as MCAM-MUC18, MMP2, PAR-1,
VEGF, BCL2, CDKN1A/p21, E-cadherin and c-KIT (Melnikova
and Bar-Eli, 2008). We were able to demonstrate that miR-214
overexpression increases the transcription of MCAM-MUC18
and VEGFA, two well-known TFAP2-repressed genes. In
addition, it decreases expression of genes transcriptionally
activated by TFAP2 family members, such as ERBB2 and
IGFBP5, as well as TGFB. c-KIT, another well-known TFAP2-
modulated gene, is expressed at very low levels in our
system, consistently with the literature (Huang et al, 1998),
so we were not able to evaluate its modulation. Other TFAP2-
regulated genes including E-Cadherin/CDH1, CTSD, EREG,
TGFBI, CDH11, CLU, PVR, EGRF, ERBB2, ICAM2, ITGAV,
MMP2, PVRL2, TIMP1, TIMP2, all somehow connected
with cell movement and/or malignancy, were found to be
differentially expressed following miR-214 modulations.
Considering that TFAP2C silencing in MA-2 cells phenocopied
miR-214 overexpression biology, while its forced expression
in miR-214-overexpressing cells rescued the migration and
extravasation phenotypes, we conclude that TFAP2C is one of
the main players through which miR-214 controls malignancy
in melanoma. TFAP2C modulations were also proven to
interfere, at least in part, with the expression of two other
miR-214-modulated genes highly involved in cell movement
and tumour progression, ITGA3 and MET, thus suggesting an
additional relevance for TFAP2C in gene expression regula-
tion in melanomas. The relevancy of TFAP2C is also under-
lined by its decreased expression in human melanoma
samples from a public data set. On the contrary, we found
that ITGA3 modulates cell migration in vitro, but it is not
sufficient per se to control the extravasation process or
metastasis formation in vivo, suggesting that the contri-
bution of ITGA3 on miR-214-mediated functions is only
partial and restricted to cell movement in culture. In line
with our in vivo results, we did not find reduced expres-
sion of ITGA3 in the human melanoma public data set
we analysed. Considering that ITGA3 is thought to pro-
mote invasion and metastasis in various human tumours
(Mitchell et al, 2010), it is possible that, even if ITGA3
is a bona fide target of miR-214, a feedback loop that
re-establishes high levels of this adhesion molecule occurs
during melanoma progression. Unfortunately, only mRNA
(no protein) data were available for the human data set we
analysed. Since miR-214 was able to downregulate ITGA3
protein expression without affecting mRNA levels in cells,
ITGA3 protein expression needs to be verified in a high
number of human melanoma samples, before drawing any
conclusions.
Considering that miR-214 is highly expressed in human
melanomas and that the pool of miR-214-modulated genes
correctly separates melanomas versus nevi or normal skin,
we can conclude that the pathway including miR-214 and its
modulated genes is able to coordinate melanoma progression
and could be considered for therapeutic intervention.
Materials and methods
Cell culture
293T, MDA-MB-231 and 4T1 cells were from American Type Culture
Collection and maintained in standard conditions. A375P and
derived variants were provided by RO Hynes (Xu et al, 2008) and
maintained in Dulbecco’s Modified Eagle’s Medium containing
10mM Glutamax and 4.5 g/ml glucose (DMEM GlutamaxTM, GIBCO
Invitrogen Life Technologies, Carlsbad, CA), supplemented with
10% heat-inactivated FCS (Seromed, GmbH), 1mM sodium
pyruvate, 25mM HEPES pH 7.4, 1 MEM vitamin solution, 1
MEM non-essential amino acids and 100mg/ml gentamicin (all from
GIBCO Invitrogen Life Technologies). 1300-Mel, GR4-Mel, WK-Mel
and Dett-Mel were provided by P Circosta and cultured according to
Circosta et al (2009) in RPMI medium supplemented with 10% heat-
inactivated FCS (Seromed, GmbH), 1mM sodium pyruvate, 25mM
HEPES pH 7.4, 1 MEM non-essential amino acids and 100 mg/ml
gentamicin. HUVECs–GFP were provided by L Primo and grown as
described (Primo et al, 2007). Human melanocytes were purchased
from Lonza (Basel, CH). SK-MEL-103, -173, -187 and -197
melanoma cell lines were obtained and cultured as described in
Segura et al (2009). Human epidermal melanocytes, derived from
adult, lightly pigmented donor (HEMa-LP), were from Invitrogen
Life Technologies (Cascade Biologics brand) and were maintained
in Medium 254, supplemented with Human Melanocyte Growth
Supplement-2, PMA-Free (Invitrogen Life Technologies, Carlsbad,
CA), as indicated by manufacturer’s guidelines.
Reagents and antibodies
pLKO.1-SCR (scramble) or pLKO.1-shTFAP2C lentiviral expression
vectors were purchased from Open Biosystems (Huntsville, AL, cat.
no. RHS3979-19745). pSP(RSV)-TFAP2C and pSP(RSV)-empty
expression vectors were a gift from H Hurst (Bosher et al, 1995,
1996). siITGA3 (Hs_ITGA3_7 HP Validated siRNA) was purchased
from Qiagen (Stanford, CA). pCMVzeo-ITGA3 and pCMVzeo-empty
were a gift from M DiPersio (Iyer et al, 2005). miR precursors and
inhibitors were pre-miRTM miRNA Precursor Molecules-Negative
Control #1, pre-miRTM miRNA Precursor Hsa-miR-214 (PM12124),
Hsa-miR-210 (PM10516), anti-miRTM miRNA Inhibitors-Negative
Control #1, anti-miRTM miRNA Inhibitors Hsa-miR-214 (AM12124)
(all from Ambion, Austin, TX). miRNA detection was TaqMans
MicroRNA Assays Hsa-miR-214 assay ID 000517 or Hsa-miR-214
assay ID 002306, Hsa-miR-210 assay ID 000512, Hsa-miR-221 assay
ID 000524, Hsa-miR-222 assay ID 002276, Hsa-miR-137 assay ID
001129, Hsa-miR-34a assay ID 000426, Hsa-RNU44 assay ID 001094,
U6 snRNA assay ID001973 (all from Applied Biosystems, Foster
City, CA). Primary antibodies were anti-TFAP2A mAb 3B5, anti-
TFAP2C mAb 6E4/4, anti-GAPDH pAb V-18, anti-hsp90 mAb F-8,
anti-MET pAb C-12 (all from Santa Cruz Biotechnology, Santa Cruz,
CA), anti-ITGA3 pAb 8-4 B7 gently provided by M DiPersio
(DiPersio et al, 1995), anti-PAK2 pAb #2608, anti-PTEN pAb
#9552 (Cell Signaling Technology, Danvers, MA), anti-Von Will-
ebrand Factor pAb A0082 (DAKO Cytomation, Glostrup, Denmark),
anti-GFPAb (ab290, Abcam, Cambridge, UK). Secondary antibodies
were goat anti-mouse IgG HRP conjugated, goat anti-rabbit IgG HRP
conjugated, donkey anti-goat IgG HRP conjugated (all from Santa
Cruz Biotechnology) and goat anti-rabbit IgG Alexa-Fluor-488
(Molecular Probes, Invitrogen Life Technologies). All antibodies
were used at the producer’s suggested concentrations.
Primers
Oligonucleotides employed in this study were cloning miR-214,
TTTCATAGGCACCACTCACTTTAC and CCCTTTCCCCTTACTCTCCA;
miR-214 synthetic binding site CTAGTCCACTGCCTGTCTGTGCCTGC
TGTCGTAGGATCTACTGCCTGTCTGTGCCTGCTGTTGGACCTGACACTG
CCTGTCTGTGCCTGCTGTCCCA and AGCTTGGGACAGCAGGCACAGA
CAGGCAGTGTCAGGTCCAACAGCAGGCACAGACAGGCAGTAGATCCTA
CGACAGCAGGCACAGACAGGCAGTGGA; cloning ARHGAP12 30UTR,
GCACTAGTGTTCCATCTTCGGACGTTGA and ATACGCGTCTTCAACAG
ACCATGCTCCC; cloning ITGA3 30UTR, ATACTAGTAGGCTGACCGACG
ACTACTG and TAACGCGTTTTTGCATACAAACTGGGAGC; cloning
ITGB8 30UTR, ATGCCGGCGCTCACGGTCATGCCAGTTGCTand TAGTT
TAAACCAGGGCTCATGGCCCGTGTA; cloning MET 30UTR, ATACTAG
TCCTCCTTCTGGGAGACATCA and TAACGCGTACAAGATGTTGCATCA
CTTTACTTT; cloning MITF 30UTR, ATACTAGTCCTCCCTGCACTGCA
TTCGC and TAACGCGTCAGTGCTATGGACCATACAG; cloning NRP1
30UTR, TAACTAGTGAGTACTTATTCGGAGGCATGAA and TAACGCGT
AATTCAACTGTTTCTTTGGAATG, cloning PAK2 30UTR, ATACTAGTC
CTGTGCCTCTAACAAGCGATTC and TAACGCGTAAGTTTAGGAAAGG
GAAAAATGCACA; cloning PLXNA1 30UTR, ATACTAGTCCCCAGCTGT
GATCATCC and TAACGCGTTGTTTAATCTCTCCTTAATGTGTGTG; clo-
ning TFAP2A 30UTR, ATACTAGTGCGGGTGACAGCTCCGGGAT and TA
ACGCGTTGATACCCTGCTCTGAACTCCAAGT; cloning TFAP2C 30UTR,
ATGAGCTCCTGGAGACCAGAGTCCAGCTGATand TAACGCGTAGGGTT
CAGCCCAACAGGAA; TFAP2C 30UTRmutagenesis, TTCTGGTTTTAGG
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AAACTTGTAGAAACGAAGCATACAGATTGATTTTTTTCTCCTTTTTTT
TTTTTTTT and AAAAAAAAAAAAAAAGGAGAAAAAAATCAATCTGT
ATGCTTCGTTTCTACAAGTTTCCTAAAACCAGAA; ITGA3 30UTR dele-
tions, CTCCTGACCCCTGCCTGCAGGCCCA and TGGGCCTGCAGGCA
GGGGTCAGGAG, ARHGAP12 RT–PCR, TCAAAACCCTGCTTTCCT
GA and CCATATTTCTCTTGATCCTTTGG and probe #7; IGFBP5,
CTACCGCGAGCAAGTCAAG and GTCTCCTCGGCCATCTCA and probe
#77; ITGA3 RT–PCR, GAGGACATGTGGCTTGGAGT and GTAGCGG
TGGGCACAGAC and probe #13, MET RT–PCR AAATGTGCATGAAGC
AGGAA and TCTCTGAATTAGAGCGATGTTGA and probe #59; NRP1
RT–PCR CACATTTCACAAGAAGATTGTGC and CATCAATTTTAATTTC
TGGGTTCTTT and probe #85; PLXNA1 RT–PCR CAGTGATGTGGCTG
TGTCG and CTCACGGGAGTTCCTCCA and probe #68 (all probes from
Universal Probe Library, Roche, Mannheim, GmbH); ERBB2 RT–PCR
QuantiTect Primer Assay QT00060746, GAPDH RT–PCR QuantiTect
Primer Assay QT00079247, ITGB8 RT–PCR QuantiTect Primer Assay
cat. no. QT00038507, MCAM-MUC18 RT–PCR QuantiTect Primer
Assay cat. no. QT00079842, MITF RT–PCR QuantiTect Primer Assay
cat. no. QT00037737, MMP2 RT–PCR QuantiTect Primer Assay cat.
no. QT00088396, PAK2 RT–PCR QuantiTect Primer Assay cat.
no. QT01677172, PTEN RT–PCR QuantiTect Primer Assay cat. no.
QT01676969, RRN18S QuantiTect Primer Assay QT00199367 (all from
Qiagen, Stanford, CA); TFAP2A RT–PCR, ACATTCCGATCCCAATGAG
CA and TGTTTTGTAGCCAGGAGCATGTTT; TFAP2C RT–PCR, AACAG
ACCCACACACTTAGCCATT and GCGGACACAAAAACCAACCA; TGFB
RT–PCR GCAACAATTCCTGGCGATACCT and AGCCCTCAATTTCCCC
TCCA; VEGFA RT–PCRCTATGTCCTCACACCATTGAAACCA and GGAA
GGTCAACCACTCACACACA. miR-214 genomic locus: TGGGCAAAAC
ACAGTGAAAA and TGACGCGTGGAAGTATCAAA; UBE2E1 genomic
locus: GGTGGGAAGTATTGCCACTCA and GTGAAACCCCAATTTATGT
AGCGTAT.
Transient transfections of pre-miRs, anti-miRs, siRNAs
or cDNAs
To obtain transient anti-miR, pre-miR or siRNA expression, cells
were plated in 6-well plates at 30–50% confluency and transfected
24 h later using RNAiFect (Qiagen, Stanford, CA) reagent, according
to the manufacturer’s instructions, with 100nM anti-miR, 75 nM
pre-miR or 170 nM siRNA. For transient cDNA overexpression, cells
were plated in 6-well plates at 90% confluency and transfected 24h
later using LipofectamineTM2000 (Invitrogen Life Technologies)
reagent, according to the manufacturer’s instruction. Cells were
tested for miR or gene overexpression/knockdown 24 or 48 h later.
Plasmid construction and generation of stable cell lines
The human miR-214 gene was amplified from genomic DNA and
cloned into pWPT (Addgene, Cambridge, MA) or pLemiR-tRFP
(Open Biosystems) vectors to obtain pWPT-miR-214 and pLemiR-
214 (still containing tRFP) vectors. For the preparation of the miR-
214 sponges two different 292 nts long sequences, containing eight
bulged target sites specific for miR-214 with linkers in-between,
were designed as described in Krol et al (2010) synthesized by
DNA2.0 (CA, USA) and cloned in the 30UTR of the GFP gene in a
pLenti-CMV-GFP-Puro vector (Addgene) generating the pLenti-
sponge1 and -sponge3 vectors. The pLenti-CMV-GFP-Puro empty
vector was used as control (pLenti-empty). All stable cell lines were
generated via lentiviral infection. Lentiviruses were produced by
calcium phosphate transfection of 20 mg vector plasmid together
with 15mg packaging (pCMVdR8.74) and 6mg envelope (pMD2.G-
VSVG) plasmids in 293T cells, according to Trono’s lab protocol
(http://tronolab.epfl.ch). Supernatant was harvested 48 h post-
transfection, filtered with 0.45mm filters, diluted and used to infect
3.5105 cells in 6-well plates, in presence of 8mg/ml Polybrene
(Sigma-Aldrich, St Louis, MO). Luciferase reporter vectors contain-
ing the full-length or partial (PTEN, PAK-2, ITGB8) 30UTR of the
indicated miR-214 target genes were generated following PCR
amplification of the 30UTR from human genomic DNA and
cloning into the Firefly Luciferase reporter pMIR-REPORTTM vector
(Ambion). When indicated the 30UTRs were mutagenized at the
miR-214 recognition site using the QuickChange Site-Directed
Mutagenesis kit (Stratagene, Cedar Creek, TX), according to the
manufacturer’s instructions. miR-214-sensor was obtained by
annealing, purifying and cloning short oligonucleotides containing
three perfect miR-214 binding sites into the SpeI and HindIII sites
of the pMIR-REPORT vector.
RNA isolation and qRT–PCR for miRNA or mRNA detection
Total RNA was isolated from cells or tumours using TRIzols
Reagent (Invitrogen Life Technologies). qRT–PCRs for miR detec-
tion were performed with the indicated TaqMan MicroRNA Assays
(Applied Biosystems) on 10 ng total RNA, according to the
manufacturer’s instructions. For mRNA detection, 1 mg of DNAse-
treated RNA (DNA-freeTM kit, Ambion) was retrotranscribed with
RETROscriptTM reagents (Ambion) and qRT–PCRs were carried out
using gene-specific primers, using a 7900HT Fast Real Time PCR
System. Quantitative normalization was performed on the expres-
sion of the RNU44 small nucleolar RNA or of GAPDH, for miR or
mRNA detection, respectively. The relative expression levels
between samples were calculated using the comparative delta CT
(threshold cycle number) method (2DDCT) with a control sample as
the reference point (Bookout and Mangelsdorf, 2003).
Motility assay
For the wound healing motility assay, cells were grown to
confluency in 6-well plates, serum starved for 24 h, then a cross
wound was made on the monolayer using a pipette tip. Cells were
rinsed with PBS buffer and placed in complete growth medium.
Photographs in different regions of the wound (at least 10 fields)
were taken at t¼ 0h and at t¼ 18 h, using Olympus IX70
microscope. The distance covered by the migrating cells is inversely
proportional to the size of the wound; motility was quantitated by
calculating the reciprocal of the wound size measured using the
ImageJ software (http://rsbweb.nih.gov/ij/) (Orso et al, 2008).
Migration, invasion and transendothelial migration transwell
assays
To measure migration 3.5104 MC-1 or 7.5104 MA-2 and WK-Mel
or 1.2105 1300-Mel, SK-Mel-187 and GR4-Mel or 2105 A375P or
105 4T1 and MDA-MB-231 were seeded in serum-free media in the
upper chambers of cell culture inserts (transwells) with 8.0mm pore
size membrane (24-well format, Becton Dickinson, NJ). To measure
invasion of MC-1 and MA-2 cells and of 1300-Mel and SK-Mel-187,
the previously mentioned inserts were pre-coated with 4 or
2 mg/well growth factor reduced Matrigel (Becton Dickinson),
respectively, and the cells seeded as indicated above. For 4T1 and
MDA-MB-231 cells, invasion assays were performed using
BioCoatTM Matrigel Invasion Chambers with 8.0 mm pore size
membrane (Becton Dickinson). For migration and invasion, the
lower chambers were filled with complete growth media. After
18–20h, the migrated cells present on the lower side of the
membrane were fixed in 2.5% glutaraldehyde, stained with 0.1%
crystal violet and photographed using an Olympus IX70 microscope
(Orso et al, 2008). For transendothelial migration assay, 105
HUVECs–GFP were seeded in complete medium in the upper part
of transwell inserts with 5.0 mm pore size membrane (24-well
format, Costar, Corning Incorporated, NY) coated by fibronectin at
5 mg/cm2, and grown for 72 h, till confluency. Then, 5104 cells
were labelled with CellTrackerTM Orange CMRA (Molecular Probes,
Invitrogen Life Technologies), according to the manufacturer’s
instructions and seeded in HUVEC’s complete medium onto the
HUVEC–GFP monolayer on the upper side of the transwell. After
20h, the HUVEC–GFP monolayer was photographed using Zeiss
Axiovert200M microscope. Then, HUVECs and non-transmigrated
cells were removed and the red-fluorescent (CMRA) cells that
migrated on the lower side of the membrane were fixed in 4%
paraformaldheyde and photographed using Zeiss AxioObserver
microscope with ApoTome Module. Migration, invasion and
transendothelial migration were evaluated by measuring the area
occupied by migrated cells using the ImageJ software (http://
rsbweb.nih.gov/ij/).
Adhesion assays
To test adhesion, 5104 cells/well were seeded onto 5mg/ml
collagen IV or 10mg/ml fibronectin or 5mg/ml laminin (all from
Sigma-Aldrich) pre-coated 96-well plates, for 1 h at 371C. Cells were
then washed thoroughly to remove non-adherent cells, fixed with
methanol and stained with haematoxylin and eosin (Diff-Quik,
Medion Diagnostics, Dudingen, CH). Wells were photographed
using Olympus IX70 microscope and the area occupied by the
adherent cell was measured using the ImageJ software (http://
rsbweb.nih.gov/ij/) (Orso et al, 2008).
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Proliferation assays
In all, 5103 cells/well were plated in 96-well plates in complete
medium and starved for 24 h. Complete medium was then added
and cells were allowed to grow for 1, 2, 3 and 5 days, fixed with
2.5% glutaraldehyde and stained with 0.1% crystal violet. The dye
was solubilized using 10% acetic acid and optical density measured
directly in plates using a Microplate Reader Mithras LB940
(Berthold Technologies, GmbH) at 570 nm wavelength (Kueng
et al, 1989).
Anchorage-independent growth assays
In all, 5104 cells were resuspended in 8ml of complete DMEM
containing 0.45% Difco Noble Agar (Becton Dickinson) and plated
in 6 cm bacterial dishes. Medium was changed every 3 days. After
20 days, the dishes were stained with nitroblue tetrazolium (Sigma-
Aldrich), photographed with Nikon SMZ1000 stereomicroscope and
colonies were counted using the ImageJ software (http://rsbweb.
nih.gov/ij/) (Hynes et al, 1990).
Anoikis analysis
Cells were plated on a 2% agarose pad in serum-free medium for
72 h, collected, washed in PBS buffer, resuspended in 10mM Hepes,
150mM NaCl, 5mM CaCl2 buffer containing FITC-conjugated
Annexin-V (Bender MedSystems, GmbH) and 200nM tetramethyl-
rhodamine-methyl-ester (TMRM, Molecular Probes, Invitrogen, CA)
and incubated at 371C for 15min. Flow cytometry analysis of
apoptosis was carried out by using a FACSCalibur flow cytometer
(Becton Dickinson). Data acquisition was performed using Cell-
Quest software (Becton Dickinson) and data analysis with WinMDI
software (version 2.8, Scripps Institute, CA). Results were displayed
in bidimensional plots, with gates indicating the percentages of
healthy and apoptotic populations (Rasola and Geuna, 2001).
In vivo tumour and metastasis assays
All experiments performed with live animals complied with ethical
animal care. Seven-week-old female CD1 nude mice (Charles River
Laboratories, Wilmington, MA) were subcutaneously injected in the
two flanks with 8106 A375P, MA-2, MC-1 cells or with 106 WK-
Mel, GR4-Mel, 1300-Mel, SK-Mel-173, SK-Mel-197 (in PBS). Tumour
growth was monitored every 3 days. Mice were dissected 4 weeks
after injection and tumours were weighted. For experimental
metastasis assays, 5105 A375P, MA-2 or MC-1 cells (in PBS) were
injected into the tail vein of 7-week-old female CB.17 SCID mice
(Charles River Laboratories). Mice were dissected 7 (MA-2 and
MC-1) or 9 (A375P) weeks later and lung macrometastases counted
in fresh total lungs using a Nikon SMZ1000 stereomicroscope.
Spontaneous metastases were evaluated in 14-week-old female
immunocompetent BALB/c mice injected with 5105 4T1 cells (in
PBS) transduced with pLemiR-214 or pLemiR-empty vectors,
expressing turbo red-fluorescent protein (tRFP), in the fourth left
mammary gland fat pad and dissected 3 weeks later. Red-
fluorescent metastatic foci were counted in the fresh total lungs
using a Leica MZ16F fluorescence stereomicroscope. For all
metastasis studies, lungs were formalin fixed, cut in small pieces
and paraffin embedded, sectioned and haematoxylin and eosin
(H&E) stained. Micrometastases were evaluated on specimens, with
an Olympus BH2 microscope, on at least three different sections.
In vivo extravasation assay
In all, 1.6106 A375P, MA-2 or MC-1 cells, previously labelled with
CellTrackerTM Orange CMRA (Molecular Probes, Invitrogen Life
Technologies) and resuspended in PBS were injected into the
tail vein of 7-week-old female CD1 nude mice (Charles River
Laboratories). After 2 or 48 h, mice were sacrificed and 4%
paraformaldehyde was injected into the trachea. Total lungs were
dissected and photographed using a Leica MZ16F fluorescence
stereomicroscope and red-fluorescent (CMRA) cells were counted
48h following injections using the ImageJ software (http://
rsbweb.nih.gov/ij/). Lungs were included in freezing resin (OCT
Killik, Bio-Optica, IT) and cryostat-cut in 6mm thick sections. For
immunofluorescent stainings for blood vessels, samples were
acetone fixed for 10min, blocked in 5% bovine serum albumin
(Sigma-Aldrich) for 1 h, incubated with anti-Von Willebrandt Factor
(vWF) primary antibody (1:50 dilution) for 1 h and anti-rabbit
Alexa-Fluor-488 secondary antibody for 30min and counterstained
with DAPI (Sigma-Aldrich) for 5min. Specimens were examined
and photographed using a Zeiss AxioObserver microscope with the
ApoTome Module.
Luciferase assays
In all, 5104 cells were cotransfected with 50ng of the pMIR-
REPORTTM (Ambion) Firefly luciferase constructs containing the
30UTRs of the indicated miR-214 potential target genes and 20ng
of pRL-TK Renilla Luciferase normalization control (Promega,
Madison, WI), using Lipofectamine2000 (Invitrogen Life Technol-
ogies). Lysates were collected 48–72 h after transfection and Firefly
and Renilla luciferase activities were measured with a Dual-
Luciferase Reporter System (Promega).
Protein preparation and immunoblotting
Total protein extracts were obtained using a boiling buffer contain-
ing 0.125M Tris/HCl, pH 6.8 and 2.5% sodium dodecyl sulphate
(SDS). In all, 25 or 50mg proteins were separated by SDS
polyacrylamide gel electrophoresis (PAGE) and electroblotted onto
polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA).
Membranes were blocked in 5% non-fat milk Tris-buffered saline
(TBS)–Tween buffer (137mM NaCl, 20mM Tris/HCl, pH 7.6, 0.1%
Tween-20) for 1 h at 371C, then incubated with appropriate primary
and secondary antibodies in 1% milk TBS–Tween buffer, respec-
tively, overnight at 41C and for 1 h at room temperature and
visualized by enhanced chemiluminescence (ECLs, Amersham
Biosciences, Piscataway, NJ).
Proteomic analysis
The expression profile of a panel of 119 soluble receptors expressed
by non-hematopoietic cells present in the Human Soluble Receptor
Array Non-Hematopoietic Panel (R&D Systems, Minneapolis, MN)
was evaluated in total protein extracts of MA-2 cells 72 h after
transfection of pre-control or pre-miR-214, according to the
manufacturer’s instructions.
Ingenuity pathway analysis systems
The Ingenuity Pathways Knowledge Base (http://www.ingenuity.-
com) is currently the world’s largest database of knowledge on
biological networks, with annotations organized by experts. We
exploited this database to look for functional network connections
among the miR-214-modulated genes.
Collection and analyses of human melanoma samples
Archival melanoma tumour samples (13 in situ melanomas, 57
primary melanomas and 18 cutaneous metastases) were collected
from the Ist. Dermatologic Clinic of the University of Torino and
institutional approvals were obtained for all samples. As reference,
seven healthy skin samples were included in the analysis. Tumour
tissue harvested from patients was quickly frozen or OCT embed-
ded and stored at 801C, or it was formalin fixed and paraffin
embedded (FFPE). Total RNA from frozen and/or OCT-embedded
samples was isolated via TRIzol Reagent (Invitrogen Life Technol-
ogies), according to the manufacturer’s guidelines. Briefly, each
sample was homogenized in the denaturing lysis solution and an
acid-phenol:chloroform extraction followed. RNA extraction from
FFPE samples was performed using the miRNeasy FFPE Kit
(Qiagen, Stanford, CA), according to the manufacturer’s guidelines.
Briefly, samples were treated with the lysis buffer with proteinase K,
then incubated at 801C to reverse formalin crosslinking. Genomic
DNA was then removed using gDNA Eliminator spin columns, and
the concentrated RNA was purified using RNeasy MinElute
spin columns. miR-214 and miR-210 expression was evaluated by
qRT–PCR as described above, starting from 10ng of total RNA.
Quantitative normalization was performed on the expression of the
RNU44 small nucleolar RNA. Relative expression was calculated
using as reference the median expression of miR-214 and miR-210 in
the healthy skin samples. Two-tailed Mann–Whitney non-para-
metric statistical test was used to assess significant differences with
a P-value o0.05 considered significant.
Analysis of human melanoma data sets
Expression data for human primary melanomas, nevi and normal
skin were obtained from the GEO series associated with Talantov
et al (2005), Accession GSE3189, log-transformed and vari-
ance stabilized by adding a constant equal to 16 before taking
the logarithm. The samples were clustered using Pearson
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correlation-based hierarchical clustering. Clustering and heatmap
were obtained using Bioconductor (Gentleman et al, 2004).
Analysis of miR-214 genomic locus
Genomic DNA was isolated from melanoma cell lines using the
Qiagen QIAmp DNA Mini kit (Qiagen, Valencia, CA). PCRs were
performed using MyiQ Single Color Real time PCR Detection System
(Bio-Rad) in 96-well plates, with reaction mixture (25ml) containing
20ng of DNA and 12.5ml of ABsolute Blue QPCR SYBR Green Mix
(Thermo Scientific, Waltham, MA). Triplicate reactions were run
with specific primers for all samples using the PCR protocol: 951C
for 15min, 40 cycles of 951C for 15 s, 551C 30 s and 721C for 30 s,
followed by melting curve analysis to ensure amplification
specificity. Under the selected conditions, only single peaks were
detected in the melting curve. The products of the PCRs were also
run on a 2% agarose gel to confirm the correct size of the amplified
product. To determine the genetic load, the DDCT method was used
according to Pfaffl (2001) and assuming 100% efficiency in the
amplification from normal human genomic DNA (Promega).
UBE2E1 housekeeping gene was used as reference. This gene has
not been found genetically altered in melanomas (Lazar et al, 2009).
Statistical analyses
Unless otherwise noted, data are presented as mean±s.e.m. and
two-tailed Student’s t-test was used for comparison, with *Po0.05;
**Po0.01; ***Po0.001 considered to be statistically significant.
NS indicates a not statistically significant P-value.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Abstract
Background: microRNAs (miRNAs) are small single-stranded non-coding RNAs that act as crucial regulators of gene 
expression. Different methods have been developed for miRNA expression profiling in order to better understand gene 
regulation in normal and pathological conditions. miRNAs expression values obtained from large scale methodologies 
such as microarrays still need a validation step with alternative technologies.
Results: Here we have applied with an innovative approach, the Luminex® xMAP™ technology validate expression data 
of differentially expressed miRNAs obtained from high throughput arrays. We have developed a novel labeling system 
of small RNA molecules (below 200 nt), optimizing the sensitive cloning method for miRNAs, termed miRNA 
amplification profiling (mRAP). The Luminex expression patterns of three miRNAs (miR-23a, miR-27a and miR-199a) in 
seven different cell lines have been validated by TaqMan miRNA assay. In all cases, bead-based meas were confirmed 
by the data obtained by TaqMan and microarray technologies.
Conclusions: We demonstrate that the measure of individual miRNA by the bead-based method is feasible, high 
speed, sensitive and low cost. The Luminex® xMAP™ technology also provides flexibility, since the central reaction can 
be scaled up with additional miRNA capturing beads, allowing validation of many differentially expressed miRNAs 
obtained from microarrays in a single experiment. We propose this technology as an alternative method to qRT-PCR for 
validating miRNAs expression data obtained with high-throughput technologies.
Background
MicroRNAs (miRNAs) are endogenous 18-24 nucleotides
(nt) long noncoding RNAs (ncRNA) that control gene
expression by targeting mRNAs and triggering either
translation repression or degradation. The degree of
complementarity between a miRNA and its mRNA target
determines, at least in part, the regulatory mechanism
[1]. Recently, a third less understood mechanism of small
RNAs interference on gene expression involves hetero-
chromatin silencing [2]. Many miRNAs are highly con-
served among animals and plants [3] and it is estimated
that up to 33% of all mRNA coding genes are negatively
regulated by miRNAs [4,5]. miRNAs exhibit temporally
and spatially regulated expression patterns during diverse
developmental and physiological processes and clearly
animals cannot survive without miRNAs [6,7]. Most of
the miRNAs that have been characterized so far in ani-
mals seem to regulate developmental processes, includ-
ing larval stage transitions and neuronal development in
C. elegans [8], growth control and apoptosis in Droso-
phila melanogaster [9] or haematopoietic differentiation
in mammals. Many miRNAs have been found to display
unique tissue [10], developmental stage [11] or disease-
specific patterns [12]. These observations imply that each
tissue is characterized by a specific set of miRNAs that
contribute to the definition of the features of that tissue.
Hundreds of novel conserved and non-conserved
microRNAs have been identified by bioinformatic analy-
ses, suggesting that the total number of human miRNAs
could reach 1,000 [13]. According to recent computa-
tional predictions, as many as 200 mRNAs can be regu-
lated by a single miRNA, which implies that over one
third of protein-coding genes in humans are regulated by
miRNA [14,15].
So, the ability to monitor changes in miRNAs expres-
sion is important for understanding gene regulation both
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Page 2 of 13in physiological and pathological conditions. Several
methodologies have been adapted for profiling miRNA
expression: northern blotting with radiolabeled probes
[16,17], cloning [18,19], massive parallel signature
sequencing (MPSS) [20], quantitative PCR-based amplifi-
cation of precursor [21] or mature miRNAs [22], SAGE-
based techniques [23], bead-based profiling methods
[24,25] and oligonucleotide microarray [26]. Microarray
technology has been successfully used for evaluating vari-
ations of miRNA expression during development [27,28],
differentiation [29], oncogenesis [30-32], disease progres-
sion [33,34] and for the primary identification of new
miRNAs that were predicted by bioinformatic
approaches [35,36]. However, at present, no standard
methodology exists for hybridization-based profiling of
miRNAs and, as a consequence, comparison of expres-
sion data from different experiments can be difficult. To
solve these problems it will be necessary to develop qual-
ity procedures for miRNA microarrays. Furthermore,
miRNA expression obtained from high throughput arrays
has to be validated with alternative technologies. Quanti-
tative real-time PCR (qRT-PCR) has become the golden
standard of miRNA quantification because it offers the
highest sensitivity from small amounts of starting mate-
rial and it is able to detect as less as 1-nt difference
between miRNAs. Another interesting method is the
Luminex® xMAP™ system that is a multiplexed micro-
sphere-based suspension array platform capable of per-
forming and reporting up to 100 different analyses in a
single reaction vessel [37,38]. In particular, oligonucle-
otide-capturing probes complementary to miRNAs of
interest are coupled to carboxilated 5-micron polystirene
beads impregnated with variable mixtures of two fluores-
cent dyes, each representing a single miRNA. Using this
technique Lu and colleagues [24] were able to differenti-
ate tumours that were instead inaccurately classified by
mRNA profiles. Recently, a study performed with
Luminex miRNA platform, identified new markers of
human breast cancer subtype [39]. When compared to
glass-slide microarrays, the bead-based miRNA arrays
show many advantages such as easy of use, low cost,
superior statistical performance, faster hybridization
kinetics (solution hybridization) and higher flexibility in
array preparation. Furthermore, the Luminex bead array
system has been used in a wide range of multianalyte
applications throughout the drug discovery and diagnos-
tics fields and it is also widely adopted for quantitative
multiplexed protein expression analysis [40,41].
In this study we have applied the Luminex® xMAP™
technology in a novel approach to validate expression
data of differentially expressed miRNAs obtained from
high throughput arrays. We have developed an innovative
system for labeling of small RNA molecules (below 200
nt) optimizing the sensitive cloning method for miRNAs,
termed mRAP, developed by Takada and Mano to define
mouse miRNA transcriptional signature [19,42,43]. The
expression patterns of three miRNAs (miR-23a, miR-27a
and miR-199a) measured by our Luminex approach in
seven different cell lines were validated by TaqMan
miRNA assay. In all cases, the two technologies gave
super imposable results. Our data demonstrate that bead-
based detection of individual miRNA is a feasible
approach, associated to high speed and low cost. The
Luminex® xMAP™ technology is also feasible for multi-
plexing, since several beads prepared to capture different
miRNAs can be added in the same reaction allowing the
validation of many differentially expressed miRNAs
obtained from large-scale approaches in a single experi-
ment.
Results and Discussion
miRNA expression in rhabdomyosarcoma cell lines
Rhabdomyosarcomas (RMS) are rare but very aggressive
tumours of childhood that arise as a consequence of reg-
ulatory disruption of the growth and differentiation path-
ways of myogenic precursor cells [44]. Based on
morphology, two major RMS subtypes can be identified:
embryonal RMS (ERMS) and alveolar (ARMS). To better
understand the global function of miRNA in RMS, we
analyzed the expression profile of 7 different RMS cell
lines (3 ARMS and 4 ERMS) using the mirVana miRNA
Probe Set V1 (Ambion) that is a collection of about 400
amino-modified DNA oligonucleotides [45]. Briefly, the
miRNA population from a single cell line was compared
to a reference sample consisting of a pool of the seven
small RNA samples ( < 200 nt) mixed in equal amounts.
The miRNA microarray platform was able to distinguish
PAX3-FKHR positive (RH4, RH30) and negative RMS
(RD, CCA, SMS-CTR, RH36, RH18) cell lines through
the expression pattern of about 120 miRNAs (data not
shown). Since the translocation positive RMS patients
fared worse than the negative counterpart [46] our results
demonstrated the potential of miRNA expression profil-
ing to classify different RMS subtypes, in agreement to
previous gene expression studies [47-49], and set the
basis for a further functional characterization of selected
miRNAs implicated in RMS pathogenesis and in the dif-
ferent clinical behaviour and aggressiveness of the two
RMS subtypes. We decided to study miRNAs with the
greatest difference in expression between PAX3-FKHR
positive and negative RMS. So expression levels for three
discriminant miRNAs (miR-23a, miR-27a and miR-199a)
were validated by xMAP™ technology and TaqMan qRT-
PCR.
Testing the hybridization specificity and sensitivity 
between targets and capture probes coupled to 
microspheres
To prepare the capture probes, 21-23 bases-long oligonu-
cleotides with sequence complementary to each of the
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Page 3 of 13three differentially expressed miRNAs (miR-23a, miR-27a
and miR-199a) in RMS cell lines, were synthesized and
coupled to different color-coded microspheres in sepa-
rate reaction tubes and then mixed for multiplexed
assays. The targets were oligonucleotides complementary
to capture probes and tagged with biotin at their 5'-end.
Capture probes (approximately 5,000 beads for each
probe) were mixed in the same tube with targets at vari-
ous amounts ranging from 15 amol to 300 fmol. Phyco-
erythrin (PE)-coniugated streptavidin was added to the
reaction mixture to detect bound targets that were bioty-
nilated. The signal of each target hybridized to its specific
capture probe coupled to microspheres was determined
by the fluorescence intensity of phycoerytrin. At least 100
microspheres of each set were analyzed by the Bio-Plex™
system to obtain a median fluorescence intensity value
(MFI) that was representative of the whole population of
each set of beads. As shown in Figure 1A, the hybridiza-
tion signal for miR-199a with capture probe varied with
the amounts of added target in a logarithmic trend,
reaching a plateau when the targets were present at the
highest concentrations. Furthermore, the specificity of
hybridization did not change while increasing from 1 to 3
the number of different microspheres in the reaction. We
have evaluated the stability of conjugated microspheres at
regular intervals during 80 days after conjugation. The
hybridization signal is stable up to 35 days. As shown in
Figure 1A, the hybridization signal for the miR-199a
slightly decreased with the distance from conjugation,
but the hybridization between the capture probe and the
corresponding target remained specific and proportional.
Furthermore, our data show that it is better to use micro-
spheres conjugated in the same day to correctly detect
miRNA expression values. We have also represented the
curve in a log-scale (Figure 1B) highlighting the linearity
range of our technique: the lower limit of sensitivity is
0.073 fmol and the upper is 18.75 fmol. We have obtained
comparable results with either miR-23a or miR-27a. We
measured the specificity of our technique by testing the
variation in hybridization signal intensity when miR-27a
and miR-199a are captured with probes that contain one
or two mismatches in their complementary sequences
(see Table 1). We have evaluated the signal of each target
(biotynilated oligonucleotides perfectly complementary
to mature miRNA sequence) hybridized to the corre-
spondent capture probes with perfect match, one or two
mismatches. As described above, capture probes were
mixed in the same tube with targets at various amounts
(from 15 amol to 300 fmol). Figure 2 shows that for both
miRNAs we obtain a significant decrease of hybridization
fluorescence intensity with capture probes containing a
single mismatch. The signal drop is even greater with two
mismatches: 62% for miR-27a and 85% for miR-199a.
We have also determined the expression levels of above
cited miRNAs, using the capture probes with perfect
match, one or two mismatches in complex RNA popula-
tions obtained from seven RMS cell lines (RD, CCA,
SMS-CTR, RH36, RH18, RH4, RH30) in comparison to a
reference sample (Pool). As shown in Figure 3, we
observe a decreasing trend in fluorescence signal for the
capture probes with two mismatches. These experiments
show that the specificity of a capture probe is propor-
tional to the number of mismatches present in its
sequence and that this specificity guarantee the correct
quantification of miRNA expression levels in complex
RNA populations.
A new application of mRAP method for miRNA labeling
We have developed a new sensitive miRNA labeling
method based on the mRAP strategy recently developed
by Mano and Takada for miRNA cloning [40,41]. This
new procedure is described schematically in Figure 4.
Small RNA molecules ( < 200-nt) purified by PureLink™
miRNA Isolation Kit (Invitrogen) were polyadenylated
with Poly(A) polymerase (PAP). Complementary DNAs
corresponding to the miRNAs were then synthesized
with the use of reverse transcriptase and a RT primer,
named Oligo-dT15-T7, complementary to the poly(A)
sequences added to the miRNA. This RT reaction was
allowed for 30 minutes in order to synthesize cDNA mol-
ecules of about 200 nt. We have used a degenerated
oligo(dT) to reduce the length of the neo-synthesized
poly(A) tails to 15 nucleotides. Given that some reverse
transcriptases possess terminal deoxynucleotidyl trans-
ferase activity, the synthesized cDNA strands frequently
result with small poly(C) overhangs at their 3' ends. After
annealing a long 5'-adptor, named SMART-16attB1-T3,
to such poly(C) overhangs, PCR was used to amplify the
miRNA-derived cDNAs. Using a T3-biotinylated forward
primer, we have obtained biotinylated cDNA that was
detected with Phycoerythrin (PE)-coniugated streptavi-
din after hybridization reaction. Every step of this proto-
col was quality checked by Agilent Bioanalyzer 2100 and
the resulting electropherograms are represented in Figure
4. Electropherogram analysis of the RT products have
revealed two major bands of ~30 and ~40 nt that corre-
spond to the 5'-adaptor (SMART-16attB1-T3) and the
oligo-dT15-T7 primer respectively. The electrophero-
grams also evidence the action of degenerated oligo(dT)
that reduces the length of neo-synthesized cDNAs to
100-110 nucleotides by shortening the poly(A) to 15 nt
(Figure 4).
We have decided to block PCR reaction during the
exponential phase at 22 cycles, to avoid distortion of the
actual concentration of miRNAs in the sample under
consideration. We have demonstrated that PCR cycles
between 20 and 25 are sufficient to achieve a good level of
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Figure 1 Stability of conjugated microspheres and sensitivity of hybridization. A) Increasing amounts of miR-199a target oligonucleotide (from 
15 amol to 300 fmol) show higher fluorescence levels reaching a plateau when the target is present at high concentrations. The curve shows a loga-
rithmic trend. We observed a slightly decrease of the hybridization signal at 50, 65 and 80 days after conjugation. B) Calibration curve (0-35 days) of 
miR-199a in a log-scale from 15 amol to 300 fmol. The two lines show the linear and plateau range of fluorescence levels representing by two different 
slopes: 0.94 and 0.15 respectively with R2 = 0.99. The linearity range of our technique is comprised between a lower value of 0.073 fmol and an upper 
value of 18.75 fmol. Mean value of expression and 95% confidence intervals are associated to each fluorescence value (MFI corresponds to Median 
Fluorescence Intensity).
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Page 5 of 13amplification without reaching the plateau phase in
which the expression differences would be invalidated
(Figure 5A).
Finally, to verify the presence of miRNAs within the
labeled cDNA population we have identified, by PCR,
three specific miRNAs (miR-1, miR-206 and miR-450)
using the sequence of each miRNA as forward primer,
and the sequence for T7 promoter, which is common to
all labeled molecules, as reverse primer. The result of
PCR amplification of the three miRNAs is shown in Fig-
ure 5B.
Validation of differentially expressed miRNAs by Luminex® 
xMAP™ technology
Using the xMAP™ assay described above we have deter-
mined the expression levels of miR-23a, miR-27a and
miR-199a in seven RMS cell lines (RD, CCA, SMS-CTR,
RH36, RH18, RH4, RH30) in comparison to a reference
sample consisting of a pool of small RNA from each cell
line mixed in equal amounts.
To evaluate the validity and feasibility of an assay, it is
necessary to compare data with that obtained by other
established technologies such as, in this case, microarray
and qRT-PCR. As shown in Figure 6, the trends of expres-
sion levels measured for all the miRNAs by the three
technologies (microarray, xMAP™ and qRT-PCR) were
very similar. Although the actual values of the relative
miRNA hybridization signals in the seven RMS cell lines
were not exactly the same for the three technologies, up-
regulated miRNAs (miR-23a and miR-27a) in PAX3-
FKHR positive RMS samples (RH4, RH30) detected origi-
nally by microarray were also up-regulated as detected by
xMAP™ and qRT-PCR, and signals for miRNAs down-
regulated in PAX3-FKHR negative RMS samples (RD,
CCA, SMS-CTR, RH36, RH18) resulted consistently low
by all three independent technologies. To better under-
stand which are the techniques that provide the most
similar results we have applied non-parametric Spearman
correlation to the following paired comparisons for each
tested miRNAs: xMAPTM vs. microarray, xMAPTM vs.
qRT-PCR and qRT-PCR vs. microarray. It is interesting to
note that data obtained with xMAP™ technology seem to
be more similar to those defined by microarray (Spear-
man correlation: miR-199a = 0.64, miR-23a = 0.64, miR-
27a = 0.84) respect to qRT-PCR (Spearman correlation:
miR-199a = 0.67, miR-23a = 0.53, miR-27a = 0.81). From
this comparison we could observe that the PCR amplifi-
cation step introduced in xMAP™ labeling method does
not affect miRNA expression levels whereas miRNA
expression data obtained from < 200-nt RNA molecules
Table 1: Capture probes
ID Nucleotide sequence (5'-3') Lenght (nt)
miR-23a GGAAATCCCTGGCAATGTGAT 21
miR-27a GCGGAACTTAGCCACTGTGAA 21
miR-27a-1MM GCGGAACTAAGCCACTGTGAA 21
miR-27a-2MM GCGGAAGTTAGCCACTGAGAA 21
miR-199a GAACAGGTAGTCTGAACACTGGG 23
miR-199a-1MM GAACAGGTAGTCTGAAGACTGGG 23
miR-199a-2MM GATCAGGTAGTGTGAACACTGGG 23
Spike 18 CATTGCCACAATCAAGACTAAGA 23
Nucleotide sequence of capture probes synthesized with 5'-amino linker and a C12 spacer. Basepair mismatches (named MM) are in bold and 
underlined
Figure 2 Specificity of hybridization between capture probes and 
miRNA targets. Biotynilated miR-199a and miR27a (bottom panel) 
were captured in solution by the corresponding probes with exactly 
matching sequences (light grey boxes) or with one (dark grey boxes) 
or two mismatched bases (black boxes). The fluorescence signal ob-
tained by the hybridization of both the perfectly matching probes was 
set to 100%. The hybridization signal between both capture probes 
and the corresponding miRNA target shows a statistically significant 
decrease (p-value < 0.05) when one or two mismatches are introduced 
into the capture sequence. Hybridization experiments were obtained 
with 18.75 fmol of biotynilated targets that fall in the linearity range of 
our method as shown in Figure 1B. Mean value of expression and 95% 
confidence intervals are associated to each fluorescence value (%MFI 
corresponds to the percentage of Median Fluorescence Intensity).
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Page 6 of 13(microarray and xMAP™) differ slightly from those
obtained from total RNA (qRT-PCR). This is particularly
evident by non-parametric Spearman correlation for
qRT-PCR vs. microarray (miR-199a = 0.94, miR-23a =
0.42, miR-27a = 0.70) with the exception of miR-199a.
Conclusions
We have described a new method that makes use of
xMAP™ technology for the quantitative determination of
single miRNAs. This approach quantifies miRNA expres-
sion levels based on hybridization of small RNA popula-
Figure 3 Specificity of hybridization between capture probes and miRNA targets in complex RNA populations. miR-199a (top panel) and 
miR27a (bottom panel) were captured from labeled total RNA populations prepared from 7 different RMS cell lines (RD, SMS-CTR, RH18, RH36, CCA, 
RH4, RH30) and a pool these RNA preparations mixed in equal amounts (POOL) with capture probes with exactly matching sequences (light grey box-
es) or with one (dark grey boxes) or two mismatched bases (black boxes). The hybridization signal in all complex RNA mixtures between both capture 
probes and the corresponding miRNA target in comparison to the reference pooled sample shows a statistically significant decrease (p-value < 0.05) 
when one or two mismatches are introduced into the capture sequence. Mean value of expression and 95% confidence intervals are associated to 
each fluorescence value (normalized MFI represents the average of the ratio between the value of fluorescence of miRNAs and the spike).
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Figure 4 Schematic representation of miRNA labeling method for bead based quantification. All protocol steps and quality checking with Ag-
ilent Bioanalyzer 2100 and gel electrophoresis (2% agarose) are schematically represented: starting material (RNA < 200 nt), the result of polyadeny-
lation reaction with PAP, the synthesis of first-strand cDNA (peaks are associated to Oligo-dT15-T7 and SMART-16attB1-T3 primers) and the second-
strand synthesis by PCR amplification.
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Page 8 of 13tions to the probes designed for miRNAs of interest that
are coupled to different color-coded microspheres. A
flow-cytometer is used to simultaneously measure the
hybridization signal associated with the surface of the
microspheres and to categorize the color-coded micro-
spheres. The method allows to obtain up to 100 indepen-
dent measures. This xMAP™ method offers affordable
cost, speed, and high flexibility with capability for multi-
plexed assays that are increasingly needed. It is valuable
for applications such as diagnostic detection of disease
miRNAs from clinical samples and validation of differen-
tially expressed miRNAs obtained from microarray anal-
ysis.
We have evaluated the stability of conjugated micro-
spheres demonstrating that they are stable for about one
month. We have also tested the specificity of hybridiza-
tion between targets and capture probes showing that the
introduction of a single mismatch in the sequence of cap-
ture probes significantly hampers its hybridization capac-
ity (Figures 2 and 3). These data have demonstrated the
specificity of our capture probes to correctly identify and
quantify the expression levels of miRNAs. We have devel-
oped a new sensitive small RNAs labeling protocol intro-
ducing some changes on mRAP strategy for miRNA
cloning. This protocol has been applied successfully to
validate the expression levels of three miRNAs that were
found differentially expressed in positive and negative
PAX3/FKHR alveolar rhabomyosarcomas by microarray
experiments. To demonstrate the reliability of this
method, the transcriptional levels of these miRNAs were
also determined by qRT-PCR with TaqMan probes. The
most significant information which emerges comparing
the data obtained by the three different technologies
(microarray, xMAP™ and qRT-PCR) is represented by the
general overlapping of the expression profiles obtained. It
is interesting to note that small differences in miRNAs
expression data could depend on the approaches used for
total RNA purification rather than on different labeling
protocols. In fact, microarray and xMAP™ data obtained
from labeling < 200-nt RNA molecules, are more similar
compared to qRT-PCR data obtained from labeling total
RNA, as demonstrated by the Spearman non parametric
correlation.
We think that the xMAP™ technology associated with
our new labeling protocol could become an alternative
and equally reliable method in the study of expression of
a limited number of miRNAs respect to qRT-PCR with
TaqMan probes. The comparison of the two experimen-
tal approaches (see Table 2) shows that the xMAP™ tech-
nique is less expensive and more flexible allowing the
simultaneous analysis of a larger number of miRNAs
from the same sample. In addition, xMAP™ does not need
for specific reverse transcription reactions for each
miRNA and provides at least 100 independent measures
for each miRNA, improving the statistical power. More-
over, xMAP™ expression data can be normalized respect
to a spike fluorescence signal added in known quantities
in the early stages of the labeling reaction, allowing the
control over all stages of the reaction. In this way there is
no need of an endogenous control, like in qRT-PCR,
whose representativeness is sample-dependent.
Probably, a negative aspect of xMAP™ technology is
represented by the use of enriched total RNA ( < 200 nt)
that requires higher amounts of starting material respect
to qRT-PCR. To avoid the enrichment step of < 200 nt
RNA molecules, we propose the use of LNA capture-
probe oligonucleotides that increase the affinity of the
oligonucleotide for its complementary RNA target lead-
ing to a significant enhance in stability and specificity of
the duplex.
We think that the technology we have developed could
be an alternative method to qRT-PCR for validating miR-
NAs expression data obtained with a large scale technol-
ogy such as microarray and it could have a wide
application in clinical, pharmaceutical, agricultural and
environmental studies.
Methods
Cell culture
Human alveolar RMS (ARMS) cell lines, positive for
PAX3-FKHR translocation (RH4, RH30), negative for
PAX3-FKHR translocation (RH18) and human embryo-
nal RMS (ERMS) cells (RD, RH36, CCA, SMS-CTR) were
maintained in modified Eagle's medium (DMEM) con-
taining 10% fetal calf serum, penicillin (100 U/ml), and
streptomycin (100 μg/ml) (Invitrogen) at 37°C, 5% CO2 in
a humidified incubator.
The human RMS cell lines RH30 and RD were pur-
chased from ATCC (Manassas, VA); RH4 and RH18 were
a gift of Dr P.J. Houghton (St Jude Children's Hospital,
Figure 5 Second-strand synthesis by PCR reaction. A)Determina-
tion of the optimal PCR amplification cycle: the 2% agarose gel shows 
the amplification products of RH30 first-strand cDNA stopped at 15, 20, 
25 and 30 PCR cycles. B) Presence of specific miRNAs in the labeled 
cDNA population: the 2.25% agarose gel shows PCR amplification 
products of three specific miRNAs (miR-1, miR-206 and miR-450) per-
formed by using the sequence of each miRNA as forward primer, and 
the sequence for T7 promoter, which is common to all labeled mole-
cules, as reverse primer.
Biscontin et al. BMC Molecular Biology 2010, 11:44
http://www.biomedcentral.com/1471-2199/11/44
Page 9 of 13
Figure 6 Comparison of three different techniques used to define miRNA expression profiles in seven RMS cell lines. Expression levels of miR-
199a, miR-23a and miR-27a in seven RMS cell lines obtained with three methods (xMAP™, qRT-PCR and microarray) are represented. Mean value of 
expression and 95% confidence intervals are associated to each miRNA. The Figure also indicate, for each tested miRNAs, non-parametric Spearman 
correlations for the following paired comparisons: xMAP™ vs. microarray, xMAP™ vs. qRT-PCR and qRT-PCR vs. microarray.
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Page 10 of 13Memphis, TN); SMS-CTR, RH36, CCA were obtained
from Dr M. Tsokos (NCI, Bethesda, MD).
Isolation of small RNA molecules
Total RNA was prepared from seven cell lines of human
rhabdomyosarcoma using a modified TRIzol (Life Tech-
nologies Corporation, Carlsbad, CA, USA) protocol for
small RNA enrichment. A pellet of about 6 × 106 - 9 × 106
cells was dissolved in 1 ml of TRIzol and the supernatant,
containing total RNA, was purified by PureLink™ miRNA
Isolation Kit (Life Technologies Corporation) that was
specifically designed to enrich total RNA preparation for
< 200-nt RNA molecules. RNA quantity and quality were
assessed by Nanodrop (NanoDrop Technologies, Wilm-
ington, DE, USA) spectrophotometry and microelectro-
phoresis using Small RNA Nano LabChip by Agilent 2100
bioanalyzer (Agilent Technologies, Palo Alto, CA, USA)
respectively.
miRNA expression profiling and statistical analysis of data
microRNA expression profiling was carried out using the
"mirVana Probe Set V1" (Ambion) that is a collection of
about 400 amine-modified DNA oligonucleotides repre-
senting a panel of the human, mouse and rat microR-
NAome in the miRNA Registry (miRBase - Release 9).
The probes are 42-46 nucleotides (nt) long, with 18-24 nt
segment targeting a specific miRNA, and the remaining
sequence serving as spacer. We analyzed the expression
profiles of 7 different rhabdomyosarcoma cell lines: 3
ARMS (RH4, RH30, RH18) and 4 ERMS (RD, RH36,
CCA, SMS-CTR). The miRNA population from each cell
line was compared to a reference sample consisting of a
pool of the 7 total RNA samples mixed in equal amounts.
Two replicates of each experiment were performed using
different microarray slides, in which sample and refer-
ence RNAs, labeled either with Cy3 or Cy5 fluoro-
chromes, were crossed in both combinations (dye-
swapping procedure). miRNAs were labeled with the
mirVana Labeling Kit (Ambion) and amine-reactive dyes
(GE Healthcare) as recommended by the manufacturer's
protocol [45]. Normalization of expression levels of all
spot replicates was performed by MIDAW [50]. Principal
component analysis, cluster analysis and profile similarity
searching were performed with tMev software [51]. One
and two class Significance Analysis of Microarray (SAM)
allowed to identify differentially expressed miRNAs [52].
Capture probe and its coupling to microspheres
A sequence of 21-23 nt complementary for each tested
miRNAs (listed in the Table 1) was chosen as capture
probe and synthesized with 5'-amino linker and a C12
spacer (PRIMM, Milan, Italy). Capture-probe oligonucle-
otides were covalently linked to carboxylated fluoro-
chrome microspheres (Bio-Rad Laboratories, Hercules,
CA, USA) in water-soluble carbodiimide. Specifically, 1 ×
106 carboxylated microspheres were pelleted in a micro-
centrifuge for 5 minutes at 12,000×g and then superna-
tant was carefully removed. The dry microspheres were
dissolved in 20 μl of a buffer containing 0.1 M MES
(Sigma-Aldrich, St. Louis, MO, USA) at pH 4.5. The
amino-substituted capture probe was dissolved in molec-
ular biology grade water at a concentration of 100 μM
and 0.5 μl of the solution (containing 0.05 nmole of cap-
ture probe oligonucleotides) was added to the beads for
the coupling reaction. The coupling reaction was per-
formed by adding 2.5 μl of a freshly made solution of 10
mg/ml 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC) (Pierce, Thermo Scientific, Wilm-
ington, DE, USA) in molecular biology grade water. The
mixture of microspheres, capture probes, and EDC was
vortexed briefly and incubated at room temperature for
30 minutes in the dark. Occasionally, the reaction was
mixed by finger flicking the tube to keep the micro-
spheres in suspension. A second incubation steps was
done adding a freshly-made solution of 10 mg/mL EDC
in molecular biology grade water. After the coupling reac-
Table 2: Comparison of xMAP™ and qRT-PCR techniques
xMAP™ qRT-PCR
< 200 nt RNA molecules enrichment YES NO
RT step YES YES
Amplification YES YES
Endogenous control NO YES
Control spike YES NO
Multiplexing YES NO
Liquid-phase hybridization YES NO
No. of measures 100 1
Custom-tailored assay YES NO
Cost Low High
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Page 11 of 13tion, 500 μl of 0.02% Tween 20 (Sigma-Aldrich) was
added to the microspheres. The solution was mixed well
by vortex and centrifuged for 6 minutes at 12,000×g. The
supernatant containing free-capture-probe oligonucle-
otides and excess EDC was carefully removed. The cou-
pled microspheres were washed in 500 μl of 0.1% SDS
(Sigma-Aldrich) by vortex and centrifuged for 5 minutes
at 12,000×g. Finally, the supernatant was removed and
the capture-probe conjugated microspheres were resus-
pended in 20 μl of TE pH 8.0 and stored at 4°C in a dark
box (stable for at least 6 months). The microspheres were
diluted in TE buffer and counted using a Bürker chamber
under the microscope at 100× magnification.
miRNA labeling
At the beginning, 1 μg of small RNA molecules (< 200-nt)
and 200 pg of a synthetic pre-labeling control RNA (5'-
UCUUAGUCUUGAUUGUGGCAAUG-3', PRIMM)
were mixed in order to control target preparation effi-
ciency and to normalize expression data. The mixture
was polyadenylated using Poly(A) Tailing Kit (Ambion)
according to the manufactures' instructions. The reaction
was precipitated with NaOAc 3 M pH 5.5 (1/10 volume)
and absolute ethanol (4 volumes) overnight at -20°C. The
polyadenylated RNA molecules were resuspended in 15
μl of H2O RNase free and then volume was reduced to 3.2
μl by vacuum (VR-1, Heto-Holten, Denmark). miRNAs
labeling was performed by mRAP modified protocol in
which miRNA-derived cDNAs were flanked by synthe-
sized oligomers at each end. The SMART (switching
mechanism at the 5'-end of RNA templates of reverse
transcriptase) oligo sequence (SMART-16attB1-T3: 5'-
TACAAAAAAGCAGGCTAATTAACCCTCAC-
TAAAggg-3') and the overhang of the oligo-dT15-T7
primer (5'-GTGAATTGTTAATACGACTCACTATAG-
GCGC [dT]15N-3') were used for first strand synthesis.
First strand cDNA synthesis was performed from 500 ng
of small RNA in a 10 μl reaction. Then, the reaction was
diluted 1:2 and incubated at 72°C for 7 min. Second
strand reaction mix was added to 3.0 μl of diluted first
strand cDNA to give a final concentration of 1X BD
Advantage 2 PCR reaction buffer (Clontech Laboratories,
Mountain View, CA, USA), 0.2 mM dNTPs, 100 nM
primers (T3-biotinylated forward primer: 5' - biotAAT-
TAACCCTCACTAAAGGG-3' and T7 reverse primer:
5'- TAATACGACTCACTATAGG-3') and 1X of Advan-
tage 2 DNA polymerase mix (Clontech Laboratories) in a
total volume of 25 μl. This second strand reaction mix-
ture was incubated for 22 cycles of the following steps: 15
sec 95°C, 20 sec 51°C and 20 sec 72°C. Only those ss
cDNAs having a SMART anchor sequence at the 5'-end
were used as template and exponentially amplified. The
second strand reaction was precipitated in sodium ace-
tate-ethanol solution and dissolved in 11 μl TE buffer pH
8.0 (10 mM TrisHCl pH 8.0, 1 mM EDTA). Biotinylated
cDNA quantity was assessed by Nanodrop spectropho-
tometer (Nanodrop Technologies) and stored at -20°C
until hybridization with microspheres. Labelled target
produced by a single PCR reaction was sufficient for two
hybridization reactions.
Hybridization of targets to capture probes coupled to 
microspheres
The microspheres of each probe set were resuspended by
vortexing for approximately 20 seconds. A microsphere
mixture was prepared by diluting coupled stocks to 150
microspheres of each set/μl in 1.5× TMAC Hybridization
Buffer (5 M tetramethylammonium chloride, 0.15%
Sarkosyl; 75 mM Tris-HCl pH 8.0; and 6 mM EDTA, pH
8.0), followed by vortex mixing for approximately 20 sec-
onds. Two μg of biotinylated DNA target in 17 μL of TE
buffer pH 8.0 was added to 33 μl of microsphere mixture
(approximately 5,000 beads per color) in the wells of a 96-
well plate. 17 μl of TE buffer pH 8.0 were added to back-
ground wells. Each well reaction was mixed gently by
pipetting up and down several times and the labeled
DNA was denatured by heating at 95-100°C for 3 min.
The hybridization mixture was incubated at 48°C for 17
h, covering the plate to prevent evaporation, in a Eppen-
dorf microplate incubator with shaking speed of 700 rpm.
After incubation, the hybridization mixture was spun
down for 3 min at 3,000×g to pellet the microspheres.
Supernatant was carefully removed with a pipette with-
out disturbing the microspheres. During centrifugation,
fresh reporter mix was prepared by diluting streptavidin-
conjugated R-phycoerythrin (Invitrogen) to 3 mg/ml in
1× TMAC Hybridization Buffer and 75 μl of reporter mix
were added to the microspheres. The solution was gently
mixed by pipetting and incubated in the dark at 48°C for
15 minutes in a Eppendorf microplate incubator. 50 μl of
each sample were transferred to a Multiscreen HTS plate
(Millipore) and analyzed on the BioPlex™ (Luminex® 100™,
BioRad) machine at hybridization temperature.
Bead-based detection
Each set of microspheres was distinguished by assigned
colour code (different percentage of red and orange)
inside the microspheres. In our experiments we have
used four different probe sets (regions: 1, 21, 51 e 57).
The fluorescence associated to the surface of each bead,
corresponding to the amounts of bound miRNAs, was
detected and measured by the laser detector. The Bio-
Plex™ (Luminex® 100™, Bio-Rad Laboratories) system
detects fluorescent dyes with an excitation wavelength of
-532 nm and emission wavelength -580 nm. For each
experiment, 100 events of each subset of microspheres
were analyzed on the Bio-Plex™ system to obtain a
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resentative of the whole population of each set of beads.
Computational analyses (data processing and quality 
control)
To eliminate bead-specific background, the reading of
every bead for every samples was first processed by sub-
tracting the average readings of that particular bead in
the absence of target miRNAs. Samples with median flu-
orescence intensity values smaller than background sig-
nals were removed. Every samples was assayed in three
wells. Each of the three wells contained 4 probes: miR-
23a, miR-27a, miR-199a and one pre-labeling control
(Spike-18). Expression data were scaled according to the
pre-labeling control in order to normalize readings from
different probe/bead sets for the same sample and to nor-
malize for the labeling efficiency. Technical replicate
samples for each probe were summarized by their mean
profile and expression data (test/control) were log2 trans-
formed. The error associated to each probe is obtained by
quadratic propagation from standard deviation.
qRT-PCR TaqMan
TaqMan® MicroRNA Assays incorporate a target-specific
stem-loop, reverse transcription primer. The stem-loop
structure provides specificity only for the mature miRNA
target and forms a RT primer/mature miRNA-chimera
that extends the 5'-end of the miRNA. The resulting lon-
ger RT amplicon presents a template amenable to stan-
dard real-time PCR using TaqMan Assays [22]. In brief,
according to the manufacture's instructions (Applied Bio-
systems), each 15 μl RT reaction contained purified 10 ng
of total RNA, 3.0 μl of 5× stem-loop RT primer, 1× RT
buffer, 0.25 mM each of dNTPs, 50 U MultiScribe™
reverse transcriptase and 3.8 U RNase inhibitor. The
reactions were incubated in a Mastercycler EP gradient S
(Eppendorf) in 0.2 ml PCR tubes for 30 min at 16°C, 30
min at 42°C, followed by 5 min at 85°C, and then held at
4°C. RT products were diluted two times with H2O prior
to setting up PCR reaction. Each real-time PCR for each
miRNA assay (10 μl volume) was carried out in triplicate,
and each 10 μl reaction mixture included 1 μl of diluted
RT product, 5 μl of 2 × TaqMan® Universal PCR Master
Mix and 0.5 μl of 20× TaqMan® MicroRNA Assay. The
reaction was incubated in a 7500 Real-Time PCR System
(Applied Biosystems) in 96- well plates at 95°C for 10 min,
followed by 40 cycles of the following steps: 95°C for 15
sec and 60°C for 1 min. The threshold cycle (CT) is
defined as the fractional cycle number at which the fluo-
rescence exceeds the fixed threshold of 0.2. To evaluate
differences in miRNA expression, a relative quantification
method was chosen where the expression of the miRNA
target is standardized by a non-regulated small non-cod-
ing RNA used as reference.
Consequently, three replicates of each sample and
endogenous control were amplified. U6B small nuclear
(RNU6B) was used as endogenous control because the
level of this small RNA remains essentially constant from
sample to sample. To calculate the relative expression
ratio, the 2-Δ ΔCt (RQ, relative quantification) method
implemented in the 7500 Real Time PCR System software
[53] was used. This method determines the change in
expression of a nucleic acid sequence (target) in a test
sample relative to the same sequence in a calibrator sam-
ple.
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